B18xxYuz28	3a51a3295717b61db395146a7779061b	365	PIRSR-2023_05	PIRSR603912-52	4	188	1	CDLWTSLDVICCTASILHLVAISMDRYWV-VTQIDYVCHRPARRILIMIALSWTVAIVISTPPLFGWKHPSSDPNHTGTC	59	137	DISULFID: 
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	C	70	70	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	K	306	306	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	G	322	322	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	D	66	66	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	T	63	63	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	N	318	318	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	W	296	296	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	G	325	325	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	I	321	321	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	W	62	62	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	Y	329	329	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	A	153	153	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	F	300	300	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	C	137	137	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	T	71	71	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	S	149	149	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	F	299	299	putative ligand binding site
B18xxYuz28	3a51a3295717b61db395146a7779061b	365	CDD-3.21	cd15331	1	350	18	V	67	67	putative ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	V	230	230	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	R	139	139	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	A	288	288	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	Y	149	149	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	E	236	236	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	S	151	151	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	R	148	148	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	F	147	147	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	L	292	292	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	I	241	241	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	Q	237	237	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	T	144	144	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	A	234	234	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	I	143	143	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	E	233	233	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	T	291	291	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	K	287	287	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	Q	70	70	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	Q	150	150	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	K	240	240	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	A	142	142	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	R	71	71	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	P	146	146	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	24	I	238	238	putative G protein interaction site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	F	201	201	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	S	211	211	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	V	102	102	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	T	203	203	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	V	326	326	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	Y	207	207	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	A	208	208	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	W	303	303	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	L	101	101	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	D	121	121	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	S	212	212	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	W	330	330	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	S	215	215	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	V	122	122	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	F	306	306	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	N	329	329	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	F	307	307	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	Y	333	333	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	W	117	117	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	N	310	310	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	CDD-3.21	cd15958	42	353	21	V	125	125	ligand binding site
YTFik3WhXc	1a1d936f3a801c37364242e77cd300a8	491	PIRSR-2023_05	PIRSR603912-52	38	235	1	CECWTSVDVLCVTASIETLCVIAIDRYLAITSPFRYQSLMTRARAKGIICTVWAISALVSFLPIMMHWWRD--EDPQALKC	114	192	DISULFID: 
U9atOteYMr	31f6d2c6d2bee600cc689e83f47edec3	392	PIRSR-2023_05	PIRSR600732-5	22	334	1	C	331	331	LIPID: S-palmitoyl cysteine
U9atOteYMr	31f6d2c6d2bee600cc689e83f47edec3	392	PIRSR-2023_05	PIRSR600732-5	22	334	1	C	332	332	LIPID: S-palmitoyl cysteine
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	PIRSR-2023_05	PIRSR600732-5	294	373	1	C	373	373	LIPID: S-palmitoyl cysteine
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	PIRSR-2023_05	PIRSR601681-50	28	210	1	CDVWTSLDVMLCTASILNLCMISVDRYFVITRPFQYAMKRTPKRMSIMIAIVWIASALISIPPVFGWKAERGP--YTC	104	179	DISULFID: 
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	S	340	340	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	T	108	108	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	A	191	191	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	W	312	312	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	V	112	112	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	M	343	343	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	A	195	195	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	T	339	339	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	C	115	115	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	C	179	179	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	F	316	316	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	T	116	116	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	D	111	111	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	Y	347	347	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	W	107	107	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	F	315	315	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	D	336	336	putative ligand binding site
ZcjF0aDH2l	2aeb39056effdf07ffe01bb99cb61e57	435	CDD-3.21	cd15329	32	368	18	R	322	322	putative ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	Y	436	436	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	T	203	203	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	Y	463	463	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	N	437	437	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	D	116	116	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	Y	117	117	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	N	121	121	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	A	207	207	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	W	168	168	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	S	120	120	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	W	433	433	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	C	462	462	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	Y	459	459	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	A	204	204	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	F	208	208	ligand binding site
N8ZBS9MGL0	3962773f916099f71da87b5119d24d0a	496	CDD-3.21	cd17790	37	484	16	T	200	200	ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	F	350	350	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	T	374	374	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	F	351	351	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	Y	378	378	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	I	139	139	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	T	143	143	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	V	218	218	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	L	211	211	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	S	221	221	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	C	142	142	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	F	134	134	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	S	225	225	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	Y	354	354	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	A	222	222	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	D	138	138	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	E	370	370	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	CDD-3.21	cd15060	58	399	17	W	347	347	putative ligand binding site
KL7O6EaeMF	1b9a889fba58eb6540cf676c892e1e1d	420	PIRSR-2023_05	PIRSR600732-5	324	406	1	C	404	404	LIPID: S-palmitoyl cysteine
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	PIRSR-2023_05	PIRSR600732-5	292	389	1	C	375	375	LIPID: S-palmitoyl cysteine
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	W	313	313	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	V	337	337	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	S	212	212	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	T	124	124	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	F	317	317	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	D	119	119	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	W	115	115	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	Y	345	345	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	S	123	123	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	F	198	198	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	S	209	209	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	F	316	316	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	Y	320	320	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	F	341	341	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	V	120	120	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	A	205	205	putative ligand binding site
L5PdHLBnAS	26b3c8e406ded3423ff8bb23ddc78e57	411	CDD-3.21	cd15066	41	366	17	S	208	208	putative ligand binding site
OmEFZmh9Xk	8a86ae7334ce8bb9dc0b23880e01cb4c	388	PIRSR-2023_05	PIRSR600732-5	302	380	1	C	380	380	LIPID: S-palmitoyl cysteine
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	PIRSR-2023_05	PIRSR601681-50	28	232	1	CDLWLSLDVTCCTASILHLCAIALDRFWAITDAAEYAHKRTPGRAA-LMIAASWLLAACISVPPLFWRR--RDPAKPRC	123	198	DISULFID: 
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	S	211	211	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	C	134	134	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	C	198	198	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	L	127	127	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	W	367	367	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	A	390	390	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	D	130	130	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	F	370	370	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	D	391	391	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	T	394	394	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	F	371	371	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	Y	398	398	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	W	126	126	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	V	377	377	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	P	387	387	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	T	135	135	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	A	215	215	ligand binding site
YI1L8xHuuM	594c9713f835701f006f72803dff92a4	429	CDD-3.21	cd15064	68	419	18	V	131	131	ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	W	105	105	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	Y	196	196	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	W	281	281	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	F	190	190	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	V	113	113	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	S	201	201	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	F	303	303	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	N	288	288	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	F	285	285	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	T	106	106	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	A	197	197	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	D	109	109	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	D	189	189	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	S	200	200	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	T	192	192	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	V	110	110	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	Y	311	311	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	S	204	204	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	F	284	284	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	20	N	307	307	putative ligand binding site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	R	59	59	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	K	136	136	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	L	229	229	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	P	134	134	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	R	225	225	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	L	270	270	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	A	223	223	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	R	127	127	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	E	138	138	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	P	58	58	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	Q	226	226	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	Y	137	137	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	V	219	219	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	I	230	230	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	A	266	266	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	V	222	222	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	L	135	135	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	M	139	139	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	T	132	132	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	I	131	131	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	T	269	269	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	A	130	130	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	V	227	227	putative G protein interaction site
36Z3LxBjPl	5b1de66ae3a65c438c0d1a6719970e33	408	CDD-3.21	cd15959	30	331	24	K	265	265	putative G protein interaction site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	PIRSR-2023_05	PIRSR600732-5	249	340	1	C	336	336	LIPID: S-palmitoyl cysteine
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	PIRSR-2023_05	PIRSR600732-5	249	340	1	C	337	337	LIPID: S-palmitoyl cysteine
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	T	102	102	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	C	193	193	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	S	194	194	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	W	280	280	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	T	101	101	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	A	197	197	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	W	302	302	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	N	287	287	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	L	306	306	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	F	183	183	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	D	97	97	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	F	284	284	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	A	190	190	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	V	98	98	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	F	283	283	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	Y	310	310	putative ligand binding site
8wPYm4i79F	eec2bb406b572852a352e5010aff0401	395	CDD-3.21	cd15056	18	331	17	R	93	93	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	W	393	393	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	S	238	238	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	F	397	397	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	Y	424	424	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	T	159	159	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	A	239	239	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	S	242	242	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	I	416	416	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	L	228	228	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	V	155	155	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	V	235	235	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	C	158	158	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	F	396	396	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	T	420	420	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	D	154	154	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	Y	400	400	putative ligand binding site
xVerh9VjXq	c3168b698139c4436f9f01628d1370a2	455	CDD-3.21	cd15060	75	445	17	W	150	150	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	V	182	182	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	L	175	175	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	F	366	366	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	S	185	185	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	Y	394	394	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	V	108	108	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	W	362	362	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	F	365	365	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	C	186	186	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	F	386	386	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	C	111	111	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	S	189	189	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	T	112	112	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	Y	103	103	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	D	107	107	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	F	390	390	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	CDD-3.21	cd15059	28	415	17	Y	369	369	putative ligand binding site
N9pESfrjq2	4fdf6f9f97520d9ee90fc72af35bbead	429	PIRSR-2023_05	PIRSR600732-5	341	421	1	C	420	420	LIPID: S-palmitoyl cysteine
AlrwQSS6wg	0bc9d84cc13a45bccbf299d2fe4c63ea	470	PIRSR-2023_05	PIRSR600732-3	33	216	1	CNIWAAMDVLCSTASIMSLCVISIDRYIGVSYPLRHPAIMTEKRGVLTLVAVWLLALVISVGPLFGWKEPEPEDESV-C	102	179	DISULFID: 
AlrwQSS6wg	0bc9d84cc13a45bccbf299d2fe4c63ea	470	PIRSR-2023_05	PIRSR600732-5	279	373	1	C	356	356	LIPID: S-palmitoyl cysteine
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	S	199	199	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	Y	334	334	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	V	112	112	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	S	198	198	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	C	115	115	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	E	350	350	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	W	327	327	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	T	116	116	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	I	195	195	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	D	111	111	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	S	202	202	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	F	330	330	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	T	354	354	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	W	107	107	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	L	188	188	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	F	331	331	putative ligand binding site
svN152ekuq	9a29b852973550ef4af4e2139c76cc42	407	CDD-3.21	cd15060	32	379	17	Y	358	358	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	PIRSR-2023_05	PIRSR600732-5	307	398	1	C	398	398	LIPID: S-palmitoyl cysteine
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	L	367	367	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	R	347	347	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	S	233	233	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	C	156	156	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	F	148	148	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	F	340	340	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	Y	371	371	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	D	152	152	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	E	363	363	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	W	337	337	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	V	153	153	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	I	149	149	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	L	360	360	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	F	341	341	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	R	364	364	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	T	157	157	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	A	237	237	putative ligand binding site
tluOISlD1A	0171e9ab8e7a30223407392a1cafd632	426	CDD-3.21	cd15329	72	392	18	C	221	221	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	PIRSR-2023_05	PIRSR600732-5	328	412	1	C	406	406	LIPID: S-palmitoyl cysteine
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	PIRSR-2023_05	PIRSR600732-5	328	412	1	C	407	407	LIPID: S-palmitoyl cysteine
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	S	211	211	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	F	350	350	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	T	374	374	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	Y	378	378	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	V	124	124	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	W	346	346	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	F	349	349	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	F	370	370	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	D	123	123	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	W	119	119	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	S	127	127	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	F	197	197	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	S	207	207	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	N	353	353	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	L	204	204	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	S	128	128	putative ligand binding site
P8Fav94ckA	ad932cb8997c19bd890ab281a475e668	442	CDD-3.21	cd15067	45	399	17	S	208	208	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	PIRSR-2023_05	PIRSR600732-5	17	320	1	C	320	320	LIPID: S-palmitoyl cysteine
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	D	94	94	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	S	179	179	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	F	286	286	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	A	176	176	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	W	255	255	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	W	90	90	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	S	180	180	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	S	183	183	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	S	98	98	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	F	258	258	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	F	259	259	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	I	95	95	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	T	99	99	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	V	169	169	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	N	262	262	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	V	290	290	putative ligand binding site
IQoDF8l5S9	ea477d71251301d2a1126d743927b75f	445	CDD-3.21	cd15057	13	314	17	W	294	294	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	PIRSR-2023_05	PIRSR600732-1	36	215	1	E	192	192	BINDING: Zn(2+)
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	F	430	430	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	D	116	116	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	S	199	199	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	V	117	117	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	Y	409	409	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	S	203	203	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	F	406	406	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	I	196	196	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	Y	434	434	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	T	121	121	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	L	189	189	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	W	402	402	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	Y	112	112	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	F	405	405	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	F	426	426	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	C	120	120	putative ligand binding site
Pfn5zv9XX5	584b3ffb9880a3e999fa195830fc93a4	469	CDD-3.21	cd15323	37	455	17	C	200	200	putative ligand binding site
v2LmFud5bE	d55c0084c6d8cc9d196646c9f324c851	542	PIRSR-2023_05	PIRSR600732-3	7	219	1	CNIWAAVDVLCCTASILSLCVISVDRYLGVSYPLRYPTIMTKKRGLITLTGVWALSMVISIGPLLGWKEPEPADEKV-C	105	182	DISULFID: 
aegE8u72ZI	54e2cb7df2daa4dd200b493fa1b2244d	398	PIRSR-2023_05	PIRSR600732-1	317	392	1	Q	349	349	BINDING: Zn(2+)
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	PIRSR-2023_05	PIRSR603912-52	62	266	1	CEFWTSVDVLCVTASIETLCVIALDRYIAITSPFRYQSLLTRARARALVCTVWAISALVSFLPILMHW--WRADGDEAMLC	140	218	DISULFID: 
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	PIRSR-2023_05	PIRSR600732-5	329	404	1	C	403	403	LIPID: S-palmitoyl cysteine
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	PIRSR-2023_05	PIRSR600732-5	329	404	1	C	402	402	LIPID: S-palmitoyl cysteine
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	Y	175	175	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	R	97	97	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	L	336	336	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	F	173	173	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	K	262	262	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	I	267	267	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	T	335	335	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	Q	263	263	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	T	170	170	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	A	260	260	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	K	331	331	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	V	256	256	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	R	165	165	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	Q	96	96	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	Q	176	176	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	K	266	266	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	A	168	168	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	S	177	177	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	R	174	174	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	P	172	172	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	A	332	332	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	I	169	169	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	E	259	259	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	24	V	264	264	putative G protein interaction site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	D	147	147	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	S	238	238	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	F	350	350	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	N	373	373	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	W	143	143	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	F	351	351	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	V	151	151	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	F	227	227	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	S	237	237	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	V	128	128	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	T	229	229	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	Y	233	233	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	Y	377	377	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	A	234	234	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	I	127	127	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	N	354	354	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	S	241	241	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	V	148	148	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	V	370	370	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	W	347	347	ligand binding site
3569NNqeHr	e1a91f16efb0668a97c34da457e6ffe4	505	CDD-3.21	cd15958	68	397	21	W	374	374	ligand binding site
LyQLXoWM3w	4c5e4c759e70045887467af808c019d9	562	PIRSR-2023_05	PIRSR600732-3	94	277	1	CDVWAAVDVLCCTASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWAVALVVSVGPLLGWKEPVPPDER-FC	163	240	DISULFID: 
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
UbOXxgqZMz	731aa2cea805edaa4c91270a42d99c7d	361	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
AbWx53yYyk	75d24078a9e8e391c9b3dba7cba87a12	413	PIRSR-2023_05	PIRSR600732-1	236	308	1	Q	284	284	BINDING: Zn(2+)
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	Y	127	127	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	D	131	131	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	F	415	415	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	Y	398	398	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	F	419	419	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	S	214	214	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	Y	423	423	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	W	391	391	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	V	132	132	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	I	211	211	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	S	218	218	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	F	394	394	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	C	135	135	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	C	215	215	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	L	204	204	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	F	395	395	putative ligand binding site
67XC96RkEo	0d848ae5b6a39ce3e7ea9cfe0e681808	458	CDD-3.21	cd15323	60	444	17	T	136	136	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	I	135	135	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	R	347	347	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	F	324	324	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	T	143	143	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	A	223	223	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	C	207	207	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	E	346	346	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	L	350	350	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	F	323	323	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	R	330	330	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	V	139	139	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	S	219	219	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	C	142	142	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	F	134	134	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	F	343	343	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	Y	354	354	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	D	138	138	putative ligand binding site
2lLPbY3bIA	d20fe7a8d046ce3cb214b14821db30c4	401	CDD-3.21	cd15329	58	375	18	W	320	320	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	I	108	108	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	W	287	287	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	F	290	290	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	F	291	291	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	V	112	112	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	A	197	197	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	L	313	313	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	C	181	181	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	S	310	310	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	C	115	115	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	S	193	193	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	Y	317	317	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	T	116	116	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	K	309	309	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	D	111	111	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	W	107	107	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	I	297	297	putative ligand binding site
IUyjhDUGkz	28d22ed3e7840753998c7125c4562b62	346	CDD-3.21	cd15328	31	338	18	P	306	306	putative ligand binding site
dT2QRC51E8	7980d4fa154a41ce972c53ec2e6bbb5d	447	PIRSR-2023_05	PIRSR600732-5	363	444	1	C	443	443	LIPID: S-palmitoyl cysteine
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	F	409	409	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	T	139	139	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	N	426	426	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	S	430	430	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	S	217	217	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	T	433	433	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	Y	437	437	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	V	135	135	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	C	138	138	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	E	416	416	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	D	134	134	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	W	130	130	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	I	131	131	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	F	410	410	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	A	221	221	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	W	406	406	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	C	205	205	ligand binding site
teZpHBAKLp	d32154e887e9c4185d1fdee9bfda0f00	468	CDD-3.21	cd15064	55	458	18	R	429	429	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	PIRSR-2023_05	PIRSR600732-3	42	243	1	CDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISISLPPFF-WRQAKAEEEVSEC	122	199	DISULFID: 
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	T	134	134	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	F	351	351	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	S	212	212	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	I	130	130	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	W	125	125	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	L	126	126	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	M	337	337	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	C	133	133	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	T	355	355	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	Y	359	359	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	A	216	216	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	W	327	327	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	D	129	129	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	F	330	330	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	C	199	199	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	F	331	331	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	D	352	352	ligand binding site
f41q2OxOjA	1c11502ef3faec838e3b00408305257f	390	CDD-3.21	cd15333	46	380	18	L	348	348	ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	F	366	366	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	F	367	367	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	Y	394	394	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	V	188	188	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	A	273	273	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	S	276	276	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	S	280	280	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	T	192	192	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	D	187	187	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	F	390	390	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	W	183	183	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	Y	370	370	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	S	191	191	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	V	386	386	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	F	266	266	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	S	277	277	putative ligand binding site
5pppL0RrpQ	3aa595fa0656c233a8ceec96ee7e2bbe	428	CDD-3.21	cd15066	109	415	17	W	363	363	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	PIRSR-2023_05	PIRSR600732-5	362	449	1	C	449	449	LIPID: S-palmitoyl cysteine
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	W	388	388	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	D	185	185	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	V	186	186	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	R	415	415	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	F	392	392	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	I	182	182	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	C	254	254	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	T	190	190	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	E	414	414	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	L	418	418	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	F	391	391	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	R	398	398	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	A	270	270	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	F	181	181	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	L	411	411	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	S	266	266	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	Y	422	422	putative ligand binding site
HPGR8QqxLN	ae998fa619292aa1fef9177a3199ee85	479	CDD-3.21	cd15329	105	443	18	C	189	189	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	PIRSR-2023_05	PIRSR600732-5	261	356	1	C	352	352	LIPID: S-palmitoyl cysteine
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	PIRSR-2023_05	PIRSR600732-5	261	356	1	C	353	353	LIPID: S-palmitoyl cysteine
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	R	96	96	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	D	100	100	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	W	296	296	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	V	101	101	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	W	318	318	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	C	197	197	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	N	303	303	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	S	198	198	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	L	322	322	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	T	105	105	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	A	201	201	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	F	300	300	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	F	187	187	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	F	299	299	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	Y	326	326	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	T	104	104	putative ligand binding site
gtfqVz6DRg	ef5cdb6ee3270f2078f896e024a52821	422	CDD-3.21	cd15056	21	347	17	A	194	194	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	W	105	105	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	C	182	182	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	M	317	317	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	E	327	327	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	C	113	113	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	T	106	106	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	L	334	334	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	W	307	307	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	D	109	109	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	S	331	331	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	V	110	110	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	S	198	198	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	F	310	310	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	F	311	311	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	Y	338	338	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	F	330	330	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	T	114	114	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	CDD-3.21	cd15331	29	359	18	A	194	194	putative ligand binding site
lSJwJYUL1Y	ab8b459164068cac661a8b5f73e638fa	373	PIRSR-2023_05	PIRSR600732-5	281	364	1	C	364	364	LIPID: S-palmitoyl cysteine
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	PIRSR-2023_05	PIRSR601681-50	37	214	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNN---ADQNEC	107	182	DISULFID: 
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	C	118	118	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	F	110	110	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	H	393	393	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	T	412	412	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	D	114	114	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	Y	408	408	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	S	194	194	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	V	190	190	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	F	390	390	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	S	193	193	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	F	389	389	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	Y	416	416	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	CDD-3.21	cd15309	35	437	13	V	115	115	putative ligand binding site
uytfIsKji3	18e89a4dd87388f86806f1dee3865a4d	443	PIRSR-2023_05	PIRSR600732-5	364	443	1	C	443	443	LIPID: S-palmitoyl cysteine
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	PIRSR-2023_05	PIRSR600732-5	27	336	1	C	333	333	LIPID: S-palmitoyl cysteine
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	PIRSR-2023_05	PIRSR600732-5	27	336	1	C	332	332	LIPID: S-palmitoyl cysteine
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	W	276	276	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	F	191	191	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	V	108	108	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	W	298	298	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	A	198	198	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	N	283	283	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	L	302	302	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	T	111	111	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	F	280	280	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	T	112	112	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	D	107	107	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	F	279	279	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	Y	306	306	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	C	201	201	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	S	202	202	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	R	103	103	putative ligand binding site
jr16YVdriy	b5111472946e6bbcefdb17f30160bd23	369	CDD-3.21	cd15056	27	327	17	A	205	205	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	PIRSR-2023_05	PIRSR600732-5	261	355	1	C	352	352	LIPID: S-palmitoyl cysteine
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	PIRSR-2023_05	PIRSR600732-5	261	355	1	C	353	353	LIPID: S-palmitoyl cysteine
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	R	96	96	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	D	100	100	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	W	296	296	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	V	101	101	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	W	318	318	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	C	197	197	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	N	303	303	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	S	198	198	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	L	322	322	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	T	105	105	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	A	201	201	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	F	300	300	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	F	187	187	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	F	299	299	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	Y	326	326	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	T	104	104	putative ligand binding site
clTHPO2kTP	94c256175f34923a8d840d355267f3bc	422	CDD-3.21	cd15056	21	347	17	A	194	194	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	S	190	190	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	T	406	406	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	F	383	383	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	Y	410	410	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	V	112	112	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	H	387	387	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	V	187	187	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	C	115	115	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	Y	402	402	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	S	191	191	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	D	111	111	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	F	107	107	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	CDD-3.21	cd15309	32	431	13	F	384	384	putative ligand binding site
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	PIRSR-2023_05	PIRSR601681-50	30	212	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMIAVVWVLSFAISSPILFGLN---KADEKEC	104	179	DISULFID: 
DycssgzfqZ	6e66c6e5dfdc201ed0d965e448bd5c2c	437	PIRSR-2023_05	PIRSR600732-5	358	437	1	C	437	437	LIPID: S-palmitoyl cysteine
fm80Plhz7F	98bd2c82ee5b705878d0363aeb595f54	445	PIRSR-2023_05	PIRSR600732-5	350	438	1	C	438	438	LIPID: S-palmitoyl cysteine
fm80Plhz7F	98bd2c82ee5b705878d0363aeb595f54	445	PIRSR-2023_05	PIRSR600732-1	36	213	1	E	187	187	BINDING: Zn(2+)
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	W	281	281	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	R	107	107	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	W	303	303	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	N	288	288	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	F	285	285	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	L	307	307	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	C	207	207	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	V	112	112	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	T	115	115	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	A	211	211	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	Y	311	311	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	F	284	284	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	T	116	116	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	F	197	197	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	D	111	111	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	A	204	204	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	CDD-3.21	cd15056	31	332	17	S	208	208	putative ligand binding site
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	PIRSR-2023_05	PIRSR600732-5	32	347	1	C	337	337	LIPID: S-palmitoyl cysteine
Y6nMrUpOQy	dee2b25f0ce176934fb8a8168e370750	398	PIRSR-2023_05	PIRSR600732-5	32	347	1	C	338	338	LIPID: S-palmitoyl cysteine
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	T	118	118	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	T	305	305	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	Y	309	309	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	W	109	109	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	F	301	301	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	N	286	286	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	S	203	203	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	A	200	200	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	W	279	279	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	D	113	113	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	S	204	204	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	S	207	207	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	V	114	114	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	F	282	282	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	S	117	117	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	F	283	283	putative ligand binding site
P8yRGntCTB	f356e572467ba4b80bfe7a01b6e0f506	399	CDD-3.21	cd15065	35	330	17	L	193	193	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	328	328	LIPID: S-palmitoyl cysteine
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	329	329	LIPID: S-palmitoyl cysteine
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	L	298	298	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	R	96	96	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	D	100	100	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	A	193	193	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	F	276	276	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	V	101	101	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	F	275	275	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	Y	302	302	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	A	200	200	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	T	105	105	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	C	196	196	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	F	186	186	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	W	272	272	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	S	197	197	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	W	294	294	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	T	104	104	putative ligand binding site
vdPYG5iEsD	8ab795d41060f40fdcc184b02f676ba8	388	CDD-3.21	cd15056	20	323	17	N	279	279	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
x6hjTTBMdw	50e34b84d4a6713c9b1d0b253c0bdea8	366	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	Y	372	372	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	I	156	156	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	E	364	364	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	L	368	368	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	A	244	244	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	V	160	160	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	L	361	361	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	F	342	342	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	C	163	163	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	C	228	228	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	W	338	338	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	T	164	164	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	F	341	341	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	R	348	348	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	D	159	159	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	F	155	155	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	S	240	240	putative ligand binding site
D2Ut2I6kRR	2ddf5372b6ebd421202262c120c70f1a	440	CDD-3.21	cd15329	80	393	18	R	365	365	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	PIRSR-2023_05	PIRSR600732-3	30	200	1	CDGLMTMDVMLCTASIFNLCAISVDRFIAVSVPLNYNRKHVDHRQLVLLSATWLLALAVASPVIFGIN-NVPDRDPSAC	96	173	DISULFID: 
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	F	329	329	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	M	349	349	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	C	107	107	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	S	185	185	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	T	353	353	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	Y	357	357	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	L	99	99	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	D	103	103	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	H	333	333	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	V	181	181	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	S	184	184	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	F	330	330	putative ligand binding site
SHrMCYIrqF	1cccd7603793dcd53f4c5b9c1b1f1551	386	CDD-3.21	cd15308	25	373	13	V	104	104	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	328	328	LIPID: S-palmitoyl cysteine
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	329	329	LIPID: S-palmitoyl cysteine
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	L	298	298	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	R	96	96	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	D	100	100	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	A	193	193	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	F	276	276	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	V	101	101	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	F	275	275	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	Y	302	302	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	A	200	200	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	T	105	105	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	C	196	196	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	F	186	186	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	W	272	272	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	S	197	197	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	W	294	294	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	T	104	104	putative ligand binding site
kUVHDKaGRa	e6ea0e81046e1417289170d977eee671	378	CDD-3.21	cd15056	20	323	17	N	279	279	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	F	286	286	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	A	192	192	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	F	287	287	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	Y	312	312	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	S	290	290	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	V	107	107	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	C	110	110	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	S	193	193	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	T	196	196	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	T	308	308	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	D	106	106	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	S	111	111	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	L	182	182	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	V	189	189	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	W	283	283	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	W	102	102	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	CDD-3.21	cd15054	29	333	17	F	304	304	putative ligand binding site
ZvBC32nrED	9ec12ec7449ccd9f8a8bc4d346527d29	440	PIRSR-2023_05	PIRSR600732-5	262	341	1	C	339	339	LIPID: S-palmitoyl cysteine
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	328	328	LIPID: S-palmitoyl cysteine
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	329	329	LIPID: S-palmitoyl cysteine
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	L	298	298	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	R	96	96	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	D	100	100	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	A	193	193	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	F	276	276	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	V	101	101	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	F	275	275	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	Y	302	302	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	A	200	200	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	T	105	105	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	C	196	196	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	F	186	186	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	W	272	272	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	S	197	197	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	W	294	294	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	T	104	104	putative ligand binding site
E8K9Lsf3mp	201ccfd0ab05d7260a93e7ff17af4923	387	CDD-3.21	cd15056	20	323	17	N	279	279	putative ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	F	457	457	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	V	113	113	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	S	116	116	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	S	194	194	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	N	436	436	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	F	184	184	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	Y	108	108	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	F	433	433	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	S	193	193	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	D	112	112	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	T	461	461	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	F	432	432	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	Y	465	465	ligand binding site
DaLSr5U1Cs	ea53c5d9671600202f0a3601650cba3c	502	CDD-3.21	cd15053	33	486	14	I	190	190	ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	PIRSR-2023_05	PIRSR601681-50	3	190	1	CDAWTSLDVLLCTASILNLCMISVDRYFVITRPFQYAMKRTPSRMALMIVAVWLGSALISIPPLLGWKTDSSSG--YC	84	159	DISULFID: 
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	A	171	171	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	W	303	303	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	V	92	92	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	S	324	324	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	A	175	175	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	F	306	306	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	C	95	95	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	C	159	159	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	F	307	307	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	T	96	96	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	Y	332	332	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	D	91	91	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	W	87	87	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	D	321	321	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	L	328	328	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	S	325	325	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	T	88	88	putative ligand binding site
fuPQWxprqQ	7a567f3ae70915ea4ecd3d32ddccc5c8	430	CDD-3.21	cd15329	12	353	18	K	313	313	putative ligand binding site
Z51fe4z5fd	07fba853201335874e0a45078ee39c80	485	PIRSR-2023_05	PIRSR600732-3	43	229	1	CDVWAAMDVLCCTASIMSLCVISVDRYIGVSYPLQYPSIVTERRALLALIALWVLSITISIGPLFGWKEPAPDDES-IC	113	190	DISULFID: 
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	R	96	96	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	D	100	100	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	W	296	296	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	V	101	101	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	W	318	318	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	C	197	197	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	N	303	303	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	S	198	198	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	L	322	322	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	T	105	105	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	A	201	201	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	F	300	300	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	F	187	187	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	F	299	299	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	Y	326	326	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	T	104	104	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	CDD-3.21	cd15056	21	347	17	A	194	194	putative ligand binding site
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	PIRSR-2023_05	PIRSR600732-5	261	356	1	C	352	352	LIPID: S-palmitoyl cysteine
0VMSCN3tjm	5110f3ac2249d967477e7d56d96c5afd	388	PIRSR-2023_05	PIRSR600732-5	261	356	1	C	353	353	LIPID: S-palmitoyl cysteine
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	PIRSR-2023_05	PIRSR600732-5	258	329	1	C	328	328	LIPID: S-palmitoyl cysteine
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	PIRSR-2023_05	PIRSR603912-52	3	186	1	CNMWVAFDITCCTASILNLCMISVDRYLAITKPLTYGVRRRSRRTYVSIGLTWVMSTLVSVPPLLILGNEHG--TEDNPTC	64	142	DISULFID: 
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	L	298	298	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	S	158	158	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	C	75	75	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	W	271	271	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	R	294	294	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	T	76	76	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	S	295	295	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	D	71	71	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	F	274	274	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	W	67	67	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	F	275	275	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	Y	302	302	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	H	291	291	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	A	154	154	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	C	142	142	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	V	68	68	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	R	281	281	putative ligand binding site
tFlbflcyeH	b9458eb547676474df3ef05cf46abcf9	400	CDD-3.21	cd15329	1	323	18	I	72	72	putative ligand binding site
KWEyzSYbsA	faf6503d713d68bd6a3259e697559777	553	PIRSR-2023_05	PIRSR600732-3	76	264	1	CDFYIALDVTCSTASIFNLVAISIDRFIAVTQPIKYSKHKNNNRVILTIAIVWIVSAAIGSPIVLGLNT-TPERTPQLC	144	221	DISULFID: 
KWEyzSYbsA	faf6503d713d68bd6a3259e697559777	553	PIRSR-2023_05	PIRSR600732-1	459	544	1	Q	504	504	BINDING: Zn(2+)
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	I	87	87	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	T	91	91	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	S	174	174	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	F	286	286	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	M	163	163	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	W	282	282	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	F	285	285	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	Y	312	312	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	C	90	90	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	I	304	304	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	S	173	173	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	A	170	170	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	D	86	86	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	S	177	177	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	W	82	82	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	T	308	308	putative ligand binding site
VJ03mkFSMH	6085802890eaa455f3998f377e9935c7	402	CDD-3.21	cd15065	7	333	17	N	289	289	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	PIRSR-2023_05	PIRSR600732-3	38	217	1	CHIWISFDVLCCTASIWNVTAIALDRYWSITRHLEYTLKTRKRISNIMILLTWLLSAVISLSPLFGWGETYSE-VNEEC	109	186	DISULFID: 
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	W	292	292	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	D	116	116	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	L	318	318	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	C	186	186	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	N	302	302	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	V	117	117	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	I	113	113	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	F	296	296	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	A	202	202	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	S	315	315	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	K	314	314	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	S	198	198	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	F	295	295	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	Y	322	322	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	T	121	121	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	W	112	112	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	C	120	120	putative ligand binding site
UVrYrLk3IT	527ab4b7ae24dfcf6980b645569b8af8	351	CDD-3.21	cd15328	36	343	18	P	311	311	putative ligand binding site
VQxoUcUS8X	d6512fd40b23f9ccc64c6bef8ca0fdd3	347	PIRSR-2023_05	PIRSR600732-5	267	345	1	C	343	343	LIPID: S-palmitoyl cysteine
VQxoUcUS8X	d6512fd40b23f9ccc64c6bef8ca0fdd3	347	PIRSR-2023_05	PIRSR600732-3	14	194	1	CEAWLSLDMTCCTCSILHLCVIALDRYWAITDAVEYARKRTARRACVMILSVWAISTLISMPPLF-WRRYDANSTSEKC	78	155	DISULFID: 
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	C	198	198	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	Y	399	399	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	I	124	124	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	W	367	367	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	D	388	388	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	A	214	214	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	G	391	391	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	N	395	395	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	S	210	210	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	F	370	370	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	F	371	371	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	V	128	128	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	L	377	377	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	C	131	131	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	A	392	392	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	T	132	132	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	D	127	127	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	CDD-3.21	cd15330	48	420	18	F	123	123	putative ligand binding site
jf8HZslfsd	a2ec6784e6a8e10d4084452bb7ff26b7	431	PIRSR-2023_05	PIRSR603912-52	65	234	1	CDIFISLDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAVLISLTWLIGFLISIPPMLGWRTPE-DRSNPDAC	120	198	DISULFID: 
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	PIRSR-2023_05	PIRSR600732-3	34	210	1	CDALMTMDVMLCTASIFNLCAISVDRFIAVSVPLNYNRRQIDLRQLILISTTWIFAFAVASPVIFGLNN-VPNRDPSLC	102	179	DISULFID: 
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	S	190	190	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	C	113	113	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	I	187	187	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	F	322	322	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	T	341	341	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	L	105	105	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	D	109	109	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	F	321	321	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	V	110	110	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	T	345	345	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	Y	349	349	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	S	191	191	putative ligand binding site
wDULa2IxJn	9b50587e102668382fbd493ed8a25be8	378	CDD-3.21	cd15308	46	370	13	H	325	325	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	PIRSR-2023_05	PIRSR600732-1	64	242	1	E	216	216	BINDING: Zn(2+)
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	S	227	227	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	F	382	382	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	I	220	220	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	F	383	383	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	Y	410	410	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	Y	133	133	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	D	137	137	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	V	138	138	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	F	402	402	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	F	406	406	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	T	142	142	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	Y	386	386	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	I	213	213	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	S	223	223	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	W	379	379	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	S	224	224	putative ligand binding site
FM3U96ERbZ	c008a2fd7eece58014e919fab282faa1	444	CDD-3.21	cd15322	58	431	17	C	141	141	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	D	110	110	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	Y	362	362	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	W	106	106	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	V	378	378	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	S	194	194	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	W	355	355	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	T	115	115	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	A	195	195	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	S	198	198	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	F	358	358	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	T	382	382	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	L	184	184	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	F	359	359	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	Y	386	386	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	V	111	111	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	V	191	191	putative ligand binding site
3qTi4z1Qys	2cdf16dd23760968010953ac35983e61	415	CDD-3.21	cd15060	31	407	17	C	114	114	putative ligand binding site
EU6bNBzxiI	d8a6b3bf914cc17644fbae794fbb329b	540	PIRSR-2023_05	PIRSR600732-5	449	540	1	C	540	540	LIPID: S-palmitoyl cysteine
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	D	116	116	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	S	199	199	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	T	431	431	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	Y	435	435	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	V	117	117	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	F	408	408	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	S	198	198	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	F	407	407	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	Y	427	427	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	C	120	120	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	F	112	112	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	H	411	411	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	CDD-3.21	cd15310	36	456	13	V	195	195	ligand binding site
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	PIRSR-2023_05	PIRSR600732-1	376	462	1	Q	418	418	BINDING: Zn(2+)
CaDxTYwAEc	62891285eca3b3024b88c206b5283b64	462	PIRSR-2023_05	PIRSR600732-5	376	462	1	C	462	462	LIPID: S-palmitoyl cysteine
9yBRcXGPW3	00d42d61433fdcc899452bcf607eb5aa	428	PIRSR-2023_05	PIRSR600732-5	343	423	1	C	423	423	LIPID: S-palmitoyl cysteine
9yBRcXGPW3	00d42d61433fdcc899452bcf607eb5aa	428	PIRSR-2023_05	PIRSR600732-1	343	423	1	Q	378	378	BINDING: Zn(2+)
vWTrh9ORZB	33a9e7de37259511e85932ed1ae1f6a2	412	PIRSR-2023_05	PIRSR600732-3	14	133	1	CDFYIAVDVTCSTASIFNLVAISIDRYIAVTQPIKYSKHKNSTRVSLTIAIVWLVSAAIGSPIVLGLNT-SPERTPQLC	14	91	DISULFID: 
tK9Y1h0vmG	aa931a067b2b6fb6ddb95abfe2680f84	408	PIRSR-2023_05	PIRSR600732-3	33	226	1	CDALMTLDVMLCTASIYNLCAISLDRFIAVRAPLHYEHKRVNVRQAALITATWLLSLALASPLALGA-NSNPERDPAVC	94	171	DISULFID: 
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	PIRSR-2023_05	PIRSR600732-5	293	370	1	C	370	370	LIPID: S-palmitoyl cysteine
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	I	199	199	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	L	319	319	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	F	335	335	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	S	210	210	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	W	312	312	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	F	339	339	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	V	128	128	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	Y	343	343	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	C	131	131	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	S	209	209	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	F	316	316	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	T	132	132	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	A	206	206	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	D	127	127	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	W	123	123	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	S	213	213	putative ligand binding site
Ih0FYSZPuQ	8a74c96b1c7a8dea3b86a5bcc215a185	505	CDD-3.21	cd15326	48	364	17	F	315	315	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	S	174	174	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	F	254	254	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	D	84	84	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	Y	282	282	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	G	274	274	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	F	253	253	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	V	85	85	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	F	163	163	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	S	173	173	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	S	88	88	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	A	170	170	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	F	278	278	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	S	177	177	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	T	89	89	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	F	250	250	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	F	80	80	putative ligand binding site
09y9SNapkT	fe583826e7d50fa484ebe217da02cde3	342	CDD-3.21	cd15066	6	303	17	Y	257	257	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	T	139	139	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	A	219	219	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	C	203	203	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	W	319	319	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	V	135	135	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	S	215	215	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	C	138	138	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	F	130	130	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	F	322	322	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	F	323	323	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	R	346	346	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	I	342	342	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	D	134	134	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	E	345	345	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	L	349	349	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	R	329	329	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	I	131	131	putative ligand binding site
NFdSHjAYfb	dc0aff0aa5d3f36e46e7e462ff3dd0c5	400	CDD-3.21	cd15329	54	374	18	Y	353	353	putative ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	PIRSR-2023_05	PIRSR600732-5	237	318	1	C	318	318	LIPID: S-palmitoyl cysteine
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	A	155	155	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	D	83	83	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	W	260	260	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	F	79	79	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	I	162	162	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	N	267	267	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	T	284	284	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	C	154	154	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	Y	291	291	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	G	165	165	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	V	80	80	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	F	264	264	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	V	283	283	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	F	161	161	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	S	166	166	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	T	270	270	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	F	263	263	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	V	84	84	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	A	169	169	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	V	287	287	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	C	87	87	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	L	156	156	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	T	88	88	ligand binding site
XIKdpG1v5e	ea483dc7b72f8b96b20763ea9a77a031	320	CDD-3.21	cd15052	1	312	24	T	280	280	ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	V	166	166	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	E	369	369	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	L	373	373	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	I	162	162	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	R	353	353	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	C	234	234	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	T	170	170	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	L	366	366	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	Y	377	377	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	A	250	250	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	F	161	161	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	S	246	246	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	W	343	343	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	C	169	169	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	F	346	346	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	F	347	347	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	R	370	370	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	CDD-3.21	cd15329	100	398	18	D	165	165	putative ligand binding site
48Sc9kpdTf	32e5fedee56e521702fb2a291afbd8c4	470	PIRSR-2023_05	PIRSR600732-5	320	404	1	C	404	404	LIPID: S-palmitoyl cysteine
x8LfXFPDl9	c93bb367aa8f8e2ba74fe061da9c9a84	454	PIRSR-2023_05	PIRSR600732-5	370	454	1	C	454	454	LIPID: S-palmitoyl cysteine
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	PIRSR-2023_05	PIRSR600732-1	9	211	1	E	166	166	BINDING: Zn(2+)
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	W	345	345	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	I	87	87	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	T	91	91	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	V	374	374	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	Y	378	378	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	F	349	349	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	C	90	90	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	V	170	170	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	L	163	163	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	S	173	173	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	D	86	86	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	S	177	177	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	W	82	82	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	F	348	348	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	A	174	174	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	Y	352	352	putative ligand binding site
VuLMFqp5mG	5929f55737801a679e47df43e5d5da2a	409	CDD-3.21	cd15060	7	399	17	T	370	370	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	PIRSR-2023_05	PIRSR600732-5	32	347	1	C	337	337	LIPID: S-palmitoyl cysteine
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	PIRSR-2023_05	PIRSR600732-5	32	347	1	C	338	338	LIPID: S-palmitoyl cysteine
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	W	281	281	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	R	107	107	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	W	303	303	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	N	288	288	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	F	285	285	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	L	307	307	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	C	207	207	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	V	112	112	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	T	115	115	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	A	211	211	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	Y	311	311	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	F	284	284	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	T	116	116	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	F	197	197	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	D	111	111	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	A	204	204	putative ligand binding site
QBg3LSoLAM	a4762275cadfe8b4aa6c975ad28b4743	381	CDD-3.21	cd15056	31	332	17	S	208	208	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	PIRSR-2023_05	PIRSR600732-5	16	326	1	C	323	323	LIPID: S-palmitoyl cysteine
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	PIRSR-2023_05	PIRSR600732-5	16	326	1	C	322	322	LIPID: S-palmitoyl cysteine
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	D	94	94	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	A	187	187	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	F	270	270	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	F	180	180	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	W	266	266	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	F	269	269	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	Y	296	296	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	L	292	292	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	R	90	90	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	T	99	99	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	C	190	190	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	V	95	95	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	S	191	191	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	W	288	288	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	T	98	98	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	N	273	273	putative ligand binding site
hou19uAfhI	cb6f8b2aa5a7d1ddb9611a2c0c90231f	381	CDD-3.21	cd15056	14	317	17	A	194	194	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	S	195	195	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	S	206	206	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	F	286	286	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	D	116	116	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	F	287	287	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	S	205	205	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	S	120	120	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	A	202	202	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	N	290	290	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	V	318	318	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	S	209	209	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	I	117	117	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	T	121	121	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	W	322	322	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	W	112	112	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	F	314	314	putative ligand binding site
bNwOjoRIYA	fb4f608b9e5796f9e1065b6cf33990af	433	CDD-3.21	cd15057	57	342	17	W	283	283	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	D	110	110	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	Y	362	362	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	W	106	106	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	V	378	378	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	S	194	194	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	W	355	355	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	T	115	115	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	A	195	195	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	S	198	198	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	F	358	358	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	T	382	382	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	L	184	184	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	F	359	359	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	Y	386	386	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	V	111	111	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	V	191	191	putative ligand binding site
xcMk1Ave5t	c58db2d6abc1cfa89c53a468b747de97	415	CDD-3.21	cd15060	31	407	17	C	114	114	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	S	227	227	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	F	409	409	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	Y	436	436	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	S	318	318	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	L	304	304	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	V	224	224	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	T	432	432	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	S	315	315	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	N	413	413	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	F	428	428	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	T	228	228	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	A	311	311	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	D	223	223	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	S	314	314	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	F	410	410	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	W	219	219	putative ligand binding site
Y0GHOyCxJS	478ebc8bd4331e4f83507ab4528a867a	511	CDD-3.21	cd15065	145	457	17	W	406	406	putative ligand binding site
AEVEctaMi5	6a19629c45c9de11378fc4d8e23cf38f	413	PIRSR-2023_05	PIRSR600732-5	273	378	1	C	371	371	LIPID: S-palmitoyl cysteine
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
XqqViB6x8a	8226d89472c9bf35bf764480bde5fa51	359	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	L	186	186	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	Y	276	276	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	A	299	299	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	Y	303	303	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	I	108	108	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	A	193	193	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	A	196	196	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	A	197	197	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	T	112	112	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	W	273	273	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	D	107	107	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	W	295	295	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	H	103	103	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	S	111	111	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	F	277	277	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	C	200	200	putative ligand binding site
wocISO5rSY	401690a513b2a252859a3c801a40a8bd	343	CDD-3.21	cd15055	32	324	17	T	280	280	putative ligand binding site
Emh5GVVBM7	1e17fc9e56dfb2aeaa7e6596d06d2130	495	PIRSR-2023_05	PIRSR600732-5	289	365	1	C	365	365	LIPID: S-palmitoyl cysteine
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	S	195	195	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	T	118	118	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	S	196	196	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	Y	389	389	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	S	199	199	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	F	386	386	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	I	192	192	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	Y	414	414	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	W	382	382	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	C	117	117	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	F	385	385	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	F	406	406	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	Y	109	109	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	D	113	113	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	V	114	114	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	F	410	410	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	CDD-3.21	cd15323	34	435	17	I	185	185	putative ligand binding site
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	PIRSR-2023_05	PIRSR600732-3	39	214	1	CDIYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKGMIVVVWLISAVISFPPLISMDRSSNETVPQ-C	106	183	DISULFID: 
XGas1ggnUa	10a2c573de7ebd38f69305e8dc251e40	447	PIRSR-2023_05	PIRSR600732-5	363	440	1	C	440	440	LIPID: S-palmitoyl cysteine
2XFOHJovxN	2c617fd308ca0ac0a3d09241f7e7a0f9	345	PIRSR-2023_05	PIRSR601681-50	29	338	1	CRLHTWLDYSLTTSSVAHLACVAADRSVAIGDPLRYRERVTPAAVALMVGLCWLSLAGYAVPILAFWPTVMVPEP--C	106	181	DISULFID: 
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	PIRSR-2023_05	PIRSR600732-5	343	423	1	C	423	423	LIPID: S-palmitoyl cysteine
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	Y	372	372	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	F	393	393	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	C	102	102	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	D	98	98	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	S	183	183	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	W	365	365	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	S	187	187	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	F	369	369	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	I	180	180	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	L	173	173	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	Y	397	397	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	F	389	389	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	T	103	103	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	F	368	368	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	I	94	94	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	V	99	99	putative ligand binding site
UW8C8HS7IW	0b6b881b2bc6492f7cf9c4bea0cfc66c	431	CDD-3.21	cd15321	15	418	17	T	184	184	putative ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	PIRSR-2023_05	PIRSR600732-5	343	437	1	C	437	437	LIPID: S-palmitoyl cysteine
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	F	382	382	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	T	406	406	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	F	383	383	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	Y	410	410	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	C	124	124	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	V	199	199	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	L	116	116	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	D	120	120	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	F	193	193	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	S	203	203	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	V	121	121	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	H	386	386	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	Y	402	402	ligand binding site
PbiyEu1KSF	dbe9723f625135112156310456803c2c	437	CDD-3.21	cd15053	41	431	14	S	202	202	ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	PIRSR-2023_05	PIRSR600732-5	23	347	1	C	325	325	LIPID: S-palmitoyl cysteine
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	Y	100	100	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	S	201	201	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	V	295	295	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	W	269	269	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	D	104	104	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	F	291	291	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	N	276	276	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	F	273	273	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	S	198	198	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	S	108	108	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	L	187	187	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	Y	299	299	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	S	197	197	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	I	105	105	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	T	109	109	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	F	272	272	putative ligand binding site
S1yXuhpUCg	5c55e8b4e0ab60d0a802a73eeab8b562	434	CDD-3.21	cd15057	36	319	17	A	194	194	putative ligand binding site
OjBEL2xomu	858c27bd0480bafb83933a7a7bc63265	456	PIRSR-2023_05	PIRSR600732-5	296	321	1	C	321	321	LIPID: S-palmitoyl cysteine
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	W	105	105	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	S	227	227	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	F	409	409	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	A	224	224	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	F	431	431	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	V	220	220	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	L	213	213	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	C	113	113	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	Y	435	435	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	D	109	109	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	F	408	408	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	Y	412	412	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	V	110	110	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	S	223	223	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	W	405	405	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	T	114	114	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	CDD-3.21	cd15063	30	456	17	F	427	427	putative ligand binding site
PMbKXaBN6F	6d94cbfc03cecf9cb79a5c987e8db770	494	PIRSR-2023_05	PIRSR600732-5	377	462	1	C	461	461	LIPID: S-palmitoyl cysteine
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	V	86	86	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	S	89	89	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	F	255	255	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	A	182	182	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	W	248	248	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	H	270	270	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	L	274	274	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	F	252	252	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	K	181	181	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	V	178	178	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	S	90	90	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	Y	171	171	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	Y	251	251	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	Y	278	278	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	I	185	185	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	Y	81	81	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	CDD-3.21	cd15051	5	299	17	D	85	85	putative ligand binding site
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	PIRSR-2023_05	PIRSR600732-5	10	309	1	C	304	304	LIPID: S-palmitoyl cysteine
jW1iHKeXfb	f64578e7acc68e42124a47464ef129fd	335	PIRSR-2023_05	PIRSR600732-5	10	309	1	C	306	306	LIPID: S-palmitoyl cysteine
rBn0zuuQO5	7e74e2a2d76bd9ecbae03f8e9e00a1f9	472	PIRSR-2023_05	PIRSR600732-3	51	238	1	CNIWAATDVLCCTASINSLCVISVDRYIGVTRPLTYSSLVTHGKAIVACILVWVLSIAISVGPLLGWKEPPPKDPF-VC	123	200	DISULFID: 
rBn0zuuQO5	7e74e2a2d76bd9ecbae03f8e9e00a1f9	472	PIRSR-2023_05	PIRSR600732-5	304	382	1	C	381	381	LIPID: S-palmitoyl cysteine
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	PIRSR-2023_05	PIRSR601681-50	55	227	1	CDIFTSLDVILCTASILNLCMISVDRYLVITRPFQYAMKRTPRRMGAMIASVWVLSVVISIPPLLGWKS--EKPAYVC	123	198	DISULFID: 
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	C	134	134	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	C	198	198	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	F	126	126	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	M	376	376	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	S	377	377	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	D	130	130	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	W	349	349	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	T	127	127	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	G	373	373	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	F	353	353	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	S	214	214	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	Y	384	384	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	T	135	135	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	R	359	359	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	N	380	380	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	F	352	352	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	V	131	131	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	CDD-3.21	cd15329	51	405	18	A	210	210	putative ligand binding site
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	PIRSR-2023_05	PIRSR600732-5	329	412	1	C	411	411	LIPID: S-palmitoyl cysteine
EAr6xfogzj	7107dc89c5e899185301b55390b1a02e	480	PIRSR-2023_05	PIRSR600732-5	329	412	1	C	410	410	LIPID: S-palmitoyl cysteine
KiDSKnq2NJ	acf84ac7bcb0ebe1beee509eeba25a5f	457	PIRSR-2023_05	PIRSR600732-3	54	236	1	CNIWAATDVLCCTASINSLCVISVDRYIGVTRPLTYSTIVTHKRAVLACILVWLLSVVISVGPLFGWRE-PPPSVPYVC	122	199	DISULFID: 
KiDSKnq2NJ	acf84ac7bcb0ebe1beee509eeba25a5f	457	PIRSR-2023_05	PIRSR600732-5	297	376	1	C	376	376	LIPID: S-palmitoyl cysteine
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	PIRSR-2023_05	PIRSR600732-5	22	304	1	C	304	304	LIPID: S-palmitoyl cysteine
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	C	102	102	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	D	185	185	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	Y	277	277	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	D	98	98	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	F	253	253	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	Y	94	94	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	G	182	182	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	Y	249	249	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	G	186	186	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	V	175	175	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	T	103	103	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	E	269	269	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	F	250	250	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	T	189	189	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	W	246	246	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	L	273	273	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	CDD-3.21	cd15051	19	298	17	V	99	99	putative ligand binding site
tiH4oqPA7P	fc2529606f6600dba770efe065fa1156	421	PIRSR-2023_05	PIRSR600732-1	22	304	1	E	179	179	BINDING: Zn(2+)
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	Y	389	389	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	I	139	139	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	T	143	143	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	V	218	218	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	E	405	405	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	L	211	211	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	F	386	386	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	S	221	221	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	W	382	382	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	F	385	385	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	C	142	142	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	F	134	134	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	S	225	225	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	T	409	409	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	Y	413	413	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	A	222	222	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	CDD-3.21	cd15060	58	434	17	D	138	138	putative ligand binding site
NtmCkSS5sJ	b26d84f3fe29a9ed20cd212adf245b20	455	PIRSR-2023_05	PIRSR600732-5	360	441	1	C	439	439	LIPID: S-palmitoyl cysteine
AsEACEZyje	1e4f5645aa7332c23859b51496843005	413	PIRSR-2023_05	PIRSR600732-5	331	408	1	C	408	408	LIPID: S-palmitoyl cysteine
AsEACEZyje	1e4f5645aa7332c23859b51496843005	413	PIRSR-2023_05	PIRSR603912-52	48	220	1	CDIFIALDVLCCTSSILHLCVIALDRYWAITNPIDYVNKRTPRRAVIMISLTWLVGFSISIPPMLGWRTPE-DRADPNAC	104	182	DISULFID: 
VzinBQX32p	f300adc5d0559217d320d13ddbed8dfe	344	PIRSR-2023_05	PIRSR600732-5	247	324	1	C	324	324	LIPID: S-palmitoyl cysteine
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	T	411	411	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	Y	415	415	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	F	388	388	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	F	109	109	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	H	392	392	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	C	117	117	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	Y	407	407	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	S	193	193	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	D	113	113	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	F	389	389	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	V	114	114	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	V	189	189	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	CDD-3.21	cd15309	35	436	13	S	192	192	putative ligand binding site
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	PIRSR-2023_05	PIRSR601681-50	37	213	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNN---ADQNEC	106	181	DISULFID: 
Fx3ux8IsHK	546e884c961c937eba315390902290b3	442	PIRSR-2023_05	PIRSR600732-5	363	442	1	C	442	442	LIPID: S-palmitoyl cysteine
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	W	105	105	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	S	195	195	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	F	302	302	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	F	303	303	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	S	199	199	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	D	109	109	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	V	110	110	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	S	198	198	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	S	113	113	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	Y	306	306	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	F	327	327	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	F	188	188	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	S	202	202	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	Y	331	331	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	T	114	114	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	W	299	299	putative ligand binding site
Vdy4TAAF9U	da13b4fcf422a3e2393c319328b5e163	384	CDD-3.21	cd15066	31	352	17	V	323	323	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	PIRSR-2023_05	PIRSR600732-5	287	363	1	C	363	363	LIPID: S-palmitoyl cysteine
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	F	308	308	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	I	194	194	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	T	127	127	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	S	205	205	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	F	328	328	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	V	123	123	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	W	305	305	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	C	126	126	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	L	312	312	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	A	201	201	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	S	204	204	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	F	332	332	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	D	122	122	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	F	309	309	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	Y	336	336	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	W	118	118	putative ligand binding site
ylLkHnrsg4	e74b654742fc31bf9503f79a9600242c	500	CDD-3.21	cd15327	43	357	17	S	208	208	putative ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	PIRSR-2023_05	PIRSR600732-5	277	349	1	C	347	347	LIPID: S-palmitoyl cysteine
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	PIRSR-2023_05	PIRSR600732-5	277	349	1	C	346	346	LIPID: S-palmitoyl cysteine
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	V	102	102	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	N	298	298	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	A	209	209	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	L	101	101	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	D	121	121	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	S	212	212	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	T	204	204	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	V	122	122	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	V	314	314	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	W	291	291	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	S	216	216	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	W	318	318	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	F	294	294	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	N	317	317	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	F	295	295	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	W	117	117	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	Y	208	208	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	F	202	202	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	V	125	125	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	S	213	213	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	21	Y	321	321	ligand binding site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	A	235	235	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	R	139	139	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	Q	238	238	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	Y	149	149	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	V	231	231	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	K	237	237	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	I	242	242	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	S	151	151	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	R	148	148	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	I	144	144	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	E	234	234	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	A	276	276	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	F	147	147	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	K	241	241	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	I	143	143	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	I	239	239	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	Q	70	70	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	Q	150	150	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	L	280	280	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	A	142	142	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	T	279	279	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	R	71	71	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	K	275	275	putative G protein interaction site
KoMzCAq4js	6b8b5207ebdcaf7f9474b95ce46c1954	407	CDD-3.21	cd15958	43	341	24	P	146	146	putative G protein interaction site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	D	115	115	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	F	382	382	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	W	111	111	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	S	199	199	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	S	200	200	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	Y	361	361	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	S	203	203	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	F	358	358	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	Y	386	386	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	V	116	116	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	V	196	196	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	W	354	354	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	F	357	357	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	F	378	378	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	C	119	119	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	V	189	189	putative ligand binding site
GETINNmEZ4	ee5b266934623119c4a925e250b58aee	415	CDD-3.21	cd15059	51	407	17	T	120	120	putative ligand binding site
dgGoVeMhfH	bc8ff945fd4ed5873796a099c7541a9a	355	PIRSR-2023_05	PIRSR600732-5	256	352	1	C	352	352	LIPID: S-palmitoyl cysteine
dgGoVeMhfH	bc8ff945fd4ed5873796a099c7541a9a	355	PIRSR-2023_05	PIRSR603912-52	47	212	1	CYVWVSCDVLCCTASIWNVTAIALDRYWSISRHLQYTLKGRRRASTLMISTAWLLSAIISLSPLFGWGNDYYSP--ELLEC	103	181	DISULFID: 
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	V	102	102	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	S	183	183	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	F	322	322	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	F	321	321	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	S	182	182	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	I	341	341	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	T	345	345	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	Y	349	349	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	C	105	105	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	H	325	325	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	L	97	97	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	D	101	101	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	CDD-3.21	cd15308	34	370	13	V	179	179	putative ligand binding site
A83Zj7fGiH	4d49757b270de24db7c59333c91cc1dc	378	PIRSR-2023_05	PIRSR600732-3	16	201	1	CDALMTMDVMLCTASIFNLCAISVDRFIAVSIPLNYNRKHIDHRQIVLISTTWIFAFAVASPVVFGLNN-VPNRDASVC	94	171	DISULFID: 
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	PIRSR-2023_05	PIRSR600732-5	365	444	1	C	444	444	LIPID: S-palmitoyl cysteine
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	PIRSR-2023_05	PIRSR601681-50	26	212	1	CNIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISVVWVLSFAISCPLLFGLNNTEE---NEC	104	179	DISULFID: 
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	S	190	190	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	H	394	394	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	V	112	112	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	Y	409	409	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	V	187	187	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	F	390	390	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	C	115	115	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	F	391	391	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	S	191	191	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	D	111	111	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	F	107	107	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	T	413	413	putative ligand binding site
lBfVMFd6OQ	653826c8830cabfa40b58d9115de076c	444	CDD-3.21	cd15309	32	438	13	Y	417	417	putative ligand binding site
fFkKaIm0M3	2d7ec642d11aff783e33ee0afe39122e	397	PIRSR-2023_05	PIRSR600732-5	44	340	1	C	339	339	LIPID: S-palmitoyl cysteine
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	PIRSR-2023_05	PIRSR600732-5	330	409	1	C	409	409	LIPID: S-palmitoyl cysteine
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	S	190	190	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	F	356	356	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	T	378	378	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	F	355	355	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	Y	382	382	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	V	112	112	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	V	187	187	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	C	115	115	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	H	359	359	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	S	191	191	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	D	111	111	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	F	107	107	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	CDD-3.21	cd15309	32	403	13	Y	374	374	putative ligand binding site
lxbMM8cWpP	df7db620e9687863f7932bc3cb9c7cce	409	PIRSR-2023_05	PIRSR601681-50	30	212	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMIAVVWVLSFAISSPILFGLN---KADEKEC	104	179	DISULFID: 
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	PIRSR-2023_05	PIRSR601681-50	26	212	1	CNIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISVVWVLSFAISCPLLFGLNNTEE---NEC	104	179	DISULFID: 
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	PIRSR-2023_05	PIRSR600732-5	336	415	1	C	415	415	LIPID: S-palmitoyl cysteine
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	F	361	361	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	Y	388	388	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	S	190	190	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	H	365	365	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	V	112	112	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	V	187	187	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	T	384	384	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	Y	380	380	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	C	115	115	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	S	191	191	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	D	111	111	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	F	362	362	putative ligand binding site
Yild6PEkHw	f773b8bf72b223a120958190937f57ae	415	CDD-3.21	cd15309	32	409	13	F	107	107	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	D	142	142	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	T	395	395	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	Y	399	399	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	W	367	367	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	W	138	138	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	V	391	391	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	S	226	226	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	F	370	370	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	F	371	371	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	T	147	147	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	A	227	227	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	S	230	230	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	L	216	216	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	V	143	143	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	V	223	223	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	C	146	146	putative ligand binding site
RVJDDAJe6D	1d46a2440f39003062275d3c7a2be565	428	CDD-3.21	cd15060	63	420	17	Y	374	374	putative ligand binding site
iiIa5izPqm	955bf96152704f4aa60aa4de4079009a	365	PIRSR-2023_05	PIRSR600732-3	24	209	1	CEVWLTVDMTCCTCSILHLCVIALDRYWAITDAIEYARKRTVKRAGVMITTVWAISIFISMPPLF-WRNHYNSGTLNQC	95	172	DISULFID: 
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	I	172	172	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	R	427	427	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	F	404	404	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	A	260	260	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	E	426	426	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	L	430	430	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	F	403	403	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	V	176	176	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	R	410	410	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	L	423	423	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	C	179	179	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	Y	434	434	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	C	244	244	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	T	180	180	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	D	175	175	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	W	400	400	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	F	171	171	putative ligand binding site
s438BUrIld	0bc719d19153d91de584b3f25ddb34da	489	CDD-3.21	cd15329	95	455	18	S	256	256	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	Y	373	373	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	S	194	194	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	F	370	370	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	Y	398	398	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	V	112	112	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	W	366	366	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	F	369	369	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	I	191	191	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	S	198	198	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	F	390	390	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	C	115	115	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	C	195	195	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	L	184	184	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	T	116	116	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	Y	107	107	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	D	111	111	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	CDD-3.21	cd15323	32	419	17	F	394	394	putative ligand binding site
srLFcibeWN	f88c29100e20a7d1866bf3efe50a54e1	433	PIRSR-2023_05	PIRSR600732-5	344	427	1	C	424	424	LIPID: S-palmitoyl cysteine
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	I	119	119	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	T	123	123	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	F	318	318	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	D	339	339	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	T	342	342	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	S	201	201	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	Y	346	346	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	C	188	188	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	W	314	314	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	F	317	317	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	C	122	122	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	L	115	115	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	F	338	338	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	P	335	335	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	L	324	324	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	D	118	118	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	W	114	114	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	CDD-3.21	cd15333	35	367	18	A	205	205	ligand binding site
0E9U3B9PUJ	2d06b9fd1178125370c0ebc8505930d3	377	PIRSR-2023_05	PIRSR600732-3	42	223	1	CDIWLSSDITCCTASILHLCVIALDRYWAITDALEYSKRRTFGRAAAMIAMVWVISVCISIPPLFWRQAKAHEEL-ADC	111	188	DISULFID: 
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	W	335	335	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	T	161	161	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	A	241	241	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	C	225	225	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	F	338	338	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	S	237	237	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	F	339	339	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	C	160	160	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	R	362	362	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	F	152	152	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	E	361	361	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	D	156	156	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	L	365	365	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	R	345	345	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	V	157	157	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	L	358	358	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	I	153	153	putative ligand binding site
VAW0U6GyrN	dace08d2a49af5f22ece6fa403be3bae	437	CDD-3.21	cd15329	76	390	18	Y	369	369	putative ligand binding site
v4fUVbAyCP	11c017efceb4c93b26020cc407aec43a	388	PIRSR-2023_05	PIRSR600732-5	304	382	1	C	382	382	LIPID: S-palmitoyl cysteine
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	W	281	281	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	F	302	302	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	A	192	192	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	N	288	288	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	F	285	285	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	V	107	107	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	C	110	110	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	S	193	193	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	F	284	284	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	T	196	196	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	D	106	106	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	S	111	111	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	L	182	182	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	V	189	189	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	T	306	306	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	Y	310	310	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	CDD-3.21	cd15054	27	331	17	W	102	102	putative ligand binding site
zm3bFk8bLu	6b69a6bcc413d7760b6ac1cbeaced191	440	PIRSR-2023_05	PIRSR600732-5	258	341	1	C	337	337	LIPID: S-palmitoyl cysteine
4uKMVhILPa	0d9c788a29b4b01946845c07e8f7c95f	409	PIRSR-2023_05	PIRSR603912-52	36	232	1	CEFWTATDVLCVTASIETLCVIALDRYIAIMWPLRYQSMLTKRKACGMVIGVWAVAALISFLPIHMEWW--VSDEPEALSC	113	191	DISULFID: 
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	PIRSR-2023_05	PIRSR603912-52	25	209	1	CDLWTSVDVLCVTASIETLCVIAVDRYIAITKPLRHKVLLNKCRARVIVCLVWVVSSLISFVPIMN--GLWRDDDRTAKEC	92	170	DISULFID: 
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	L	218	218	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	V	129	129	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	R	214	214	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	H	127	127	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	I	219	219	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	K	278	278	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	Q	215	215	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	T	122	122	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	A	212	212	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	T	282	282	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	V	208	208	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	R	117	117	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	A	120	120	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	R	126	126	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	K	128	128	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	Q	49	49	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	L	125	125	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	I	211	211	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	A	279	279	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	L	283	283	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	P	124	124	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	I	216	216	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	I	121	121	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	24	S	48	48	G protein interaction site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	F	297	297	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	Y	324	324	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	D	99	99	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	S	190	190	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	W	95	95	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	N	320	320	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	V	103	103	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	D	178	178	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	F	179	179	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	S	189	189	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	T	181	181	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	Y	185	185	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	T	96	96	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	A	186	186	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	N	301	301	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	S	193	193	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	V	100	100	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	F	316	316	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	F	298	298	ligand binding site
ySc3s7zJpX	6ac4b5d84057be660c3bff843b6db7e4	427	CDD-3.21	cd15058	36	344	20	W	294	294	ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	S	291	291	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	C	123	123	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	F	271	271	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	Y	298	298	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	R	278	278	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	T	124	124	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	D	119	119	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	W	115	115	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	A	202	202	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	C	190	190	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	W	268	268	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	H	290	290	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	V	116	116	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	E	287	287	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	A	206	206	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	L	294	294	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	V	120	120	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	CDD-3.21	cd15329	41	319	18	F	272	272	putative ligand binding site
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	PIRSR-2023_05	PIRSR600732-5	41	329	1	C	324	324	LIPID: S-palmitoyl cysteine
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	PIRSR-2023_05	PIRSR600732-5	41	329	1	C	327	327	LIPID: S-palmitoyl cysteine
oEPBj45bmy	8ef1a2f380d55f29fdce444c32578c53	360	PIRSR-2023_05	PIRSR603912-52	25	328	1	CDAWVSVDVASCTASILNLCMISVDRYLAITRPLTYGVRRTARRAWACIGAVWLLAALISVPPLLVLGNEHGTPTM--PTC	112	190	DISULFID: 
jxhNFGngrh	ab4df7b598645161aef30660a2596bde	359	PIRSR-2023_05	PIRSR603912-52	58	195	1	CDVWISCDVLCCTASIWNVTAIALDRFWSITRHLEYTTRARKCISNLMIALTWLLSATISLSPLFGWGEGYYSAESQR--C	115	193	DISULFID: 
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	PIRSR-2023_05	PIRSR600732-5	332	414	1	C	408	408	LIPID: S-palmitoyl cysteine
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	D	94	94	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	F	377	377	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	W	351	351	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	W	90	90	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	F	354	354	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	F	355	355	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	L	178	178	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	T	99	99	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	S	188	188	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	Y	381	381	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	V	95	95	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	R	185	185	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	F	373	373	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	C	98	98	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	Y	358	358	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	A	189	189	putative ligand binding site
yAtKAqFh3f	fb05f5eda7766566805d033c1f17bb95	442	CDD-3.21	cd15063	15	402	17	S	192	192	putative ligand binding site
n3cpwW2FHB	6c7fea13b38937aebb205019654bcfa2	491	PIRSR-2023_05	PIRSR600732-3	39	223	1	CNIWAAVDVLCCTASILSLCVISIDRYIGVKHCLKYPTIMTERKAGVILVLVWVSSMVISIGPLLGWKEPPPSD-ESIC	109	186	DISULFID: 
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	PIRSR-2023_05	PIRSR600732-5	317	411	1	C	411	411	LIPID: S-palmitoyl cysteine
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	L	186	186	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	V	113	113	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	V	193	193	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	S	196	196	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	T	117	117	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	A	197	197	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	S	200	200	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	Y	361	361	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	W	108	108	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	F	358	358	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	V	377	377	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	C	116	116	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	W	354	354	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	F	357	357	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	D	112	112	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	T	381	381	putative ligand binding site
BYFesQEetd	f0350671425fbc2b26ab50a76096ef9e	414	CDD-3.21	cd15060	33	406	17	Y	385	385	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	PIRSR-2023_05	PIRSR600732-5	289	365	1	C	365	365	LIPID: S-palmitoyl cysteine
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	PIRSR-2023_05	PIRSR600732-3	54	233	1	CDIWAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRKKAILALLSVWVLSMVISIGPLLGWKEPAPKDE-KEC	118	195	DISULFID: 
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	W	121	121	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	S	211	211	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	L	314	314	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	F	334	334	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	C	129	129	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	V	197	197	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	W	307	307	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	D	125	125	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	V	126	126	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	F	310	310	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	F	311	311	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	Y	338	338	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	S	207	207	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	F	330	330	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	T	130	130	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	A	204	204	putative ligand binding site
91qOAjAIgi	76e575478fc0294b84c538014aabac9a	505	CDD-3.21	cd15326	46	359	17	S	208	208	putative ligand binding site
b74PatoLe4	29475a36f2c71ac6c277581a66412f6e	510	PIRSR-2023_05	PIRSR600732-1	44	227	1	E	200	200	BINDING: Zn(2+)
b74PatoLe4	29475a36f2c71ac6c277581a66412f6e	510	PIRSR-2023_05	PIRSR600732-5	424	502	1	C	502	502	LIPID: S-palmitoyl cysteine
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	T	427	427	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	F	94	94	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	Y	431	431	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	E	423	423	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	F	404	404	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	D	98	98	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	T	186	186	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	S	189	189	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	F	403	403	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	S	102	102	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	Y	407	407	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	S	193	193	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	A	190	190	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	I	99	99	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	T	103	103	ligand binding site
GxVu84Vrfo	39984520bf261247446ac918b40514fb	468	CDD-3.21	cd14967	20	452	16	W	400	400	ligand binding site
AICC2u7c3U	b295b4938ee34b7a20cac655e252ae2b	400	PIRSR-2023_05	PIRSR600732-1	301	375	1	Q	337	337	BINDING: Zn(2+)
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
eINFQI5Akd	f73c92bbeb404f878b521e74c287d5d6	369	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	PIRSR-2023_05	PIRSR600732-5	41	329	1	C	329	329	LIPID: S-palmitoyl cysteine
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	Y	276	276	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	D	115	115	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	Y	303	303	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	W	111	111	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	V	204	204	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	F	280	280	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	T	208	208	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	F	193	193	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	W	273	273	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	Y	295	295	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	V	116	116	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	F	277	277	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	L	299	299	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	C	119	119	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	I	201	201	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	A	205	205	putative ligand binding site
ioXzsSSnhq	db9a0f7f985544307b6dff6004c359f0	359	CDD-3.21	cd15051	36	324	17	T	120	120	putative ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	Y	303	303	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	T	118	118	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	K	295	295	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	D	292	292	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	S	196	196	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	F	276	276	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	W	109	109	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	F	275	275	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	S	296	296	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	C	117	117	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	A	200	200	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	G	282	282	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	D	113	113	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	V	114	114	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	W	272	272	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	L	299	299	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	C	184	184	ligand binding site
4AQGhYYqZd	295cfa5c2cca388a915e0f0dd23078f4	332	CDD-3.21	cd15064	34	324	18	I	110	110	ligand binding site
6RP65KbJuF	3e98c18a95c9453ded8eee7cd15b1541	387	PIRSR-2023_05	PIRSR601681-50	43	182	1	CDTLMAMDVMLCTASIFNLCAISVDRFVAVTVPLRYNQQGQCQLLLIAATWLLSAAVASPVVCGLNDVPGRDPAVC	105	180	DISULFID: 
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	I	139	139	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	T	143	143	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	V	218	218	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	L	211	211	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	S	221	221	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	Y	366	366	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	C	142	142	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	F	134	134	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	E	382	382	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	S	225	225	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	W	359	359	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	A	222	222	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	D	138	138	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	F	362	362	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	T	386	386	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	F	363	363	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	CDD-3.21	cd15060	58	411	17	Y	390	390	putative ligand binding site
yw1iXIVGCB	bc686e001c25b458eb181e88771bcf37	432	PIRSR-2023_05	PIRSR600732-5	337	418	1	C	416	416	LIPID: S-palmitoyl cysteine
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	S	227	227	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	F	334	334	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	F	335	335	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	D	137	137	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	V	138	138	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	A	223	223	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	S	226	226	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	S	141	141	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	F	216	216	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	S	230	230	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	T	142	142	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	Y	338	338	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	F	359	359	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	W	133	133	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	Y	363	363	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	W	331	331	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	CDD-3.21	cd15066	59	384	17	V	355	355	putative ligand binding site
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	PIRSR-2023_05	PIRSR600732-5	306	401	1	C	395	395	LIPID: S-palmitoyl cysteine
9BwJpkykrC	5455c5d52014b7fc931e00432ff39217	431	PIRSR-2023_05	PIRSR600732-5	306	401	1	C	394	394	LIPID: S-palmitoyl cysteine
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	PIRSR-2023_05	PIRSR600732-1	355	430	1	Q	390	390	BINDING: Zn(2+)
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	F	399	399	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	T	97	97	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	I	173	173	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	S	180	180	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	Y	88	88	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	Y	382	382	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	F	403	403	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	C	96	96	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	Y	407	407	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	D	92	92	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	S	177	177	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	W	375	375	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	L	166	166	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	F	378	378	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	V	93	93	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	F	379	379	putative ligand binding site
seCpqYzobh	677e2abab1a55d1ebc9c820aed92cb37	441	CDD-3.21	cd15321	7	428	17	S	176	176	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	PIRSR-2023_05	PIRSR600732-5	295	372	1	C	372	372	LIPID: S-palmitoyl cysteine
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	E	337	337	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	F	318	318	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	F	319	319	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	L	341	341	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	I	114	114	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	C	186	186	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	S	338	338	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	T	122	122	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	Y	345	345	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	I	118	118	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	A	202	202	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	R	325	325	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	W	113	113	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	S	198	198	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	R	334	334	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	C	121	121	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	W	315	315	putative ligand binding site
xarXCvI4gY	1971e8ee6e5c301e3d400dac0cd8c8bc	413	CDD-3.21	cd15329	38	366	18	D	117	117	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	PIRSR-2023_05	PIRSR600732-5	353	430	1	C	430	430	LIPID: S-palmitoyl cysteine
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	S	211	211	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	Y	404	404	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	S	212	212	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	S	215	215	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	I	208	208	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	Y	382	382	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	V	128	128	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	C	131	131	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	W	375	375	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	F	396	396	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	T	132	132	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	Y	123	123	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	D	127	127	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	F	378	378	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	F	379	379	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	I	201	201	putative ligand binding site
oHJYtIofr8	791362dc1708c0ad7844a473a46a0d7c	438	CDD-3.21	cd15322	48	425	17	F	400	400	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	F	313	313	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	W	100	100	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	W	292	292	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	S	201	201	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	T	108	108	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	T	204	204	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	N	299	299	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	L	190	190	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	D	104	104	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	S	109	109	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	A	197	197	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	F	296	296	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	V	105	105	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	A	200	200	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	F	295	295	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	T	317	317	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	CDD-3.21	cd15054	26	342	17	Y	321	321	putative ligand binding site
RrHy6Wx7gZ	774b81036199074f45f837f50099e4c8	442	PIRSR-2023_05	PIRSR600732-5	278	352	1	C	348	348	LIPID: S-palmitoyl cysteine
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	T	155	155	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	L	394	394	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	S	233	233	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	F	388	388	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	V	151	151	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	C	154	154	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	E	405	405	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	F	146	146	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	F	387	387	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	D	150	150	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	A	409	409	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	Y	416	416	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	I	147	147	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	G	408	408	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	W	384	384	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	A	237	237	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	N	412	412	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	CDD-3.21	cd15330	71	437	18	C	221	221	putative ligand binding site
Z6xloI3oDo	e7697f0c47cb251daea8a0cd9871e2b6	448	PIRSR-2023_05	PIRSR603912-52	83	258	1	CDLFIALDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAVLISVTWLIGFSISIPPMLGWRSAE-DRANPDAC	143	221	DISULFID: 
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	W	132	132	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	F	334	334	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	Y	362	362	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	W	330	330	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	F	333	333	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	S	226	226	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	D	136	136	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	F	358	358	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	V	137	137	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	F	215	215	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	S	225	225	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	S	140	140	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	A	222	222	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	V	354	354	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	S	229	229	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	T	141	141	putative ligand binding site
eKnOV3MSYr	7470517533177c7011360b169e8a7e66	430	CDD-3.21	cd15066	58	383	17	Y	337	337	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	D	142	142	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	T	139	139	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	G	369	369	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	W	138	138	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	F	372	372	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	S	231	231	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	W	349	349	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	M	359	359	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	F	353	353	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	Y	380	380	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	T	147	147	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	A	227	227	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	V	143	143	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	L	376	376	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	C	146	146	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	C	215	215	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	S	373	373	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	CDD-3.21	cd15331	62	401	18	F	352	352	putative ligand binding site
3JBHsIlGYM	9d2e477901e78df458ab13dffb802ecf	415	PIRSR-2023_05	PIRSR600732-5	309	406	1	C	406	406	LIPID: S-palmitoyl cysteine
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	A	224	224	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	T	129	129	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	C	220	220	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	F	210	210	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	W	296	296	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	S	221	221	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	W	318	318	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	T	128	128	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	N	303	303	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	R	120	120	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	L	322	322	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	D	124	124	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	A	217	217	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	F	300	300	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	V	125	125	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	F	299	299	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	CDD-3.21	cd15056	44	347	17	Y	326	326	putative ligand binding site
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	PIRSR-2023_05	PIRSR600732-5	47	356	1	C	352	352	LIPID: S-palmitoyl cysteine
yHRzKl9mM4	e77fe5bdf4c2ad0bd5e8e9dc07bcf5d9	402	PIRSR-2023_05	PIRSR600732-5	47	356	1	C	353	353	LIPID: S-palmitoyl cysteine
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	A	203	203	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	V	113	113	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	C	187	187	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	D	116	116	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	S	361	361	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	L	357	357	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	F	340	340	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	S	199	199	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	V	117	117	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	F	339	339	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	R	360	360	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	T	121	121	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	G	346	346	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	Y	112	112	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	Y	368	368	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	W	336	336	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	C	120	120	putative ligand binding site
zlKlE9DMy9	bdeeb2ca9d8742fb56ae1409fb9fbc0d	404	CDD-3.21	cd15331	37	389	18	L	364	364	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	PIRSR-2023_05	PIRSR600732-5	266	344	1	C	342	342	LIPID: S-palmitoyl cysteine
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	A	192	192	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	N	293	293	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	S	196	196	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	V	103	103	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	C	106	106	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	F	290	290	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	F	307	307	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	L	185	185	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	W	286	286	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	D	102	102	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	S	107	107	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	F	289	289	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	A	195	195	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	W	98	98	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	T	199	199	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	T	311	311	putative ligand binding site
y26Opks9vx	397f8ef64d42927bb27879440bdb108e	433	CDD-3.21	cd15054	23	336	17	Y	315	315	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	R	379	379	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	T	177	177	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	A	257	257	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	F	356	356	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	C	241	241	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	E	378	378	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	L	382	382	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	S	253	253	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	F	355	355	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	C	176	176	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	R	362	362	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	F	168	168	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	L	375	375	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	D	172	172	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	Y	386	386	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	W	352	352	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	V	173	173	putative ligand binding site
XGLNFOZD35	a2033b48e257569b16c7f401797f6e9d	454	CDD-3.21	cd15329	92	407	18	I	169	169	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	PIRSR-2023_05	PIRSR600732-5	21	332	1	C	328	328	LIPID: S-palmitoyl cysteine
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	PIRSR-2023_05	PIRSR600732-5	21	332	1	C	327	327	LIPID: S-palmitoyl cysteine
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	F	185	185	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	D	99	99	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	A	192	192	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	W	271	271	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	S	196	196	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	F	274	274	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	R	95	95	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	F	275	275	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	L	297	297	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	C	195	195	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	V	100	100	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	Y	301	301	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	W	293	293	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	T	103	103	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	A	199	199	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	N	278	278	putative ligand binding site
gKCRpYXhm3	94575021f3005e65507456e5853de4cb	386	CDD-3.21	cd15056	19	322	17	T	104	104	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	A	203	203	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	S	206	206	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	W	324	324	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	W	287	287	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	T	124	124	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	D	119	119	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	S	210	210	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	F	290	290	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	A	196	196	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	W	115	115	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	F	291	291	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	V	320	320	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	S	123	123	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	F	316	316	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	S	207	207	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	N	294	294	putative ligand binding site
cIWfP7c97u	6fc13a37cf12220abda9bd2bb039e1cc	463	CDD-3.21	cd15057	40	344	17	I	120	120	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	P	400	400	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	D	132	132	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	S	217	217	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	W	381	381	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	V	133	133	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	I	129	129	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	F	385	385	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	L	407	407	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	T	137	137	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	Q	404	404	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	W	128	128	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	Y	411	411	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	R	391	391	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	C	136	136	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	A	221	221	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	E	403	403	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	F	384	384	putative ligand binding site
1CZE4qjrds	89455d141e2ed0db6cd1d255954ba1cf	445	CDD-3.21	cd15331	52	432	18	C	205	205	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	PIRSR-2023_05	PIRSR600732-5	329	408	1	C	408	408	LIPID: S-palmitoyl cysteine
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	S	190	190	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	Y	373	373	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	F	354	354	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	F	355	355	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	V	112	112	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	V	187	187	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	C	115	115	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	T	377	377	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	Y	381	381	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	S	191	191	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	D	111	111	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	F	107	107	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	CDD-3.21	cd15309	32	402	13	H	358	358	putative ligand binding site
TsxAsI4JHX	9e1ee7a7022fb598b338f1a6db6060f4	408	PIRSR-2023_05	PIRSR601681-50	30	212	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMIAVVWVLSFAISSPILFGLN---KADEKEC	104	179	DISULFID: 
vtxKriXTJb	1b727ba8241d88a994dd801808a84462	464	PIRSR-2023_05	PIRSR600732-3	30	217	1	CNIWAAVDVLCCTASIMSLCVISIDRYIGVSYPLRYPSIVTEKRGLLALLCIWVLSLVISIGPLFGWKQPAPEDEKI-C	101	178	DISULFID: 
Nq94vUXx6J	06acd6bd245ce331a073febc593961b7	452	PIRSR-2023_05	PIRSR600732-3	38	220	1	CDIWAAVDVLCCTASIMSLCAISIDRYIGVRYPLQYPMIVTEQRALLAMLGVWILSIVISIGPLLGWKQP-PSQDDTVC	107	184	DISULFID: 
Nq94vUXx6J	06acd6bd245ce331a073febc593961b7	452	PIRSR-2023_05	PIRSR600732-5	283	359	1	C	359	359	LIPID: S-palmitoyl cysteine
cIJDI1ElWX	b24c07284b487e33f2490d79ab8c3ed1	458	PIRSR-2023_05	PIRSR603912-52	47	239	1	CDIFIALDVLCCTSSILHLCAIALDRYWAITNPIDYVNKRTPRRAVIMISLTWLVGFSISIPPMLGWRTP-ADRADPNAC	110	188	DISULFID: 
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	F	217	217	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	Y	324	324	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	I	135	135	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	T	139	139	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	N	298	298	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	L	320	320	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	S	228	228	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	S	231	231	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	F	130	130	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	T	138	138	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	W	291	291	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	D	134	134	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	A	227	227	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	F	294	294	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	F	295	295	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	L	316	316	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	CDD-3.21	cd15056	55	345	17	S	224	224	putative ligand binding site
uM6QBwh65Q	5148a25a59723f705a612a962b7a9d51	387	PIRSR-2023_05	PIRSR600732-5	56	354	1	C	351	351	LIPID: S-palmitoyl cysteine
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	Y	383	383	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	L	362	362	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	D	116	116	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	T	113	113	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	F	356	356	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	F	372	372	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	V	117	117	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	S	205	205	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	F	355	355	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	S	376	376	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	F	375	375	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	T	121	121	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	A	201	201	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	L	379	379	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	W	112	112	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	W	352	352	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	C	120	120	putative ligand binding site
58zEgjfaCA	ee3c1bc315565ce52ec8f5de835e055a	419	CDD-3.21	cd15331	40	404	18	C	189	189	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	S	211	211	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	W	287	287	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	F	308	308	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	D	114	114	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	F	290	290	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	F	291	291	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	A	197	197	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	W	110	110	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	S	118	118	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	W	316	316	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	S	207	207	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	I	115	115	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	T	119	119	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	N	294	294	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	A	204	204	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	V	312	312	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	CDD-3.21	cd15057	35	336	17	S	208	208	putative ligand binding site
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	PIRSR-2023_05	PIRSR600732-5	36	344	1	C	342	342	LIPID: S-palmitoyl cysteine
1DJDCpVFUF	e3ed07466c6fd700e6c1a2797fa1dd14	447	PIRSR-2023_05	PIRSR600732-1	36	344	1	Q	301	301	BINDING: Zn(2+)
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	F	281	281	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	I	109	109	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	T	113	113	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	S	199	199	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	V	314	314	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	W	104	104	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	A	196	196	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	S	189	189	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	S	200	200	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	F	280	280	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	W	318	318	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	S	203	203	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	F	310	310	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	D	108	108	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	W	277	277	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	N	284	284	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	CDD-3.21	cd15057	46	338	17	S	112	112	putative ligand binding site
ynb7xQYAay	7a31f7bb5ab4d57f678b260d0da78791	465	PIRSR-2023_05	PIRSR600732-5	32	359	1	C	344	344	LIPID: S-palmitoyl cysteine
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	T	107	107	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	C	198	198	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	T	108	108	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	S	199	199	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	D	103	103	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	W	296	296	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	N	281	281	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	A	202	202	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	A	195	195	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	F	278	278	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	R	99	99	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	F	188	188	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	W	274	274	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	F	277	277	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	Y	304	304	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	L	300	300	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	CDD-3.21	cd15056	23	325	17	V	104	104	putative ligand binding site
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	PIRSR-2023_05	PIRSR600732-5	25	337	1	C	331	331	LIPID: S-palmitoyl cysteine
BEwYUowpIl	98328c5cf198879a0c2065ffcf0f8926	390	PIRSR-2023_05	PIRSR600732-5	25	337	1	C	330	330	LIPID: S-palmitoyl cysteine
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	V	230	230	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	R	139	139	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	A	288	288	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	Y	149	149	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	E	236	236	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	S	151	151	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	R	148	148	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	F	147	147	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	L	292	292	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	I	241	241	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	Q	237	237	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	T	144	144	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	A	234	234	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	I	143	143	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	E	233	233	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	T	291	291	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	K	287	287	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	Q	70	70	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	Q	150	150	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	K	240	240	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	A	142	142	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	R	71	71	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	P	146	146	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	24	I	238	238	putative G protein interaction site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	F	201	201	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	S	211	211	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	V	102	102	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	T	203	203	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	V	326	326	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	Y	207	207	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	A	208	208	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	W	303	303	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	L	101	101	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	D	121	121	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	S	212	212	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	W	330	330	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	S	215	215	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	V	122	122	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	F	306	306	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	N	329	329	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	F	307	307	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	Y	333	333	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	W	117	117	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	N	310	310	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	CDD-3.21	cd15958	42	353	21	V	125	125	ligand binding site
c2nvJkfrfN	880417ea1ee5015780758771a28997a0	459	PIRSR-2023_05	PIRSR603912-52	38	235	1	CECWTSVDVLCVTASIETLCVIAIDRYLAITSPFRYQSLMTRARAKGIICTVWAISALVSFLPIMMHWWRD--EDPQALKC	114	192	DISULFID: 
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	L	138	138	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	V	230	230	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	V	225	225	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	L	272	272	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	P	137	137	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	R	228	228	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	T	271	271	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	K	267	267	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	A	133	133	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	I	134	134	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	Y	140	140	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	V	222	222	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	P	61	61	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	Q	139	139	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	L	232	232	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	R	62	62	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	A	142	142	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	T	135	135	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	E	141	141	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	H	229	229	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	A	268	268	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	R	130	130	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	I	233	233	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	24	A	226	226	putative G protein interaction site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	F	286	286	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	V	113	113	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	N	309	309	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	F	287	287	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	Y	313	313	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	F	193	193	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	S	203	203	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	F	305	305	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	T	195	195	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	N	290	290	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	W	108	108	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	Y	199	199	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	A	200	200	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	V	116	116	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	S	204	204	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	S	207	207	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	D	112	112	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	D	192	192	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	W	283	283	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	CDD-3.21	cd15959	33	333	20	T	109	109	putative ligand binding site
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	PIRSR-2023_05	PIRSR600732-5	268	339	1	C	339	339	LIPID: S-palmitoyl cysteine
ObxFZPrSW5	0c3b7c7e47d4a5cfd6b943323a916b31	437	PIRSR-2023_05	PIRSR600732-5	268	339	1	C	338	338	LIPID: S-palmitoyl cysteine
pa6NxCQ1gj	e46db6643216ad9ea3686c6b8b12bd03	354	PIRSR-2023_05	PIRSR600732-5	258	333	1	C	333	333	LIPID: S-palmitoyl cysteine
ZKBdy0qp0c	966cac4a54b0c6ca4e4aadfabf07a7dc	377	PIRSR-2023_05	PIRSR600732-5	21	313	1	C	313	313	LIPID: S-palmitoyl cysteine
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	F	361	361	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	Y	388	388	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	C	118	118	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	F	110	110	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	D	114	114	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	S	194	194	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	H	365	365	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	T	384	384	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	Y	380	380	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	V	190	190	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	S	193	193	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	F	362	362	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	CDD-3.21	cd15309	35	409	13	V	115	115	putative ligand binding site
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	PIRSR-2023_05	PIRSR600732-5	336	415	1	C	415	415	LIPID: S-palmitoyl cysteine
gU7e6pWBTH	9ce0181a86a071f096ba825d8060df3e	415	PIRSR-2023_05	PIRSR601681-50	36	215	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMITVVWVLSFAISCPLLFGLNNT---DQNEC	107	182	DISULFID: 
1tOEEBFDV2	e1568140e7ed7f3703c5b2f046ddc3e0	367	PIRSR-2023_05	PIRSR600732-5	55	349	1	C	347	347	LIPID: S-palmitoyl cysteine
1tOEEBFDV2	e1568140e7ed7f3703c5b2f046ddc3e0	367	PIRSR-2023_05	PIRSR600732-5	55	349	1	C	346	346	LIPID: S-palmitoyl cysteine
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	T	97	97	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	I	173	173	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	S	180	180	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	F	388	388	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	Y	88	88	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	F	387	387	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	C	96	96	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	F	408	408	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	Y	391	391	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	D	92	92	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	S	177	177	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	F	412	412	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	L	166	166	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	Y	416	416	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	W	384	384	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	V	93	93	putative ligand binding site
9DaFjhZRiW	dfa2a213c38c18ac34be5bed331d9135	450	CDD-3.21	cd15321	7	437	17	S	176	176	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	W	105	105	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	F	286	286	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	W	282	282	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	S	292	292	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	C	113	113	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	F	285	285	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	Y	312	312	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	L	308	308	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	D	109	109	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	V	110	110	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	A	195	195	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	P	301	301	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	C	179	179	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	S	305	305	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	K	304	304	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	I	106	106	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	S	191	191	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	CDD-3.21	cd15328	38	333	18	T	114	114	putative ligand binding site
LwSMZzdDZc	6d3d2050f971c3e933a4d182b5ee0d2d	341	PIRSR-2023_05	PIRSR600732-3	35	212	1	CQVWISFDVLCCTASIWNVTAIALDRYWSITRHLEYTLRARKKVSNMMIVLTWLLSAVISLSPLFGWGKTYSERDQ-RC	102	179	DISULFID: 
6vAAbz5B5K	7abf71892789856463b18e9c0a15ed28	354	PIRSR-2023_05	PIRSR603912-52	47	212	1	CYVWVSCDVLCCTASIWNVTAIALDRYWSISRHLQYTLKGRRRASTLMISTAWLLSAIISLSPLFGWGNDYYSP--ELLEC	103	181	DISULFID: 
6vAAbz5B5K	7abf71892789856463b18e9c0a15ed28	354	PIRSR-2023_05	PIRSR600732-5	255	351	1	C	351	351	LIPID: S-palmitoyl cysteine
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	PIRSR-2023_05	PIRSR600732-5	368	448	1	C	448	448	LIPID: S-palmitoyl cysteine
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	PIRSR-2023_05	PIRSR603912-52	38	227	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVALPMLYNTRYSSRRRVTVMISVVWTLSFVISCPLLFGFNNTETRVDT--IC	105	183	DISULFID: 
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	S	195	195	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	F	393	393	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	V	113	113	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	T	417	417	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	Y	421	421	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	S	194	194	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	H	397	397	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	C	116	116	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	F	108	108	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	Y	413	413	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	V	191	191	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	F	394	394	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	D	112	112	ligand binding site
jUHGi3sC6A	0ad671b9ea6f6c54610aa12e95a921ff	448	CDD-3.21	cd15053	33	442	14	I	185	185	ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	PIRSR-2023_05	PIRSR600732-5	304	395	1	C	392	392	LIPID: S-palmitoyl cysteine
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	PIRSR-2023_05	PIRSR600732-5	304	395	1	C	391	391	LIPID: S-palmitoyl cysteine
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	F	238	238	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	S	249	249	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	W	335	335	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	T	156	156	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	R	148	148	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	F	338	338	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	D	152	152	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	F	339	339	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	A	245	245	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	L	361	361	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	V	153	153	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	Y	365	365	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	W	357	357	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	N	342	342	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	A	252	252	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	T	157	157	putative ligand binding site
rDwRatbDPi	3bc2c7c676be012c2ca6525a33a082a0	450	CDD-3.21	cd15056	73	386	17	C	248	248	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	PIRSR-2023_05	PIRSR600732-5	240	322	1	C	320	320	LIPID: S-palmitoyl cysteine
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	PIRSR-2023_05	PIRSR600732-5	240	322	1	C	321	321	LIPID: S-palmitoyl cysteine
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	F	265	265	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	T	86	86	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	F	159	159	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	S	169	169	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	F	77	77	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	F	290	290	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	S	173	173	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	G	166	166	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	V	286	286	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	D	81	81	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	Y	269	269	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	V	82	82	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	S	170	170	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	F	266	266	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	S	85	85	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	Y	294	294	putative ligand binding site
2WeFoqGNAI	a1b033e50cb828e91b6b2b7a7fb5d9d2	326	CDD-3.21	cd15066	3	315	17	W	262	262	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	S	211	211	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	F	334	334	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	T	134	134	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	A	208	208	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	S	212	212	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	W	125	125	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	S	215	215	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	L	318	318	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	F	338	338	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	C	133	133	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	W	311	311	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	D	129	129	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	V	130	130	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	F	314	314	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	F	315	315	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	Y	342	342	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	CDD-3.21	cd15326	50	363	17	I	201	201	putative ligand binding site
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	PIRSR-2023_05	PIRSR600732-5	293	369	1	C	369	369	LIPID: S-palmitoyl cysteine
r36YE0G9qX	9a834a097d55b7717342112c44549437	507	PIRSR-2023_05	PIRSR600732-3	59	238	1	CDIWAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRRAILALLGVWVLSMVISIGPLLGWKEPAPKDD-KEC	122	199	DISULFID: 
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	V	86	86	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	T	182	182	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	S	185	185	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	F	255	255	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	Y	181	181	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	H	271	271	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	W	248	248	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	L	275	275	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	T	90	90	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	Y	279	279	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	F	252	252	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	C	89	89	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	V	178	178	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	Y	251	251	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	F	171	171	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	Y	81	81	putative ligand binding site
SuSbie4gj4	757a37ddc0ab47df0e9d7e3baf126ba2	366	CDD-3.21	cd15051	8	300	17	D	85	85	putative ligand binding site
WYxLjs2S65	4950eb6688dd119e4b7336db86c0df7b	425	PIRSR-2023_05	PIRSR600732-5	21	342	1	C	317	317	LIPID: S-palmitoyl cysteine
WYxLjs2S65	4950eb6688dd119e4b7336db86c0df7b	425	PIRSR-2023_05	PIRSR600732-5	21	342	1	C	318	318	LIPID: S-palmitoyl cysteine
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	F	286	286	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	V	97	97	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	S	185	185	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	S	100	100	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	L	174	174	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	W	264	264	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	T	101	101	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	A	181	181	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	S	184	184	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	N	271	271	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	W	92	92	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	S	188	188	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	F	268	268	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	T	290	290	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	D	96	96	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	F	267	267	putative ligand binding site
0yHxvrsVBy	4ab1536de00048c6dcdb01bcc596d3a7	344	CDD-3.21	cd15065	18	315	17	Y	294	294	putative ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	PIRSR-2023_05	PIRSR603912-52	77	249	1	CDILLTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSRRRVAVMIAVVWFLSFAISCPLLFGLNNT--ANRDGTTC	135	213	DISULFID: 
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	L	138	138	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	D	142	142	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	F	431	431	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	Y	451	451	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	H	435	435	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	F	215	215	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	S	225	225	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	V	143	143	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	C	146	146	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	T	455	455	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	Y	459	459	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	V	221	221	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	S	224	224	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	CDD-3.21	cd15053	63	480	14	F	432	432	ligand binding site
QtvS12YqJG	5f7125593b27ef0a7d051706c4f13810	486	PIRSR-2023_05	PIRSR600732-5	406	486	1	C	486	486	LIPID: S-palmitoyl cysteine
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	T	123	123	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	A	203	203	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	F	334	334	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	V	119	119	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	N	331	331	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	C	122	122	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	T	207	207	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	M	321	321	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	C	191	191	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	D	118	118	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	T	115	115	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	L	338	338	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	W	311	311	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	W	114	114	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	S	335	335	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	F	314	314	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	F	315	315	putative ligand binding site
BfAlPFZr1B	4e3e93e7cb323f40b9140eb657aeb167	373	CDD-3.21	cd15331	39	363	18	Y	342	342	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	F	398	398	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	T	182	182	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	P	416	416	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	W	394	394	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	S	420	420	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	A	262	262	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	W	173	173	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	F	397	397	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	C	250	250	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	T	266	266	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	F	419	419	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	C	181	181	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	L	423	423	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	T	174	174	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	D	177	177	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	V	178	178	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	Y	427	427	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	CDD-3.21	cd15331	108	448	18	M	404	404	putative ligand binding site
bSHRAKMHsK	cf51c4a038a92d09f22cd3b3e057b290	461	PIRSR-2023_05	PIRSR600732-5	372	455	1	C	453	453	LIPID: S-palmitoyl cysteine
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	C	118	118	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	L	111	111	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	W	324	324	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	D	114	114	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	T	351	351	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	Y	355	355	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	W	110	110	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	F	328	328	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	P	344	344	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	F	327	327	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	D	348	348	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	A	201	201	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	M	334	334	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	I	115	115	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	T	119	119	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	S	197	197	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	F	347	347	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	CDD-3.21	cd15333	31	376	18	C	184	184	ligand binding site
ZuKEAqXmfv	1ec4d24b0b2812fefaa811cd9d38ab88	386	PIRSR-2023_05	PIRSR600732-3	48	221	1	CDIWLSSDITFCTASILHLCVIALDRYWAITDALEYSKRRTMRRAALMIVIVWVISVSISLPPLFWRQAKAHEEL-TEC	107	184	DISULFID: 
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	PIRSR-2023_05	PIRSR600732-5	25	335	1	C	331	331	LIPID: S-palmitoyl cysteine
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	PIRSR-2023_05	PIRSR600732-5	25	335	1	C	332	332	LIPID: S-palmitoyl cysteine
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	W	297	297	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	N	282	282	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	F	190	190	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	S	201	201	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	T	108	108	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	R	100	100	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	D	104	104	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	W	275	275	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	A	197	197	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	F	278	278	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	V	105	105	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	F	279	279	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	L	301	301	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	A	204	204	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	T	109	109	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	C	200	200	putative ligand binding site
oZNYuBDmJR	0138425826fd66665ef93949ecc63528	361	CDD-3.21	cd15056	24	326	17	Y	305	305	putative ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	PIRSR-2023_05	PIRSR603912-52	49	181	1	CDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTG----DPTVC	103	181	DISULFID: 
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	PIRSR-2023_05	PIRSR600732-1	291	367	1	Q	323	323	BINDING: Zn(2+)
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	D	110	110	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	F	313	313	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	Y	340	340	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	F	312	312	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	T	336	336	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	H	316	316	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	Y	332	332	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	S	193	193	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	V	111	111	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	C	114	114	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	F	106	106	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	V	189	189	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	CDD-3.21	cd15310	30	361	13	S	192	192	ligand binding site
OZhs3p2Q8V	393983767c868f381301ed6f63872f17	367	PIRSR-2023_05	PIRSR600732-5	291	367	1	C	367	367	LIPID: S-palmitoyl cysteine
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	D	126	126	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	W	122	122	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	F	324	324	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	F	205	205	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	S	215	215	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	Y	328	328	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	F	349	349	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	S	130	130	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	S	216	216	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	S	219	219	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	W	321	321	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	T	131	131	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	V	345	345	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	C	212	212	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	V	127	127	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	F	325	325	putative ligand binding site
CFlZ3Yynoy	26ba13b1d9c8dc6ed7e8a678fbd91303	421	CDD-3.21	cd15066	48	374	17	Y	353	353	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	PIRSR-2023_05	PIRSR600732-5	256	333	1	C	332	332	LIPID: S-palmitoyl cysteine
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	F	297	297	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	D	99	99	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	W	276	276	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	A	192	192	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	W	95	95	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	N	283	283	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	S	104	104	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	F	280	280	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	S	193	193	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	F	279	279	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	V	100	100	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	T	196	196	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	L	182	182	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	C	103	103	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	A	189	189	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	T	301	301	putative ligand binding site
AjttkrIBDE	d09b1d357961b06c75e23ba7ead407d4	418	CDD-3.21	cd15054	20	326	17	Y	305	305	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	D	110	110	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	F	271	271	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	A	193	193	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	S	196	196	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	W	307	307	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	S	200	200	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	T	115	115	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	W	268	268	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	E	303	303	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	V	111	111	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	N	275	275	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	C	114	114	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	F	106	106	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	S	186	186	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	S	197	197	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	F	299	299	putative ligand binding site
E9L67zu1wF	ba4afd911de9d03a10723400e75d0821	370	CDD-3.21	cd15057	31	327	17	F	272	272	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	W	100	100	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	W	269	269	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	S	194	194	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	D	104	104	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	F	291	291	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	N	276	276	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	F	273	273	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	L	183	183	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	V	105	105	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	S	193	193	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	S	108	108	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	A	190	190	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	T	295	295	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	Y	299	299	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	S	197	197	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	T	109	109	putative ligand binding site
vbF4MCqUpC	3d73c21dd64b217636f82e1542f883fd	379	CDD-3.21	cd15065	26	320	17	F	272	272	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	V	118	118	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	A	203	203	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	S	121	121	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	F	287	287	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	S	210	210	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	T	122	122	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	L	196	196	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	Y	286	286	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	A	309	309	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	Y	313	313	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	W	305	305	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	H	113	113	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	S	207	207	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	T	290	290	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	W	283	283	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	G	206	206	putative ligand binding site
eTS75PP6iB	21e6858aa32bb0dd755c85576646db49	353	CDD-3.21	cd15055	32	334	17	D	117	117	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	PIRSR-2023_05	PIRSR600732-5	322	402	1	C	399	399	LIPID: S-palmitoyl cysteine
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	F	345	345	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	W	116	116	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	T	369	369	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	F	194	194	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	D	120	120	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	S	205	205	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	L	201	201	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	F	344	344	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	V	121	121	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	S	124	124	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	S	204	204	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	W	341	341	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	W	373	373	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	V	365	365	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	T	125	125	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	N	348	348	putative ligand binding site
8dUDNlp73q	264bb60e48b4c15d4a675cb40fcaf56d	440	CDD-3.21	cd15067	40	394	17	S	208	208	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	Y	127	127	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	D	131	131	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	F	398	398	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	F	399	399	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	F	419	419	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	S	214	214	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	Y	402	402	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	F	423	423	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	V	132	132	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	I	211	211	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	S	218	218	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	Y	427	427	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	C	135	135	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	C	215	215	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	L	204	204	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	W	395	395	putative ligand binding site
IXVYbhEiFa	11d31e46a0fcd7f1b057f3401151a7a2	462	CDD-3.21	cd15323	60	448	17	T	136	136	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	PIRSR-2023_05	PIRSR600732-5	345	425	1	C	425	425	LIPID: S-palmitoyl cysteine
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	Y	111	111	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	D	115	115	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	Y	399	399	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	W	367	367	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	S	199	199	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	F	370	370	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	F	371	371	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	S	198	198	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	F	391	391	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	V	116	116	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	I	195	195	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	S	202	202	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	C	119	119	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	L	188	188	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	Y	374	374	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	F	395	395	putative ligand binding site
VbeUA5Lmv1	a38d84822e972132df9f9eaedae61fc1	432	CDD-3.21	cd15323	36	420	17	T	120	120	putative ligand binding site
ZuL1ZJlBoc	48c2758d5a9857226313f835f5c79bfa	455	PIRSR-2023_05	PIRSR600732-5	376	455	1	C	455	455	LIPID: S-palmitoyl cysteine
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	C	118	118	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	Y	463	463	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	V	455	455	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	D	114	114	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	I	459	459	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	F	435	435	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	W	110	110	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	L	436	436	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	Y	439	439	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	V	201	201	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	S	204	204	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	T	119	119	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	W	432	432	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	A	205	205	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	S	208	208	ligand binding site
x6ifFLyvtH	db1029571214007c945edbf8f3c66e6e	497	CDD-3.21	cd14967	49	484	16	V	115	115	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	Y	308	308	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	T	118	118	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	N	293	293	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	W	109	109	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	F	290	290	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	V	117	117	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	W	286	286	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	F	193	193	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	S	203	203	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	F	289	289	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	Y	316	316	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	Y	199	199	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	N	312	312	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	D	113	113	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	S	204	204	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	S	207	207	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	V	114	114	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	18	D	192	192	ligand binding site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	I	135	135	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	V	225	225	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	Q	142	142	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	K	232	232	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	A	134	134	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	R	228	228	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	A	271	271	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	L	275	275	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	R	63	63	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	K	140	140	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	P	138	138	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	V	222	222	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	E	62	62	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	R	131	131	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	Y	141	141	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	S	143	143	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	L	230	230	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	K	270	270	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	T	274	274	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	F	139	139	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	I	233	233	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	Q	229	229	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	T	136	136	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	CDD-3.21	cd15957	34	336	24	A	226	226	G protein interaction site
COqJyjUzEG	8d9424eafd30053b33b292422f3a9df6	418	PIRSR-2023_05	PIRSR603912-52	42	227	1	CEFWTSIDVLCVTASIETLCVIAVDRYVAITSPFKYQSLLTKNKARVVILMVWIVSGLTSFLPIQMH--WYRATHKKAIDC	106	184	DISULFID: 
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	F	302	302	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	T	113	113	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	S	199	199	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	W	104	104	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	W	280	280	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	N	287	287	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	A	195	195	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	S	198	198	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	D	108	108	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	F	284	284	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	S	202	202	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	V	109	109	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	T	306	306	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	L	188	188	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	F	283	283	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	Y	310	310	putative ligand binding site
PsaQsrOOic	ace6b3c69b565b6c2fd26a10605bbb36	385	CDD-3.21	cd15065	30	331	17	S	112	112	putative ligand binding site
h265AZ8Nuy	999dc6d45d27d83c82f6c72b0f20ded7	413	PIRSR-2023_05	PIRSR600732-5	331	408	1	C	408	408	LIPID: S-palmitoyl cysteine
h265AZ8Nuy	999dc6d45d27d83c82f6c72b0f20ded7	413	PIRSR-2023_05	PIRSR603912-52	48	220	1	CDIFIALDVLCCTSSILHLCVIALDRYWAITNPIDYVNKRTPRRAVIMISLTWLVGFSISIPPMLGWRTPE-DRADPNAC	104	182	DISULFID: 
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	D	126	126	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	F	366	366	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	A	385	385	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	W	122	122	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	W	362	362	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	F	365	365	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	D	386	386	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	T	389	389	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	Y	393	393	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	T	131	131	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	A	211	211	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	V	372	372	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	V	127	127	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	P	382	382	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	S	207	207	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	C	130	130	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	C	194	194	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	CDD-3.21	cd15064	64	414	18	L	123	123	ligand binding site
eK3i9pb9zV	266c9bfe775634b39cf1723a6ccdfcbb	424	PIRSR-2023_05	PIRSR601681-50	48	227	1	CDLWLSLDVTCCTASILHLCAIALDRFWAITDAAEYAHKRTPGRAA-LMIAASWLLAACISVPPLFWRR--RDPTKPRC	119	194	DISULFID: 
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	T	139	139	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	Y	431	431	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	Y	405	405	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	V	135	135	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	C	138	138	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	L	211	211	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	F	402	402	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	S	221	221	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	W	398	398	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	D	134	134	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	F	401	401	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	C	222	222	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	Y	130	130	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	S	225	225	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	F	423	423	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	I	218	218	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	CDD-3.21	cd15321	49	452	17	F	427	427	putative ligand binding site
T4ND5HkViV	fee5a16a6d52db192b1dd8691a10de04	464	PIRSR-2023_05	PIRSR600732-5	375	459	1	C	457	457	LIPID: S-palmitoyl cysteine
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	S	211	211	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	F	313	313	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	V	129	129	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	Y	341	341	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	F	333	333	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	A	207	207	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	S	210	210	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	T	133	133	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	F	337	337	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	W	124	124	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	S	214	214	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	C	132	132	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	L	317	317	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	F	314	314	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	I	200	200	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	D	128	128	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	CDD-3.21	cd15326	51	362	17	W	310	310	putative ligand binding site
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	PIRSR-2023_05	PIRSR600732-3	57	236	1	CDIWAAVDVLCCTASIMSLCVISIDRYIGVRYSLQYPTVVTRKKAILALLGVWVLSMVISIGPLLGWKEPAPKDEKV-C	121	198	DISULFID: 
LsoOtPQfJ5	85ebbeea20e6bbae15524f76aec42a54	488	PIRSR-2023_05	PIRSR600732-5	291	368	1	C	368	368	LIPID: S-palmitoyl cysteine
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	PIRSR-2023_05	PIRSR600732-5	262	342	1	C	342	342	LIPID: S-palmitoyl cysteine
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	W	281	281	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	D	83	83	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	W	79	79	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	S	308	308	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	R	305	305	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	F	285	285	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	S	189	189	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	V	80	80	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	Y	316	316	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	R	291	291	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	L	312	312	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	V	84	84	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	A	185	185	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	F	284	284	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	C	87	87	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	S	309	309	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	T	88	88	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	CDD-3.21	cd15329	4	337	18	C	173	173	putative ligand binding site
52ZDhjNETE	a12b27166a0b193278d1a69184b6d052	363	PIRSR-2023_05	PIRSR600732-1	262	342	1	Q	297	297	BINDING: Zn(2+)
ahsba9i3Ki	50384f5fcbb709144dd6c62eda7d35f1	453	PIRSR-2023_05	PIRSR600732-5	373	453	1	C	453	453	LIPID: S-palmitoyl cysteine
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	I	103	103	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	T	107	107	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	W	324	324	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	S	201	201	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	F	287	287	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	I	320	320	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	D	102	102	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	S	187	187	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	S	198	198	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	W	284	284	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	W	98	98	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	F	316	316	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	N	291	291	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	S	106	106	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	S	197	197	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	F	288	288	putative ligand binding site
XxkDhc1q71	a92e3b8a43043bd6be62b901baf9fef3	451	CDD-3.21	cd15320	22	344	17	A	194	194	putative ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	PIRSR-2023_05	PIRSR600732-5	15	315	1	C	307	307	LIPID: S-palmitoyl cysteine
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	PIRSR-2023_05	PIRSR600732-5	15	315	1	C	308	308	LIPID: S-palmitoyl cysteine
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	A	171	171	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	S	174	174	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	F	254	254	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	D	89	89	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	W	250	250	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	R	273	273	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	F	253	253	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	V	90	90	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	S	178	178	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	T	277	277	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	Y	281	281	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	T	94	94	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	W	85	85	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	S	175	175	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	Y	257	257	ligand binding site
b3rYWyuQhm	b4383b616601830ac816db2f202266a8	369	CDD-3.21	cd14967	13	302	16	C	93	93	ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	PIRSR-2023_05	PIRSR603912-52	31	219	1	CDIFISLDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPKRAAILISLTWLIGFSISIPPMLGWRTPE-DRADPNAC	103	181	DISULFID: 
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	PIRSR-2023_05	PIRSR600732-5	328	405	1	C	405	405	LIPID: S-palmitoyl cysteine
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	D	110	110	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	F	350	350	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	Y	378	378	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	G	370	370	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	W	346	346	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	F	349	349	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	I	107	107	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	A	197	197	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	C	181	181	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	L	356	356	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	D	374	374	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	T	115	115	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	A	371	371	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	S	193	193	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	V	111	111	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	V	367	367	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	C	114	114	putative ligand binding site
zZpSRhtEjp	567c7c29f20cd8278526ae6e76506302	410	CDD-3.21	cd15330	31	399	18	F	106	106	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	PIRSR-2023_05	PIRSR601681-50	20	244	1	CDVWTSLDVFLCTASILNLCVISVDRYFVITRPFQYAMKRTPLRMTCMIVFVWLLSALISIPPMFGW--KEDPKKDHC	138	213	DISULFID: 
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	T	150	150	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	K	327	327	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	L	346	346	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	A	225	225	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	W	141	141	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	W	317	317	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	Y	350	350	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	A	229	229	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	H	339	339	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	C	149	149	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	C	213	213	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	F	321	321	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	T	142	142	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	D	145	145	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	V	146	146	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	N	342	342	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	A	343	343	putative ligand binding site
GN9LlBOOkT	6dad65fe5d3cf87bca5c4fb88270b69b	403	CDD-3.21	cd15329	67	371	18	F	320	320	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	V	134	134	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	S	222	222	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	Y	303	303	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	Y	330	330	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	T	225	225	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	D	322	322	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	V	218	218	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	L	211	211	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	T	138	138	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	F	307	307	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	F	129	129	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	W	300	300	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	C	137	137	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	V	221	221	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	L	326	326	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	D	133	133	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	CDD-3.21	cd15051	53	351	17	F	304	304	putative ligand binding site
UuXrZQLZFl	eb7120ae8957288fd8b5751881d2bb8f	373	PIRSR-2023_05	PIRSR600732-5	61	356	1	C	356	356	LIPID: S-palmitoyl cysteine
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	PIRSR-2023_05	PIRSR600732-3	55	233	1	CDIWAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGPLLGWKEPAPND-DKEC	118	195	DISULFID: 
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	W	121	121	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	S	211	211	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	L	314	314	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	F	334	334	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	C	129	129	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	V	197	197	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	W	307	307	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	D	125	125	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	V	126	126	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	F	310	310	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	F	311	311	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	Y	338	338	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	S	207	207	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	F	330	330	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	T	130	130	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	A	204	204	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	CDD-3.21	cd15326	46	359	17	S	208	208	putative ligand binding site
yTN3HKtHgW	499eccff081e6f2e55013bb106d191ee	520	PIRSR-2023_05	PIRSR600732-5	289	365	1	C	365	365	LIPID: S-palmitoyl cysteine
EJJZSJV6we	71c4bf743c6c376ce27f779596c37a79	611	PIRSR-2023_05	PIRSR600732-5	507	594	1	C	594	594	LIPID: S-palmitoyl cysteine
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	F	334	334	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	C	107	107	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	T	358	358	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	S	185	185	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	F	335	335	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	Y	362	362	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	I	354	354	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	L	99	99	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	D	103	103	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	V	181	181	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	S	184	184	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	H	338	338	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	CDD-3.21	cd15308	43	383	13	V	104	104	putative ligand binding site
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	PIRSR-2023_05	PIRSR600732-3	20	204	1	CDALMTMDVMLCTASILNLCAISVDRYIAVLVPLRYNRNQFSG-RQLVLIVATWVLSLGVASPVIFGLNR-VPNRDPRVC	96	173	DISULFID: 
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	PIRSR-2023_05	PIRSR600732-5	313	389	1	C	389	389	LIPID: S-palmitoyl cysteine
OuhfLRByWk	2def13f53df381ef3caaaa9ffdc54ec6	391	PIRSR-2023_05	PIRSR600732-5	313	389	1	C	388	388	LIPID: S-palmitoyl cysteine
uYncJzfw24	8303d5b4b72786707485769819de882e	345	PIRSR-2023_05	PIRSR600732-5	63	335	1	C	333	333	LIPID: S-palmitoyl cysteine
htw6R69tCN	89f337f07c670a1e9ada9648f0285af0	492	PIRSR-2023_05	PIRSR600732-5	266	342	1	C	342	342	LIPID: S-palmitoyl cysteine
htw6R69tCN	89f337f07c670a1e9ada9648f0285af0	492	PIRSR-2023_05	PIRSR600732-3	27	216	1	CDIWAAVDVLCCTASIMSLCIISIDRYIGVRYSLRYPTIMTEKKAVWILIVLWLSSMVISIGPLLGWKEPAPDDET-VC	99	176	DISULFID: 
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	S	195	195	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	V	102	102	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	T	198	198	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	F	287	287	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	A	191	191	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	T	309	309	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	Y	313	313	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	W	97	97	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	F	305	305	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	W	284	284	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	L	184	184	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	C	105	105	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	N	291	291	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	S	106	106	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	D	101	101	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	F	288	288	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	CDD-3.21	cd15054	22	334	17	A	194	194	putative ligand binding site
gZEsHkbcuV	ad607415e112e4d8230668c166c4da08	437	PIRSR-2023_05	PIRSR600732-5	265	352	1	C	340	340	LIPID: S-palmitoyl cysteine
ymVJcPnJaj	0e33b7b7e5be92745f2924087b6d1902	424	PIRSR-2023_05	PIRSR600732-5	57	360	1	C	357	357	LIPID: S-palmitoyl cysteine
ymVJcPnJaj	0e33b7b7e5be92745f2924087b6d1902	424	PIRSR-2023_05	PIRSR600732-5	57	360	1	C	358	358	LIPID: S-palmitoyl cysteine
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	329	329	LIPID: S-palmitoyl cysteine
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	L	298	298	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	R	96	96	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	D	100	100	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	A	193	193	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	F	276	276	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	V	101	101	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	F	275	275	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	Y	302	302	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	A	200	200	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	T	105	105	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	C	196	196	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	F	186	186	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	W	272	272	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	S	197	197	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	W	294	294	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	T	104	104	putative ligand binding site
ahgmxOmQsg	b01ec59644456201423a82110c8d5076	388	CDD-3.21	cd15056	20	323	17	N	279	279	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	PIRSR-2023_05	PIRSR603912-52	42	229	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSRRRVTVMISVVWVLSFAISCPLLFGLNNT--ATRDQSLC	105	183	DISULFID: 
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	PIRSR-2023_05	PIRSR600732-5	383	463	1	C	463	463	LIPID: S-palmitoyl cysteine
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	S	195	195	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	F	409	409	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	Y	436	436	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	V	113	113	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	S	194	194	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	F	408	408	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	T	432	432	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	H	412	412	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	Y	428	428	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	C	116	116	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	F	108	108	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	V	191	191	putative ligand binding site
9PxYEmwaIA	7805d6b5717831e8e19005ad3439167d	463	CDD-3.21	cd15309	33	457	13	D	112	112	putative ligand binding site
vaw91nJbps	77e32af3a7030a28f57da3826910eb5b	270	PIRSR-2023_05	PIRSR600732-3	9	201	1	CDVWAAVDVLCCTASIMSLCVISIDRYIGVTRPLQHSTIMSERRAGYIILIVWILAMTISIAPLLGWKEPPPDNPSV-C	80	157	DISULFID: 
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	I	103	103	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	T	107	107	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	W	324	324	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	S	201	201	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	F	287	287	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	V	320	320	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	D	102	102	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	S	187	187	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	S	198	198	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	W	284	284	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	W	98	98	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	F	316	316	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	N	291	291	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	S	106	106	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	S	197	197	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	F	288	288	putative ligand binding site
FqYn2MmbdV	0eebdfa1bfce06e97a3f727044764509	451	CDD-3.21	cd15320	22	344	17	A	194	194	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	PIRSR-2023_05	PIRSR600732-1	363	442	1	Q	402	402	BINDING: Zn(2+)
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	T	102	102	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	S	185	185	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	Y	394	394	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	F	415	415	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	I	178	178	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	Y	419	419	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	W	387	387	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	C	101	101	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	S	182	182	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	F	390	390	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	F	391	391	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	Y	93	93	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	D	97	97	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	V	98	98	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	L	171	171	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	S	181	181	putative ligand binding site
EbHYNkVDGh	a478be456af1e0e19177e571b5dfc0c4	453	CDD-3.21	cd15321	12	440	17	F	411	411	putative ligand binding site
YK0jHEV8EG	04e994b77a74df81b43d7a5fa7464299	1256	PIRSR-2023_05	PIRSR600732-5	1157	1241	1	C	1240	1240	LIPID: S-palmitoyl cysteine
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	W	297	297	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	S	307	307	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	C	123	123	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	T	124	124	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	F	301	301	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	L	323	323	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	D	119	119	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	W	115	115	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	C	190	190	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	Y	327	327	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	I	116	116	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	K	319	319	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	F	300	300	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	A	206	206	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	S	202	202	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	P	316	316	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	V	120	120	putative ligand binding site
UNGc5H2ZuT	b8ac258808f1b848d007eab05a067039	356	CDD-3.21	cd15328	39	348	18	S	320	320	putative ligand binding site
FFrTeYpcZP	6342740d1d0d8116bc9c15f8de0dcbdf	601	PIRSR-2023_05	PIRSR600732-1	524	593	1	Q	556	556	BINDING: Zn(2+)
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	S	179	179	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	C	102	102	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	M	344	344	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	S	180	180	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	F	324	324	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	T	348	348	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	L	94	94	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	D	98	98	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	H	328	328	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	V	176	176	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	F	325	325	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	Y	352	352	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	CDD-3.21	cd15308	20	373	13	V	99	99	putative ligand binding site
Yu2cfILHmc	b842a1a6f641459d0adafe1536b66578	382	PIRSR-2023_05	PIRSR600732-3	23	196	1	CDGLMTMDVMLCTASIFNLCAISVDRFIAVSIPLNYNRKHVDYRQIILLSATWLLALAVASPVIFGIN-NVPQRDPSEC	91	168	DISULFID: 
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	I	119	119	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	T	123	123	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	F	318	318	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	D	339	339	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	T	342	342	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	S	201	201	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	Y	346	346	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	C	188	188	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	W	314	314	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	F	317	317	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	C	122	122	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	L	115	115	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	F	338	338	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	P	335	335	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	L	324	324	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	D	118	118	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	W	114	114	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	CDD-3.21	cd15333	35	367	18	A	205	205	ligand binding site
ej0NOsAKz0	d400ed5813ff221160aef215829837fb	377	PIRSR-2023_05	PIRSR600732-3	42	222	1	CDIWLSSDITCCTASILHLCVIALDRYWAITDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAKAQEEMS-DC	111	188	DISULFID: 
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	PIRSR-2023_05	PIRSR600732-3	48	225	1	CDIWLSSDITCCTASILHLCVIALDRYWAITDALEYTKRRTAGRVAIMIAVVWVISICISMPPLFWRQAKVSEEVK-EC	112	189	DISULFID: 
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	PIRSR-2023_05	PIRSR600732-1	296	368	1	Q	329	329	BINDING: Zn(2+)
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	F	318	318	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	C	123	123	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	P	336	336	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	F	319	319	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	D	340	340	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	L	325	325	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	T	124	124	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	D	119	119	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	W	115	115	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	L	116	116	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	F	339	339	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	A	206	206	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	T	343	343	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	S	202	202	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	Y	347	347	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	I	120	120	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	W	315	315	ligand binding site
hsGr8UQtI6	21936ea615dae6a34b86de39ea098f85	378	CDD-3.21	cd15333	37	368	18	C	189	189	ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	W	308	308	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	T	145	145	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	W	330	330	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	N	315	315	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	C	234	234	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	L	334	334	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	F	312	312	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	T	144	144	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	S	235	235	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	R	136	136	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	D	140	140	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	F	311	311	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	Y	338	338	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	A	238	238	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	A	231	231	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	V	141	141	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	CDD-3.21	cd15056	60	359	17	F	224	224	putative ligand binding site
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	PIRSR-2023_05	PIRSR600732-5	63	368	1	C	365	365	LIPID: S-palmitoyl cysteine
b2HrLIUlsY	8acff4ac6ab46df738af9182ead71ec1	415	PIRSR-2023_05	PIRSR600732-5	63	368	1	C	364	364	LIPID: S-palmitoyl cysteine
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	N	330	330	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	C	107	107	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	E	326	326	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	S	185	185	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	S	329	329	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	C	172	172	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	V	316	316	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	T	108	108	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	D	103	103	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	W	99	99	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	L	100	100	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	F	310	310	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	W	306	306	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	F	309	309	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	I	104	104	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	A	189	189	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	A	333	333	putative ligand binding site
BFiAxqEaEq	34ca2868f2f1b05d081c518307b848de	366	CDD-3.21	cd15334	24	359	18	Y	337	337	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	F	377	377	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	Y	404	404	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	V	166	166	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	L	400	400	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	T	170	170	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	S	397	397	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	F	376	376	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	A	250	250	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	W	161	161	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	C	238	238	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	T	254	254	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	G	393	393	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	F	396	396	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	C	169	169	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	W	373	373	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	T	162	162	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	D	165	165	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	CDD-3.21	cd15331	86	425	18	M	383	383	putative ligand binding site
21jyHNEWgh	42e53bd799b5cca57f09c8e86a0ff3e2	441	PIRSR-2023_05	PIRSR600732-5	351	432	1	C	430	430	LIPID: S-palmitoyl cysteine
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	PIRSR-2023_05	PIRSR600732-5	307	401	1	C	398	398	LIPID: S-palmitoyl cysteine
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	L	367	367	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	R	347	347	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	S	233	233	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	C	156	156	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	F	148	148	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	F	340	340	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	Y	371	371	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	D	152	152	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	E	363	363	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	W	337	337	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	V	153	153	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	I	149	149	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	L	360	360	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	F	341	341	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	R	364	364	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	T	157	157	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	A	237	237	putative ligand binding site
yQ6RZhmbOA	9801ef36f74169337ca23d707d71cd6e	426	CDD-3.21	cd15329	72	392	18	C	221	221	putative ligand binding site
h3Ii0A6nh9	ed8a3b086c0ec78f420beb616e4eb196	467	PIRSR-2023_05	PIRSR600732-5	383	467	1	C	467	467	LIPID: S-palmitoyl cysteine
BhNqusWZNJ	81b5fd93743975292d38830c49bdd0ee	378	PIRSR-2023_05	PIRSR600732-3	39	221	1	CEAWLSVDVTCCTCSILHLCVIALDRYWAITKAIEYARKRTARRAGVMVAIVWVISIFISIPPLFWRQRGDANGPQQ-C	107	184	DISULFID: 
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	PIRSR-2023_05	PIRSR600732-3	100	284	1	CDVWAAVDVLCCTASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVPPDER-FC	169	246	DISULFID: 
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	S	259	259	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	W	361	361	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	V	177	177	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	F	388	388	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	L	368	368	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	F	365	365	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	Y	392	392	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	A	255	255	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	S	258	258	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	T	181	181	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	W	172	172	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	S	262	262	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	C	180	180	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	F	364	364	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	I	248	248	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	D	176	176	putative ligand binding site
E6EKU7XJH7	ded742346f60b559b3a764abfc6fb708	572	CDD-3.21	cd15327	97	413	17	F	384	384	putative ligand binding site
jva1qkj7r3	296755331e2876c112d7cdbb210ab648	528	PIRSR-2023_05	PIRSR600732-3	68	245	1	CDFYIAVDVTCSTASIFNLVAISIDRYIAVTKPIKYSKHKNGKRVSLMIAIVWLVSAAIGSPIVLGLNTSV-ERIPELC	128	205	DISULFID: 
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	D	137	137	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	Y	357	357	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	V	138	138	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	V	346	346	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	W	323	323	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	I	134	134	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	C	206	206	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	F	326	326	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	T	142	142	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	F	327	327	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	R	350	350	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	A	222	222	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	F	133	133	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	E	349	349	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	S	218	218	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	L	353	353	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	C	141	141	putative ligand binding site
fN41cBZ9Qz	1a36909a26a28da348997d806a82c683	404	CDD-3.21	cd15329	57	378	18	R	333	333	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	PIRSR-2023_05	PIRSR600732-3	28	230	1	CNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDET-IC	99	176	DISULFID: 
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	F	308	308	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	I	178	178	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	W	285	285	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	T	111	111	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	F	312	312	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	V	107	107	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	F	289	289	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	Y	316	316	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	C	110	110	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	V	185	185	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	S	188	188	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	D	106	106	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	M	292	292	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	A	189	189	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	W	102	102	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	S	192	192	putative ligand binding site
sxrh8HYpqN	24dc3b59f9707089e81ee874ce901500	466	CDD-3.21	cd15325	27	337	17	F	288	288	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	PIRSR-2023_05	PIRSR600732-5	25	337	1	C	331	331	LIPID: S-palmitoyl cysteine
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	PIRSR-2023_05	PIRSR600732-5	25	337	1	C	330	330	LIPID: S-palmitoyl cysteine
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	T	107	107	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	C	198	198	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	T	108	108	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	S	199	199	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	D	103	103	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	W	296	296	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	N	281	281	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	A	202	202	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	A	195	195	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	F	278	278	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	R	99	99	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	F	188	188	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	W	274	274	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	F	277	277	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	Y	304	304	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	L	300	300	putative ligand binding site
bYeLQbb9ef	de476f3aaf5c6fc0722419ecf68118c3	362	CDD-3.21	cd15056	23	325	17	V	104	104	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	H	329	329	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	V	103	103	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	S	183	183	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	C	106	106	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	S	184	184	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	L	98	98	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	D	102	102	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	F	326	326	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	V	180	180	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	F	325	325	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	M	345	345	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	T	349	349	putative ligand binding site
setTvQyVfa	b01162a6f9fd9f8556e312a091ceaade	386	CDD-3.21	cd15308	24	374	13	Y	353	353	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	F	308	308	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	I	178	178	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	W	285	285	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	T	111	111	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	F	312	312	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	V	107	107	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	F	289	289	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	Y	316	316	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	C	110	110	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	V	185	185	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	S	188	188	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	D	106	106	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	M	292	292	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	A	189	189	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	W	102	102	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	S	192	192	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	CDD-3.21	cd15325	27	337	17	F	288	288	putative ligand binding site
vYl2dMskHr	0cd2c4ac0378a2db05c8a9628264942d	465	PIRSR-2023_05	PIRSR600732-3	28	231	1	CNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQKRGLLALMCVWALSLTISIGPLFGWKEQPPEDET-IC	99	176	DISULFID: 
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	PIRSR-2023_05	PIRSR600732-5	47	356	1	C	352	352	LIPID: S-palmitoyl cysteine
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	PIRSR-2023_05	PIRSR600732-5	47	356	1	C	353	353	LIPID: S-palmitoyl cysteine
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	A	224	224	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	T	129	129	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	C	220	220	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	F	210	210	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	W	296	296	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	S	221	221	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	W	318	318	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	T	128	128	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	N	303	303	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	R	120	120	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	L	322	322	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	D	124	124	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	A	217	217	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	F	300	300	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	V	125	125	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	F	299	299	putative ligand binding site
mNe8TaePHN	ca38f2a38c5363e9c6bd672f6ec591f0	419	CDD-3.21	cd15056	44	347	17	Y	326	326	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	Y	431	431	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	V	129	129	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	I	205	205	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	S	215	215	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	T	133	133	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	S	216	216	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	Y	409	409	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	Y	124	124	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	S	219	219	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	F	406	406	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	F	423	423	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	C	132	132	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	V	212	212	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	W	402	402	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	F	405	405	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	D	128	128	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	CDD-3.21	cd15322	49	452	17	F	427	427	putative ligand binding site
G6A0PCY4Wi	0043f4ee5ea45e23061358e28d5c7e4c	465	PIRSR-2023_05	PIRSR600732-5	380	460	1	C	457	457	LIPID: S-palmitoyl cysteine
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	W	281	281	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	S	190	190	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	V	97	97	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	F	303	303	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	N	288	288	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	F	285	285	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	L	179	179	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	S	189	189	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	T	101	101	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	A	186	186	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	T	307	307	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	W	92	92	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	Y	311	311	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	S	193	193	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	C	100	100	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	F	284	284	putative ligand binding site
lbOxXnN8b7	27df726adfcb8905e32ed67c1609288d	357	CDD-3.21	cd15065	18	332	17	D	96	96	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	M	354	354	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	S	355	355	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	V	86	86	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	F	334	334	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	Y	362	362	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	D	89	89	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	W	330	330	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	F	333	333	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	V	90	90	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	A	175	175	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	R	340	340	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	C	159	159	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	G	358	358	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	S	171	171	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	T	94	94	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	F	85	85	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	D	351	351	putative ligand binding site
UrVDM79A7d	6b6ab39842e7fbd5b460161ca1edf70a	406	CDD-3.21	cd15331	10	383	18	C	93	93	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	PIRSR-2023_05	PIRSR600732-5	312	399	1	C	398	398	LIPID: S-palmitoyl cysteine
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	L	367	367	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	R	347	347	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	S	233	233	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	C	156	156	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	F	148	148	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	F	340	340	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	Y	371	371	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	D	152	152	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	E	363	363	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	W	337	337	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	V	153	153	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	I	149	149	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	L	360	360	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	F	341	341	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	R	364	364	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	T	157	157	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	A	237	237	putative ligand binding site
oxTFCHgUrH	764dc6ef108ff283a851cac8fd2cc93a	427	CDD-3.21	cd15329	72	392	18	C	221	221	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	PIRSR-2023_05	PIRSR600732-3	55	233	1	CDIWAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGPLLGWKEPAPND-DKEC	118	195	DISULFID: 
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	W	121	121	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	S	211	211	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	L	314	314	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	F	334	334	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	C	129	129	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	V	197	197	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	W	307	307	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	D	125	125	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	V	126	126	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	F	310	310	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	F	311	311	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	Y	338	338	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	S	207	207	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	F	330	330	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	T	130	130	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	A	204	204	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	CDD-3.21	cd15326	46	359	17	S	208	208	putative ligand binding site
W2E0YxuufI	87f9cac134cfa9378cb0832de34bcf30	515	PIRSR-2023_05	PIRSR600732-5	289	365	1	C	365	365	LIPID: S-palmitoyl cysteine
RuVhpbVOFn	d9a3e983b89b155b6500e2bc20d20116	375	PIRSR-2023_05	PIRSR600732-3	28	231	1	CNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQKRGLLALMCVWALSLTISIGPLFGWKEQPPEDET-IC	99	176	DISULFID: 
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	C	246	246	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	S	489	489	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	A	326	326	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	A	486	486	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	D	242	242	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	C	314	314	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	W	467	467	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	W	238	238	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	F	470	470	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	F	471	471	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	L	493	493	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	V	239	239	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	T	247	247	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	S	330	330	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	S	490	490	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	Y	497	497	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	V	243	243	putative ligand binding site
qgjFiArfem	553600117b5c3c023fd1b6dc927bd269	564	CDD-3.21	cd15329	163	518	18	R	477	477	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	S	227	227	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	Y	335	335	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	D	137	137	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	Y	328	328	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	V	138	138	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	A	223	223	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	S	226	226	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	F	354	354	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	S	141	141	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	F	216	216	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	V	350	350	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	S	230	230	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	T	142	142	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	F	332	332	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	F	133	133	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	F	331	331	putative ligand binding site
LMuYGPQkEA	84eb9fd39d943005298438a644a0795b	422	CDD-3.21	cd15066	58	379	17	Y	358	358	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	F	313	313	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	T	108	108	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	S	199	199	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	W	285	285	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	D	103	103	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	W	99	99	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	N	292	292	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	S	107	107	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	F	289	289	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	W	321	321	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	A	195	195	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	S	198	198	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	S	188	188	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	S	202	202	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	I	104	104	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	V	317	317	putative ligand binding site
OQQhZ3TkSQ	6737fb98621dbfe99e5728efe7c1dc05	446	CDD-3.21	cd15320	23	341	17	F	288	288	putative ligand binding site
o4DTptAEa7	8c6ad7ccf314b56b597affb6dbd07331	431	PIRSR-2023_05	PIRSR600732-3	38	229	1	CNAWTALDVLCCTASILSLCVISVDRCMAVSYPLQYPSFATGRRAMTAVAALWALSAAISVGPLFGWREPMPEDESV-C	109	186	DISULFID: 
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	S	195	195	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	Y	303	303	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	D	105	105	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	V	106	106	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	A	191	191	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	S	194	194	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	W	296	296	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	S	109	109	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	F	323	323	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	F	184	184	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	S	198	198	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	Y	327	327	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	T	110	110	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	F	300	300	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	V	319	319	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	W	101	101	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	CDD-3.21	cd15066	27	348	17	F	299	299	putative ligand binding site
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	PIRSR-2023_05	PIRSR600732-5	275	371	1	C	357	357	LIPID: S-palmitoyl cysteine
N4QKA4HR97	91fa7d3e1993a3b5fdf36ed1baa2cfd8	397	PIRSR-2023_05	PIRSR600732-5	275	371	1	C	358	358	LIPID: S-palmitoyl cysteine
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	PIRSR-2023_05	PIRSR600732-5	88	396	1	C	395	395	LIPID: S-palmitoyl cysteine
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	PIRSR-2023_05	PIRSR600732-5	88	396	1	C	394	394	LIPID: S-palmitoyl cysteine
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	F	361	361	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	N	346	346	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	T	182	182	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	W	173	173	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	F	258	258	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	S	269	269	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	W	339	339	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	W	369	369	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	F	342	342	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	F	343	343	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	T	265	265	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	D	177	177	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	S	268	268	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	V	178	178	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	S	181	181	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	T	365	365	putative ligand binding site
pCZ3qSydBt	0265b96a4250f3c2cddb3fcb581ef93f	453	CDD-3.21	cd15057	99	389	17	S	272	272	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
wlz41bBw8B	f9f7cd3e037aff107be860de859e8d9b	377	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
ItIzhSIr0M	5d579c18a5fba9a20baf9a44c483bea3	364	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	S	195	195	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	Y	388	388	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	W	356	356	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	T	118	118	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	I	188	188	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	L	181	181	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	C	192	192	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	F	360	360	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	C	117	117	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	F	359	359	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	Y	109	109	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	D	113	113	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	F	380	380	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	S	191	191	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	V	114	114	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	Y	363	363	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	CDD-3.21	cd15324	50	409	17	F	384	384	putative ligand binding site
IVTbt8Udzq	508381edef392d47b1e89cb0d34f60ba	420	PIRSR-2023_05	PIRSR600732-5	328	414	1	C	414	414	LIPID: S-palmitoyl cysteine
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	PIRSR-2023_05	PIRSR600732-5	346	426	1	C	424	424	LIPID: S-palmitoyl cysteine
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	C	150	150	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	W	367	367	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	D	146	146	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	S	231	231	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	F	370	370	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	T	394	394	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	F	371	371	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	Y	398	398	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	W	142	142	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	I	390	390	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	S	230	230	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	T	151	151	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	S	234	234	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	L	220	220	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	Y	374	374	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	V	147	147	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	CDD-3.21	cd15060	67	418	17	V	227	227	putative ligand binding site
KDpd1z6UK2	5bfa76c565004860b6b09f836c09461a	427	PIRSR-2023_05	PIRSR600732-1	346	426	1	Q	381	381	BINDING: Zn(2+)
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	PIRSR-2023_05	PIRSR600732-1	309	389	1	Q	341	341	BINDING: Zn(2+)
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	PIRSR-2023_05	PIRSR600732-5	309	389	1	C	385	385	LIPID: S-palmitoyl cysteine
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	V	81	81	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	S	84	84	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	S	183	183	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	L	179	179	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	T	85	85	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	Y	172	172	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	W	76	76	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	S	182	182	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	T	334	334	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	W	327	327	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	W	359	359	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	G	351	351	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	N	355	355	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	S	186	186	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	F	330	330	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	D	80	80	putative ligand binding site
RwbpMgInso	400a96aa8ca580b7a94d878ce9bebb89	392	CDD-3.21	cd15067	1	380	17	F	331	331	putative ligand binding site
bd5KfgBYoV	da7ae47dd5dae620af92716d25d1e151	531	PIRSR-2023_05	PIRSR600732-5	440	531	1	C	531	531	LIPID: S-palmitoyl cysteine
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	PIRSR-2023_05	PIRSR600732-5	348	433	1	C	433	433	LIPID: S-palmitoyl cysteine
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	S	206	206	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	H	382	382	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	Y	398	398	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	C	128	128	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	F	120	120	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	V	203	203	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	D	124	124	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	S	207	207	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	F	378	378	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	V	125	125	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	T	402	402	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	F	379	379	ligand binding site
1mNDukfNbs	4cd01a553e494419737ec375444ca59b	433	CDD-3.21	cd15310	44	427	13	Y	406	406	ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	S	211	211	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	F	297	297	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	T	123	123	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	Y	325	325	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	V	119	119	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	F	114	114	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	F	296	296	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	D	118	118	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	Y	300	300	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	F	321	321	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	F	197	197	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	S	207	207	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	F	293	293	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	S	122	122	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	A	204	204	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	G	317	317	putative ligand binding site
s1HvKHReky	4d55eed390b9220f726edcca5b05cac9	390	CDD-3.21	cd15066	39	346	17	S	208	208	putative ligand binding site
kvpaBQTK2F	14658bd9ca85782c0b00778bb4c8be93	408	PIRSR-2023_05	PIRSR600732-5	26	335	1	C	333	333	LIPID: S-palmitoyl cysteine
kvpaBQTK2F	14658bd9ca85782c0b00778bb4c8be93	408	PIRSR-2023_05	PIRSR600732-5	26	335	1	C	332	332	LIPID: S-palmitoyl cysteine
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	PIRSR-2023_05	PIRSR600732-1	45	224	1	E	199	199	BINDING: Zn(2+)
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	S	206	206	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	F	382	382	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	F	383	383	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	V	124	124	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	I	203	203	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	S	210	210	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	C	127	127	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	C	207	207	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	L	196	196	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	F	403	403	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	T	128	128	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	Y	119	119	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	D	123	123	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	Y	386	386	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	F	407	407	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	Y	411	411	putative ligand binding site
Ez9ZtxssKH	cf8d156995c04cea01aeeecaf2e2d0a8	446	CDD-3.21	cd15323	51	432	17	W	379	379	putative ligand binding site
VqjTynTS3x	4d7dc4a5c1a6762b4268a8ccf63c0d88	374	PIRSR-2023_05	PIRSR600732-3	44	222	1	CDIWVSSDITCCTASILHLCVIALDRYWAITDALEYSKRRTAGHAAAMIAAVWIISICISIPPLFWRQATAHEEM-SDC	108	185	DISULFID: 
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	D	110	110	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	Y	196	196	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	F	190	190	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	S	201	201	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	W	106	106	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	W	280	280	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	Y	302	302	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	D	189	189	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	S	200	200	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	N	287	287	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	T	115	115	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	N	306	306	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	S	204	204	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	F	284	284	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	V	111	111	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	V	114	114	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	F	283	283	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	18	Y	310	310	ligand binding site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	R	128	128	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	Y	138	138	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	K	264	264	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	T	268	268	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	A	223	223	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	L	227	227	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	Q	226	226	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	T	133	133	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	F	136	136	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	V	219	219	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	K	225	225	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	I	230	230	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	A	131	131	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	V	222	222	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	Q	59	59	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	Q	139	139	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	I	132	132	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	A	265	265	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	S	140	140	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	L	269	269	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	K	229	229	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	R	60	60	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	P	135	135	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	CDD-3.21	cd15957	31	330	24	K	137	137	G protein interaction site
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	PIRSR-2023_05	PIRSR603912-52	36	223	1	CEFWTSLDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKSKARVVILVVWAISALTSFLPIQMH--WYRADRDEAILC	103	181	DISULFID: 
kbUXzYwyJT	c3f0d1206d3c5d0c4a175a9ac73073f3	470	PIRSR-2023_05	PIRSR600732-1	34	321	1	Q	293	293	BINDING: Zn(2+)
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	PIRSR-2023_05	PIRSR600732-5	338	423	1	C	420	420	LIPID: S-palmitoyl cysteine
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	Y	116	116	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	I	199	199	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	S	206	206	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	F	366	366	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	C	203	203	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	L	192	192	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	Y	394	394	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	C	124	124	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	W	362	362	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	F	365	365	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	F	386	386	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	D	120	120	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	F	390	390	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	V	121	121	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	S	202	202	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	T	125	125	putative ligand binding site
iLQ3EX95bZ	8891c244422c3472046a2cf70b159be7	430	CDD-3.21	cd15321	35	415	17	Y	369	369	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	PIRSR-2023_05	PIRSR600732-5	22	304	1	C	304	304	LIPID: S-palmitoyl cysteine
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	C	102	102	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	D	185	185	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	Y	277	277	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	D	98	98	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	F	253	253	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	Y	94	94	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	G	182	182	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	Y	249	249	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	G	186	186	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	V	175	175	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	T	103	103	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	E	269	269	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	F	250	250	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	T	189	189	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	W	246	246	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	L	273	273	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	CDD-3.21	cd15051	19	298	17	V	99	99	putative ligand binding site
0IdEYSXVDV	d0df52c7b91392ab543f00199564943f	371	PIRSR-2023_05	PIRSR600732-1	22	304	1	E	179	179	BINDING: Zn(2+)
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	329	329	LIPID: S-palmitoyl cysteine
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	L	298	298	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	R	96	96	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	D	100	100	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	A	193	193	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	F	276	276	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	V	101	101	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	F	275	275	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	Y	302	302	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	A	200	200	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	T	105	105	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	C	196	196	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	F	186	186	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	W	272	272	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	S	197	197	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	W	294	294	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	T	104	104	putative ligand binding site
SEPcH2aA2u	213e2f4f466b474be1cf17db4c6d67d6	371	CDD-3.21	cd15056	20	323	17	N	279	279	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	T	129	129	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	A	209	209	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	F	356	356	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	W	333	333	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	W	120	120	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	C	128	128	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	T	213	213	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	M	343	343	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	C	197	197	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	F	337	337	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	Y	364	364	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	D	124	124	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	T	121	121	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	D	353	353	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	L	360	360	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	V	125	125	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	S	357	357	putative ligand binding site
HR9CNTg3nN	8074d5f331b8e466e99b5f74f0652074	398	CDD-3.21	cd15331	45	385	18	F	336	336	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	F	345	345	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	R	368	368	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	T	161	161	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	A	241	241	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	C	225	225	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	L	371	371	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	R	351	351	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	S	237	237	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	C	160	160	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	F	152	152	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	F	344	344	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	Y	375	375	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	D	156	156	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	E	367	367	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	W	341	341	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	V	157	157	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	I	153	153	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	CDD-3.21	cd15329	76	396	18	L	364	364	putative ligand binding site
lyrWZMVXT3	504821db62733b0f230300f2388d0781	430	PIRSR-2023_05	PIRSR600732-5	317	403	1	C	402	402	LIPID: S-palmitoyl cysteine
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	PIRSR-2023_05	PIRSR600732-1	22	304	1	E	179	179	BINDING: Zn(2+)
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	C	102	102	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	D	185	185	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	Y	277	277	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	D	98	98	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	F	253	253	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	Y	94	94	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	G	182	182	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	Y	249	249	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	G	186	186	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	V	175	175	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	T	103	103	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	E	269	269	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	F	250	250	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	T	189	189	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	W	246	246	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	L	273	273	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	CDD-3.21	cd15051	19	298	17	V	99	99	putative ligand binding site
2YniQvqTqL	27c93d04cb41ed27ec187a38a681d5e2	397	PIRSR-2023_05	PIRSR600732-5	22	304	1	C	304	304	LIPID: S-palmitoyl cysteine
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	PIRSR-2023_05	PIRSR603912-52	53	231	1	CEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKCIIFIVWVISAVISFPPLITIEKESGKVEMPI--C	119	197	DISULFID: 
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	PIRSR-2023_05	PIRSR600732-5	348	429	1	C	426	426	LIPID: S-palmitoyl cysteine
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	D	126	126	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	I	199	199	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	Y	122	122	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	F	372	372	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	Y	376	376	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	S	210	210	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	F	392	392	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	W	369	369	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	T	131	131	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	S	209	209	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	F	396	396	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	V	127	127	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	F	373	373	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	Y	400	400	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	C	130	130	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	S	213	213	putative ligand binding site
0BEqzqGTzo	2a21e964a90063a0b0aeb636cf04f6c9	434	CDD-3.21	cd15322	47	421	17	I	206	206	putative ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	PIRSR-2023_05	PIRSR600732-1	295	369	1	Q	328	328	BINDING: Zn(2+)
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	I	119	119	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	T	123	123	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	F	318	318	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	D	339	339	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	T	342	342	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	S	201	201	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	Y	346	346	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	C	188	188	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	W	314	314	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	F	317	317	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	C	122	122	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	L	115	115	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	P	335	335	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	L	324	324	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	D	118	118	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	L	338	338	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	W	114	114	ligand binding site
rddJIJqTyp	2c9a915a5db9853e798f9343c61a2590	378	CDD-3.21	cd15333	35	367	18	A	205	205	ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	W	185	185	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	F	436	436	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	T	460	460	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	L	270	270	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	S	274	274	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	F	435	435	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	D	189	189	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	S	456	456	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	V	190	190	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	S	193	193	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	F	263	263	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	S	273	273	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	W	432	432	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	W	464	464	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	T	194	194	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	S	277	277	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	CDD-3.21	cd15067	122	485	17	N	439	439	putative ligand binding site
vY0zbb7ZvE	f78d5e5dbfa1e2df69951c3368382628	539	PIRSR-2023_05	PIRSR600732-5	414	492	1	C	490	490	LIPID: S-palmitoyl cysteine
A9MeIBAjV9	60b621ac2a3e6cd5b8f27d8eb6d2b000	364	PIRSR-2023_05	PIRSR600732-1	15	309	1	Q	264	264	BINDING: Zn(2+)
A9MeIBAjV9	60b621ac2a3e6cd5b8f27d8eb6d2b000	364	PIRSR-2023_05	PIRSR600732-5	15	309	1	C	307	307	LIPID: S-palmitoyl cysteine
pilO8HNY9a	0b1133abdeabb4acab73b0cfa5bc95e6	532	PIRSR-2023_05	PIRSR600732-5	441	532	1	C	532	532	LIPID: S-palmitoyl cysteine
g7dYmmGDi4	79f23d8d935f584a8a48ac603091f391	500	PIRSR-2023_05	PIRSR600732-1	84	413	1	Q	356	356	BINDING: Zn(2+)
g7dYmmGDi4	79f23d8d935f584a8a48ac603091f391	500	PIRSR-2023_05	PIRSR600732-5	84	413	1	C	401	401	LIPID: S-palmitoyl cysteine
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	D	158	158	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	R	363	363	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	F	340	340	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	I	155	155	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	E	362	362	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	L	366	366	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	F	339	339	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	R	346	346	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	T	163	163	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	A	243	243	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	L	359	359	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	C	227	227	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	Y	370	370	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	V	159	159	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	S	239	239	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	C	162	162	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	F	154	154	putative ligand binding site
pKC9lygYBQ	c77f00ece9b66c012eda7812c4208d53	436	CDD-3.21	cd15329	78	391	18	W	336	336	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	PIRSR-2023_05	PIRSR601681-50	36	215	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMITVVWVLSFAISCPLLFGLNNT---DQNEC	107	182	DISULFID: 
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	PIRSR-2023_05	PIRSR600732-5	369	448	1	C	448	448	LIPID: S-palmitoyl cysteine
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	C	118	118	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	F	110	110	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	T	417	417	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	Y	421	421	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	D	114	114	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	S	194	194	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	H	398	398	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	V	190	190	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	S	193	193	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	Y	413	413	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	F	394	394	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	F	395	395	putative ligand binding site
NAkrmgTROX	1e3846836fe8026e95274c1f2bbe4b93	448	CDD-3.21	cd15309	35	442	13	V	115	115	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	PIRSR-2023_05	PIRSR600732-5	21	332	1	C	328	328	LIPID: S-palmitoyl cysteine
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	PIRSR-2023_05	PIRSR600732-5	21	332	1	C	327	327	LIPID: S-palmitoyl cysteine
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	F	185	185	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	D	99	99	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	A	192	192	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	W	271	271	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	S	196	196	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	F	274	274	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	R	95	95	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	F	275	275	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	L	297	297	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	C	195	195	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	V	100	100	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	Y	301	301	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	W	293	293	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	T	103	103	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	A	199	199	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	N	278	278	putative ligand binding site
7tcXpq9NAE	262bf7c42a72ad429bacc7e4ba0258d0	377	CDD-3.21	cd15056	19	322	17	T	104	104	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	T	75	75	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	V	150	150	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	L	143	143	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	F	334	334	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	S	153	153	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	W	330	330	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	V	71	71	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	F	333	333	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	C	74	74	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	S	157	157	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	Y	361	361	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	A	154	154	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	D	70	70	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	F	353	353	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	H	66	66	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	F	357	357	putative ligand binding site
4ZqxZcHI4u	aa6527e1b3d9bfa544e6b50db8dae489	394	CDD-3.21	cd15059	1	382	17	Y	337	337	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	R	96	96	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	D	100	100	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	W	296	296	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	V	101	101	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	W	318	318	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	C	197	197	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	N	303	303	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	S	198	198	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	L	322	322	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	T	105	105	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	A	201	201	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	F	300	300	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	F	187	187	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	F	299	299	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	Y	326	326	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	T	104	104	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	CDD-3.21	cd15056	21	347	17	A	194	194	putative ligand binding site
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	PIRSR-2023_05	PIRSR600732-5	261	355	1	C	352	352	LIPID: S-palmitoyl cysteine
WGtSrGB9Z9	01696c8a6609def375e48c3b5502bdc6	388	PIRSR-2023_05	PIRSR600732-5	261	355	1	C	353	353	LIPID: S-palmitoyl cysteine
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	F	393	393	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	D	163	163	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	W	159	159	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	T	417	417	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	Y	421	421	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	S	247	247	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	S	251	251	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	A	248	248	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	V	164	164	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	V	244	244	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	L	237	237	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	Y	397	397	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	F	394	394	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	C	167	167	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	V	413	413	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	W	390	390	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	CDD-3.21	cd15060	84	442	17	T	168	168	putative ligand binding site
HLSHb7xvOH	d2cfa7e8ba39b607e5bb81a2c970e372	451	PIRSR-2023_05	PIRSR600732-5	372	447	1	C	447	447	LIPID: S-palmitoyl cysteine
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	F	393	393	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	C	214	214	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	R	400	400	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	T	150	150	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	L	469	469	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	A	230	230	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	F	141	141	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	S	226	226	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	C	149	149	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	D	145	145	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	R	473	473	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	Y	480	480	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	V	146	146	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	F	394	394	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	W	390	390	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	I	142	142	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	E	472	472	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	CDD-3.21	cd15329	65	501	18	L	476	476	putative ligand binding site
MkMSopoYv7	5ff44543eb6e3520a16de07cb4de7187	535	PIRSR-2023_05	PIRSR600732-5	481	507	1	C	507	507	LIPID: S-palmitoyl cysteine
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	Y	127	127	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	D	131	131	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	S	212	212	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	S	135	135	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	N	462	462	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	F	483	483	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	I	209	209	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	V	132	132	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	T	487	487	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	F	458	458	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	Y	491	491	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	F	203	203	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	S	213	213	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	CDD-3.21	cd15053	52	512	14	F	459	459	ligand binding site
jsiVJptAow	3dec8cbb06ed6cb94f04bd775ae60bf4	528	PIRSR-2023_05	PIRSR600732-3	63	247	1	CDFYIAVDVTCSTASIFNLVAISIDRYIAVTQPIKYSKHRNNKRVFLTIAIVWIVSAAIGSPIVLGLNT-SPERIPQLC	124	201	DISULFID: 
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	W	260	260	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	F	287	287	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	S	100	100	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	N	267	267	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	S	183	183	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	A	180	180	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	I	97	97	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	T	101	101	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	S	184	184	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	F	264	264	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	S	187	187	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	W	92	92	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	F	263	263	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	W	295	295	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	D	96	96	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	A	173	173	putative ligand binding site
zGvhs5K1Au	148ced0fbf419c07ea28634fe4a350bd	426	CDD-3.21	cd15057	17	315	17	V	291	291	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	PIRSR-2023_05	PIRSR603912-52	71	223	1	CDLFIALDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPE-DRSDPDAC	109	187	DISULFID: 
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	F	361	361	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	A	203	203	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	T	379	379	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	C	187	187	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	D	116	116	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	L	368	368	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	S	199	199	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	A	383	383	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	V	117	117	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	I	113	113	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	N	386	386	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	T	121	121	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	F	362	362	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	Y	390	390	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	C	120	120	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	G	382	382	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	F	112	112	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	CDD-3.21	cd15330	37	411	18	W	358	358	putative ligand binding site
tdaWGFkQKB	cf40229fe7a23bc3e1e4e19e4bafebfd	422	PIRSR-2023_05	PIRSR600732-5	339	417	1	C	417	417	LIPID: S-palmitoyl cysteine
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	PIRSR-2023_05	PIRSR600732-5	261	356	1	C	352	352	LIPID: S-palmitoyl cysteine
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	PIRSR-2023_05	PIRSR600732-5	261	356	1	C	353	353	LIPID: S-palmitoyl cysteine
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	R	96	96	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	D	100	100	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	W	296	296	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	V	101	101	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	W	318	318	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	C	197	197	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	N	303	303	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	S	198	198	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	L	322	322	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	T	105	105	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	A	201	201	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	F	300	300	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	F	187	187	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	F	299	299	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	Y	326	326	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	T	104	104	putative ligand binding site
q34kgPxjJj	8b6b454fb87f48a9b474a07cbf176616	419	CDD-3.21	cd15056	21	347	17	A	194	194	putative ligand binding site
yKB0rmTTAd	d7014a8d10e3f24de3addd46bdea041e	486	PIRSR-2023_05	PIRSR600732-3	51	228	1	CDIWAAVDVLCCTASIMSLCVISIDRYIGVRYPLQYPSIVTEKRALLAMLGVWVLAFVISIGPLLGWKEPPSE-DDTVC	115	192	DISULFID: 
yKB0rmTTAd	d7014a8d10e3f24de3addd46bdea041e	486	PIRSR-2023_05	PIRSR600732-5	282	359	1	C	358	358	LIPID: S-palmitoyl cysteine
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	PIRSR-2023_05	PIRSR600732-5	23	332	1	C	328	328	LIPID: S-palmitoyl cysteine
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	PIRSR-2023_05	PIRSR600732-5	23	332	1	C	329	329	LIPID: S-palmitoyl cysteine
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	L	298	298	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	R	96	96	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	D	100	100	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	A	193	193	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	F	276	276	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	V	101	101	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	F	275	275	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	Y	302	302	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	A	200	200	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	T	105	105	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	C	196	196	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	F	186	186	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	W	272	272	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	S	197	197	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	W	294	294	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	T	104	104	putative ligand binding site
Kj5hAn4v6q	d5a88aeb3a7ccf05c19f75fb2bd4af89	427	CDD-3.21	cd15056	20	323	17	N	279	279	putative ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	E	417	417	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	F	94	94	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	F	398	398	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	W	394	394	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	D	98	98	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	F	397	397	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	T	186	186	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	S	189	189	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	T	421	421	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	Y	425	425	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	S	102	102	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	S	193	193	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	A	190	190	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	I	99	99	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	T	103	103	ligand binding site
MYgqGdKqbZ	6f13875c87fa945da73e6841af5f6083	462	CDD-3.21	cd14967	20	446	16	Y	401	401	ligand binding site
cClFy4z1Nm	93a5e791b48ce9c7c7f28782f0167d28	366	PIRSR-2023_05	PIRSR600732-3	5	169	1	CDAWTSMDVLCCTASILHLVAIALDRYWAVTKVNYVHHRPLKTIVVMIILSWGISAIICLPPLMGWRQNGDQTPFLNC	61	138	DISULFID: 
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	D	99	99	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	P	320	320	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	W	95	95	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	L	96	96	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	D	324	324	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	V	311	311	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	W	301	301	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	A	186	186	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	F	305	305	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	A	323	323	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	S	182	182	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	C	169	169	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	T	327	327	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	Y	331	331	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	C	103	103	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	F	304	304	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	M	100	100	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	CDD-3.21	cd15335	20	352	18	T	104	104	putative ligand binding site
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	PIRSR-2023_05	PIRSR600732-3	21	207	1	CEIWLSVDMTCCTCSILHLCVIALDRYWAITDAIEYARKRTVKRAGIMILTVWTISVFISIPPLF-WRNHHNINIPSKC	92	169	DISULFID: 
PaflaJa5jF	b6bfa9ca54ebcc24607343cb37c49e1c	362	PIRSR-2023_05	PIRSR600732-1	276	356	1	Q	314	314	BINDING: Zn(2+)
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	S	323	323	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	I	119	119	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	K	322	322	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	F	303	303	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	Y	330	330	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	A	209	209	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	C	193	193	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	T	127	127	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	S	205	205	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	P	319	319	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	V	123	123	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	C	126	126	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	W	300	300	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	D	122	122	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	N	310	310	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	L	326	326	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	W	118	118	putative ligand binding site
tPS4ZlQpLO	011fd24a0a5017469254ccf85d3bb96f	359	CDD-3.21	cd15328	42	351	18	F	304	304	putative ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	W	313	313	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	C	187	187	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	F	317	317	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	D	338	338	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	L	323	323	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	T	122	122	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	T	341	341	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	S	200	200	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	Y	345	345	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	I	118	118	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	W	113	113	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	L	114	114	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	F	337	337	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	F	316	316	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	C	121	121	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	P	334	334	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	A	204	204	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	CDD-3.21	cd15333	34	366	18	D	117	117	ligand binding site
BAxjMqLOrV	e39cdea865c68ab605402d700493d3bc	376	PIRSR-2023_05	PIRSR600732-3	40	224	1	CDIWLLSDITCCTASILHLCVIALDRYWAITDALEYTKHRTARRAAVMILVVWIISICISIPPLFWRQAKAHEELTV-C	110	187	DISULFID: 
Uw4WAsVs2V	716e4143e1c3c7e4e5c42761b6686658	488	PIRSR-2023_05	PIRSR600732-5	409	488	1	C	488	488	LIPID: S-palmitoyl cysteine
0rCW1GYw10	955867157a9d522a29e5440557ce179d	579	PIRSR-2023_05	PIRSR600732-5	481	560	1	C	560	560	LIPID: S-palmitoyl cysteine
XdXJPD1B99	b6058613756d158af716a124162475cf	434	PIRSR-2023_05	PIRSR603912-52	15	238	1	CDFWTSLDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTKCKARLVVLLVWMVAGLTSFLPIYMR--WWRLSDTESLRC	118	196	DISULFID: 
XdXJPD1B99	b6058613756d158af716a124162475cf	434	PIRSR-2023_05	PIRSR600732-1	291	349	1	Q	321	321	BINDING: Zn(2+)
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	F	329	329	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	D	350	350	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	L	335	335	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	L	346	346	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	Y	357	357	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	A	214	214	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	F	349	349	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	S	210	210	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	I	129	129	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	T	133	133	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	F	328	328	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	C	197	197	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	W	124	124	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	C	132	132	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	L	125	125	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	W	325	325	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	N	353	353	ligand binding site
V7UFl5t0og	5f84c7e96b0fcbd5f80d9e96a77942c5	388	CDD-3.21	cd15333	45	378	18	D	128	128	ligand binding site
rTOE0myIj1	4dbd52e2842aefc5a0e93ce7e8592723	501	PIRSR-2023_05	PIRSR600732-3	89	255	1	CDALMTMDVMLCTASIFNLCAISVDRYIAVVVPFQYNRSRFGC-RQLVLIGATWVLSLGVASPVIFGLNDVERR-DPAVC	153	230	DISULFID: 
rTOE0myIj1	4dbd52e2842aefc5a0e93ce7e8592723	501	PIRSR-2023_05	PIRSR600732-5	421	498	1	C	496	496	LIPID: S-palmitoyl cysteine
rTOE0myIj1	4dbd52e2842aefc5a0e93ce7e8592723	501	PIRSR-2023_05	PIRSR600732-5	421	498	1	C	497	497	LIPID: S-palmitoyl cysteine
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	PIRSR-2023_05	PIRSR600732-5	261	355	1	C	352	352	LIPID: S-palmitoyl cysteine
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	PIRSR-2023_05	PIRSR600732-5	261	355	1	C	353	353	LIPID: S-palmitoyl cysteine
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	R	96	96	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	D	100	100	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	W	296	296	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	V	101	101	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	W	318	318	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	C	197	197	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	N	303	303	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	S	198	198	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	L	322	322	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	T	105	105	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	A	201	201	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	F	300	300	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	F	187	187	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	F	299	299	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	Y	326	326	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	T	104	104	putative ligand binding site
KQQrdIkUBC	1a028226c7dafb2f6af6759defaf522f	419	CDD-3.21	cd15056	21	347	17	A	194	194	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	D	115	115	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	W	111	111	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	C	188	188	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	F	388	388	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	W	365	365	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	T	112	112	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	F	369	369	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	F	385	385	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	Y	396	396	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	L	375	375	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	A	200	200	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	V	116	116	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	S	204	204	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	L	392	392	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	C	119	119	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	S	389	389	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	F	368	368	putative ligand binding site
ZU0eod1TC4	93e2d9a1eafea7bba78893adf97113b7	433	CDD-3.21	cd15331	36	417	18	T	120	120	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	D	137	137	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	Y	357	357	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	V	138	138	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	V	346	346	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	W	323	323	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	I	134	134	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	C	206	206	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	F	326	326	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	T	142	142	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	F	327	327	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	R	350	350	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	A	222	222	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	F	133	133	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	E	349	349	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	S	218	218	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	L	353	353	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	C	141	141	putative ligand binding site
VyRxiwg9OH	ad4b9fdffa3fa7225b648f147ae6894c	404	CDD-3.21	cd15329	57	378	18	R	333	333	putative ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	W	121	121	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	L	122	122	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	F	345	345	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	F	324	324	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	C	129	129	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	P	342	342	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	D	125	125	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	W	321	321	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	A	211	211	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	N	349	349	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	M	331	331	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	S	207	207	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	F	325	325	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	D	346	346	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	C	194	194	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	T	130	130	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	Y	353	353	ligand binding site
rOES4svmOR	c60681a7d5c3eee8c08dc88797a6af13	385	CDD-3.21	cd15333	42	374	18	I	126	126	ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	W	249	249	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	W	84	84	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	F	271	271	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	N	256	256	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	F	253	253	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	S	178	178	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	D	88	88	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	T	275	275	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	Y	279	279	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	F	167	167	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	S	177	177	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	S	92	92	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	F	252	252	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	A	174	174	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	S	181	181	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	I	89	89	putative ligand binding site
50AYMHqNK0	274b0718a0d97b1d9a065e97a13c7739	304	CDD-3.21	cd15065	11	300	17	T	93	93	putative ligand binding site
GsNfFnNm9k	ed81e5bbd962939cd52032488557ba28	512	PIRSR-2023_05	PIRSR600732-3	53	238	1	CDIWAAVDVLCCTASIMSLCIISVDRYIGVKYSLKYPTIMTEKKAVIIMVAVWISSMVISIGPLLGWKEAPPENDQ-HC	124	201	DISULFID: 
GsNfFnNm9k	ed81e5bbd962939cd52032488557ba28	512	PIRSR-2023_05	PIRSR600732-5	295	371	1	C	371	371	LIPID: S-palmitoyl cysteine
q3Fhp7fRfS	e5e769b0fb8db689328f741d12eef26f	343	PIRSR-2023_05	PIRSR600732-3	26	211	1	CDVWVSFDVLCCTASIWNVTAIALDRYWSITRHLEYTLKTRKRISNIMIGLTWALSAIISLSPLFGWGKAYT-AAQESC	101	178	DISULFID: 
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	I	103	103	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	T	107	107	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	C	171	171	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	F	308	308	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	D	329	329	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	T	332	332	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	C	106	106	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	L	99	99	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	A	325	325	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	S	184	184	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	S	328	328	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	V	315	315	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	D	102	102	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	W	305	305	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	W	98	98	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	F	309	309	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	Y	336	336	putative ligand binding site
4erBqEBFMP	395d079f86feb4c9bd10d1ce0b7dbabc	367	CDD-3.21	cd15334	23	358	18	A	188	188	putative ligand binding site
YCsFSoRXqE	31109f5bb8ad90753678545851ade532	497	PIRSR-2023_05	PIRSR600732-5	410	492	1	C	489	489	LIPID: S-palmitoyl cysteine
YCsFSoRXqE	31109f5bb8ad90753678545851ade532	497	PIRSR-2023_05	PIRSR600732-1	410	492	1	Q	446	446	BINDING: Zn(2+)
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	PIRSR-2023_05	PIRSR600732-5	317	401	1	C	401	401	LIPID: S-palmitoyl cysteine
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	S	243	243	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	C	166	166	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	F	158	158	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	W	340	340	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	D	162	162	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	R	367	367	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	F	344	344	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	I	159	159	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	E	366	366	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	L	370	370	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	F	343	343	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	R	350	350	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	T	167	167	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	A	247	247	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	L	363	363	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	C	231	231	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	Y	374	374	putative ligand binding site
eCQKmw2pOP	d53bbf72c63e66e06a7a111aec812ed9	479	CDD-3.21	cd15329	97	395	18	V	163	163	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	PIRSR-2023_05	PIRSR600732-5	25	317	1	C	316	316	LIPID: S-palmitoyl cysteine
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	F	281	281	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	C	107	107	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	G	194	194	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	T	108	108	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	Y	99	99	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	D	103	103	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	W	259	259	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	T	197	197	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	V	190	190	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	L	183	183	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	F	263	263	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	D	193	193	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	L	285	285	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	F	266	266	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	Y	262	262	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	V	104	104	putative ligand binding site
6CsniPjxAT	2346ff7d16b132c1193b2dc67b27b27c	387	CDD-3.21	cd15051	24	310	17	Y	289	289	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	V	65	65	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	W	287	287	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	S	313	313	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	F	290	290	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	F	291	291	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	T	69	69	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	A	149	149	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	W	60	60	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	C	68	68	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	T	153	153	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	C	137	137	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	Y	320	320	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	M	297	297	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	D	64	64	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	L	316	316	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	T	61	61	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	V	312	312	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	CDD-3.21	cd15331	1	341	18	D	309	309	putative ligand binding site
E4FfNlOcFq	9ce740592558980b2a8d143eeb95cd93	409	PIRSR-2023_05	PIRSR600732-1	267	351	1	Q	301	301	BINDING: Zn(2+)
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	F	308	308	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	I	178	178	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	W	285	285	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	T	111	111	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	F	312	312	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	V	107	107	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	F	289	289	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	Y	316	316	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	C	110	110	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	V	185	185	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	S	188	188	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	D	106	106	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	M	292	292	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	A	189	189	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	W	102	102	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	S	192	192	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	CDD-3.21	cd15325	27	337	17	F	288	288	putative ligand binding site
bwh7BDV3Cs	51fcf41423fcaeb1d59754492af19740	427	PIRSR-2023_05	PIRSR600732-3	28	231	1	CNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGVRALLCVWALSLVISIGPLFGWRQQAPEDET-IC	99	176	DISULFID: 
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	PIRSR-2023_05	PIRSR600732-5	312	402	1	C	402	402	LIPID: S-palmitoyl cysteine
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	D	110	110	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	Y	351	351	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	Y	106	106	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	F	372	372	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	I	178	178	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	Y	376	376	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	W	344	344	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	T	115	115	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	S	188	188	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	F	348	348	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	V	111	111	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	C	114	114	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	F	347	347	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	I	185	185	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	S	192	192	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	F	368	368	putative ligand binding site
9zCo3T9kHs	af2eeb03ddc2cc5eb4698c88db46092f	408	CDD-3.21	cd15324	44	397	17	C	189	189	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	C	102	102	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	A	187	187	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	F	254	254	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	W	250	250	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	V	183	183	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	D	98	98	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	Y	280	280	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	Y	94	94	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	L	276	276	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	F	257	257	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	T	190	190	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	Y	253	253	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	D	186	186	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	T	103	103	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	F	176	176	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	S	272	272	putative ligand binding site
IDqCgXNOAR	43da6394c2b3854d1394a5a611927975	363	CDD-3.21	cd15051	19	301	17	V	99	99	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	D	110	110	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	F	351	351	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	D	372	372	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	I	107	107	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	F	371	371	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	A	197	197	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	C	181	181	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	T	115	115	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	W	348	348	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	S	193	193	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	V	111	111	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	H	368	368	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	C	114	114	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	F	106	106	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	Y	379	379	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	L	358	358	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	F	352	352	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	CDD-3.21	cd15330	31	400	18	N	375	375	putative ligand binding site
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	PIRSR-2023_05	PIRSR600732-5	328	406	1	C	406	406	LIPID: S-palmitoyl cysteine
aJXccw9WVd	0b7fd04c8fac77d2c84a33a88e5d6bd7	411	PIRSR-2023_05	PIRSR603912-52	44	219	1	CDIFISLDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAVLISITWIVGFSISIPPMLGWRTPE-DRSDPNAC	103	181	DISULFID: 
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	D	131	131	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	M	349	349	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	W	127	127	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	L	128	128	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	Y	360	360	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	W	328	328	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	I	132	132	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	L	338	338	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	A	217	217	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	F	332	332	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	D	353	353	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	T	356	356	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	C	135	135	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	S	213	213	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	F	331	331	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	C	200	200	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	S	352	352	ligand binding site
J9JRrc39aH	b304419e74ad562898c174970e581fee	391	CDD-3.21	cd15333	48	381	18	T	136	136	ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	PIRSR-2023_05	PIRSR600732-5	334	414	1	C	412	412	LIPID: S-palmitoyl cysteine
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	PIRSR-2023_05	PIRSR600732-1	334	414	1	Q	369	369	BINDING: Zn(2+)
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	D	147	147	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	M	365	365	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	W	143	143	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	C	220	220	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	T	236	236	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	D	375	375	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	L	382	382	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	W	355	355	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	T	144	144	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	S	379	379	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	F	358	358	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	A	232	232	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	F	359	359	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	Y	386	386	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	V	148	148	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	F	378	378	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	C	151	151	putative ligand binding site
9NFHCOJ3mt	11479a833f0a69fd55e338206f6aefed	421	CDD-3.21	cd15331	68	407	18	T	152	152	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	W	281	281	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	C	86	86	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	T	171	171	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	C	155	155	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	M	291	291	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	D	82	82	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	F	285	285	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	Y	312	312	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	T	79	79	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	L	308	308	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	W	78	78	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	N	301	301	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	S	305	305	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	F	284	284	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	T	87	87	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	A	167	167	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	F	304	304	putative ligand binding site
wnz3wTBjSm	678702de9227be3d0a3519db445fa367	343	CDD-3.21	cd15331	3	333	18	V	83	83	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	V	166	166	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	E	369	369	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	L	373	373	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	I	162	162	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	R	353	353	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	C	234	234	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	T	170	170	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	L	366	366	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	Y	377	377	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	A	250	250	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	F	161	161	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	S	246	246	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	W	343	343	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	C	169	169	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	F	346	346	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	F	347	347	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	R	370	370	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	CDD-3.21	cd15329	100	398	18	D	165	165	putative ligand binding site
1xotnW2EDm	a0e7061afaa72bee7b66149849422422	448	PIRSR-2023_05	PIRSR600732-5	320	404	1	C	404	404	LIPID: S-palmitoyl cysteine
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	PIRSR-2023_05	PIRSR603912-52	26	215	1	CEFWTSIDVLCVTASIETLCVIAVDRYFAITAPFRYQSMLTKGKARVVILVVWVVSGLTSFLPIQMH--WYRASHKEALSC	94	172	DISULFID: 
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	PIRSR-2023_05	PIRSR600732-1	24	313	1	Q	285	285	BINDING: Zn(2+)
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	S	131	131	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	L	218	218	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	R	128	128	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	F	127	127	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	K	216	216	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	I	221	221	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	A	257	257	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	Q	217	217	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	L	261	261	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	T	124	124	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	A	214	214	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	I	123	123	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	V	213	213	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	Q	50	50	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	Q	130	130	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	K	220	220	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	A	122	122	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	R	51	51	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	K	256	256	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	P	126	126	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	T	260	260	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	V	210	210	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	R	119	119	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	24	Y	129	129	G protein interaction site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	S	195	195	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	V	102	102	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	N	298	298	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	D	180	180	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	F	276	276	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	T	106	106	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	F	275	275	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	Y	302	302	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	W	97	97	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	V	105	105	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	F	181	181	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	S	191	191	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	Y	187	187	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	W	272	272	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	Y	294	294	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	D	101	101	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	S	192	192	ligand binding site
vAy89NrOZT	a4fda8b0430e46e7916722cc84985fc5	393	CDD-3.21	cd15957	22	322	18	N	279	279	ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	W	345	345	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	D	115	115	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	F	366	366	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	W	111	111	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	S	233	233	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	N	352	352	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	T	236	236	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	L	222	222	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	F	349	349	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	A	229	229	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	S	120	120	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	A	232	232	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	V	116	116	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	F	348	348	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	C	119	119	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	T	370	370	putative ligand binding site
5cKSP1mz8P	f1dc5f258d592c1ca0f81ef310c7483b	473	CDD-3.21	cd15054	36	395	17	Y	374	374	putative ligand binding site
HzW9kYfmiG	b8a5722785f902c63a8f36ee895aba53	458	PIRSR-2023_05	PIRSR603912-52	66	267	1	CDAFIALDVLCCTSSILHLCAIALDRYWAITDPVDYVNKRTPRRAALMIAVTWAVGFSISIPPVLGWRQAE-DRADRDAC	128	206	DISULFID: 
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	W	105	105	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	L	106	106	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	F	313	313	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	Y	340	340	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	C	113	113	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	P	329	329	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	A	196	196	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	V	320	320	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	D	109	109	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	D	333	333	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	T	336	336	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	C	179	179	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	F	314	314	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	M	110	110	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	T	114	114	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	A	332	332	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	S	192	192	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	CDD-3.21	cd15335	47	361	18	W	310	310	putative ligand binding site
umBzDKge6m	077415117759efef720861a813cace0b	371	PIRSR-2023_05	PIRSR600732-3	32	216	1	CEIWLSVDMTCCTCSILHLCVIALDRYWAITDAIEYARKRTAKRAGLMIVTVWTISIFISMPPLF-WRNHHSVSIPSEC	102	179	DISULFID: 
jK7QnIACUx	4237754907d7e7e491b5f643ca408e4c	417	PIRSR-2023_05	PIRSR603912-52	30	228	1	CEFWTATDVLCVTASIETLCVIAIDRYLAITSPFRYQSMLTKCRARIVVVLVWVIAALISFLPIHMKWWIS--DDEEAKRC	107	185	DISULFID: 
jK7QnIACUx	4237754907d7e7e491b5f643ca408e4c	417	PIRSR-2023_05	PIRSR600732-5	267	350	1	C	342	342	LIPID: S-palmitoyl cysteine
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	L	186	186	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	Y	276	276	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	A	299	299	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	Y	303	303	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	V	108	108	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	A	193	193	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	S	200	200	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	T	112	112	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	W	273	273	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	G	196	196	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	D	107	107	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	W	295	295	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	H	103	103	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	S	111	111	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	F	277	277	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	S	197	197	putative ligand binding site
IHQzmWGdBd	c309339b47deee19d5e19cad28630621	343	CDD-3.21	cd15055	32	324	17	T	280	280	putative ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	C	123	123	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	S	201	201	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	F	319	319	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	C	188	188	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	F	340	340	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	T	124	124	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	D	119	119	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	M	337	337	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	W	115	115	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	L	116	116	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	Y	348	348	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	W	316	316	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	I	120	120	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	L	326	326	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	A	205	205	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	F	320	320	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	D	341	341	ligand binding site
Qg9v0LKSOo	bbc9eeb11921e367694d0e118d8c9f57	379	CDD-3.21	cd15333	36	369	18	T	344	344	ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	PIRSR-2023_05	PIRSR600732-5	326	401	1	C	401	401	LIPID: S-palmitoyl cysteine
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	Y	351	351	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	D	121	121	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	V	122	122	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	V	202	202	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	L	195	195	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	W	344	344	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	S	205	205	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	T	371	371	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	Y	375	375	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	T	126	126	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	S	209	209	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	F	348	348	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	A	206	206	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	V	367	367	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	W	117	117	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	F	347	347	putative ligand binding site
H8w47ZcyKP	ccfe522048bd93a6e3d1203d5891a28e	405	CDD-3.21	cd15060	42	396	17	C	125	125	putative ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	PIRSR-2023_05	PIRSR603912-52	39	221	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVSVMIAVVWVLSFAISCPLLFGLNKT--ATREITKC	101	179	DISULFID: 
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	PIRSR-2023_05	PIRSR600732-5	366	446	1	C	446	446	LIPID: S-palmitoyl cysteine
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	S	190	190	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	T	415	415	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	Y	419	419	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	C	112	112	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	F	104	104	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	F	392	392	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	V	187	187	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	D	108	108	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	F	391	391	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	I	181	181	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	S	191	191	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	Y	411	411	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	V	109	109	ligand binding site
GtjFllqeG4	a35b7c1a2ff9e672fa717e92236a0f7f	446	CDD-3.21	cd15053	29	440	14	H	395	395	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	PIRSR-2023_05	PIRSR603912-52	45	231	1	CEFWTSVDILCVTASIETLCVIAVDRYFAITSPFRYQSLLTKCKARIVILLVWVVSTLTSFLPIYMH--WYRIEEESALHC	110	188	DISULFID: 
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	S	147	147	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	L	234	234	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	R	144	144	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	A	272	272	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	F	143	143	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	K	232	232	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	I	237	237	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	Q	233	233	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	T	140	140	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	A	230	230	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	I	139	139	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	E	229	229	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	Q	66	66	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	Q	146	146	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	L	276	276	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	K	236	236	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	A	138	138	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	T	275	275	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	R	67	67	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	K	271	271	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	P	142	142	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	V	226	226	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	R	135	135	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	24	Y	145	145	G protein interaction site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	S	211	211	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	W	287	287	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	F	196	196	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	Y	309	309	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	F	290	290	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	T	122	122	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	N	313	313	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	F	291	291	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	I	118	118	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	W	113	113	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	V	121	121	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	Y	317	317	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	F	197	197	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	S	207	207	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	N	294	294	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	Y	203	203	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	D	117	117	ligand binding site
Nvc3tne6MO	8eec7590f5a4a8db9ac8ed242c7908a6	419	CDD-3.21	cd15957	38	337	18	S	208	208	ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	PIRSR-2023_05	PIRSR603912-52	50	246	1	CDMWITFDMLCCTASILHLVAISVDRYWAVT-NIDYVRNRSAKTILIMIAIAWFVGLCISMPRLLGWRNPDNVPSK-SGMC	118	196	DISULFID: 
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	W	121	121	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	W	351	351	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	C	129	129	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	F	354	354	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	A	212	212	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	N	361	361	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	F	355	355	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	N	372	372	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	D	125	125	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	Y	380	380	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	C	196	196	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	D	369	369	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	I	122	122	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	L	376	376	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	M	126	126	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	T	130	130	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	S	373	373	putative ligand binding site
fP4fRY7tjS	de4d462c2d4746b07f3ec998544fd9aa	414	CDD-3.21	cd15331	48	401	18	S	208	208	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	F	313	313	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	T	113	113	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	A	193	193	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	W	104	104	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	M	300	300	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	C	112	112	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	C	181	181	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	D	310	310	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	F	294	294	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	D	108	108	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	T	105	105	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	W	290	290	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	L	317	317	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	F	293	293	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	S	314	314	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	V	109	109	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	S	197	197	putative ligand binding site
HdLYk2vd7J	1cda285f14a0ef30f9981806a7546f1c	349	CDD-3.21	cd15331	45	342	18	Y	321	321	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	PIRSR-2023_05	PIRSR600732-5	245	318	1	C	317	317	LIPID: S-palmitoyl cysteine
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	F	265	265	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	A	171	171	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	W	84	84	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	L	287	287	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	C	92	92	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	A	175	175	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	Y	291	291	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	V	85	85	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	C	159	159	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	R	271	271	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	D	88	88	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	F	264	264	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	V	89	89	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	P	280	280	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	S	284	284	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	W	261	261	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	T	93	93	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	CDD-3.21	cd15329	10	312	18	H	283	283	putative ligand binding site
DzXQl3ixjn	5c50037188db8684f14141b719c1c0bd	380	PIRSR-2023_05	PIRSR603912-52	27	191	1	CDMWVSFDVTSCTASILNLCMISVDRYLAITRPLTYGVRRTARRIWSCIGAVWLLSCLISVPPLLVLGNEHGTAHA--PTC	81	159	DISULFID: 
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	PIRSR-2023_05	PIRSR600732-5	274	361	1	C	360	360	LIPID: S-palmitoyl cysteine
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	Q	323	323	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	T	102	102	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	L	330	330	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	D	105	105	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	F	308	308	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	S	327	327	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	V	106	106	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	S	194	194	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	F	307	307	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	Y	334	334	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	M	314	314	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	F	326	326	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	T	110	110	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	A	190	190	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	W	101	101	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	C	178	178	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	W	304	304	putative ligand binding site
aHVp2cBgGN	9dcd56eb9b82f86249e0104979739b95	368	CDD-3.21	cd15331	26	355	18	C	109	109	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	PIRSR-2023_05	PIRSR600732-5	337	416	1	C	416	416	LIPID: S-palmitoyl cysteine
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	PIRSR-2023_05	PIRSR600732-5	337	416	1	C	415	415	LIPID: S-palmitoyl cysteine
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	PIRSR-2023_05	PIRSR600732-3	27	199	1	CDALMTMDVMLCTASILNLCAISVDRYIAVVVPLKYNRNQFSVRQLALITATWVLSLGVASPVIFGLNQ-VPNRNPHVC	92	169	DISULFID: 
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	F	361	361	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	L	95	95	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	D	99	99	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	V	177	177	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	I	381	381	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	T	385	385	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	S	180	180	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	Y	389	389	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	H	365	365	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	V	100	100	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	F	362	362	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	C	103	103	putative ligand binding site
XqkZ6LiZzb	dde66bb8e0a00e6b93a7e0b9880e77f7	418	CDD-3.21	cd15308	19	410	13	S	181	181	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	F	281	281	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	Y	308	308	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	R	91	91	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	L	304	304	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	C	191	191	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	V	96	96	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	T	99	99	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	A	195	195	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	W	300	300	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	N	285	285	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	T	100	100	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	F	181	181	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	D	95	95	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	F	282	282	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	A	188	188	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	S	192	192	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	CDD-3.21	cd15056	16	329	17	W	278	278	putative ligand binding site
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	PIRSR-2023_05	PIRSR600732-5	247	338	1	C	334	334	LIPID: S-palmitoyl cysteine
bBDiticFhs	4232246a4ffb06c8995c2ce421aac086	393	PIRSR-2023_05	PIRSR600732-5	247	338	1	C	335	335	LIPID: S-palmitoyl cysteine
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	I	87	87	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	T	91	91	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	S	174	174	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	F	286	286	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	M	163	163	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	W	282	282	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	F	285	285	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	Y	312	312	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	C	90	90	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	I	304	304	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	S	173	173	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	A	170	170	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	D	86	86	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	S	177	177	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	W	82	82	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	T	308	308	putative ligand binding site
6HUk0H2zCI	cbd5c50792c6b24652ff73ffa9860e52	399	CDD-3.21	cd15065	7	333	17	N	289	289	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	F	329	329	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	W	132	132	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	Y	357	357	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	S	226	226	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	D	136	136	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	F	328	328	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	Y	332	332	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	F	353	353	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	V	137	137	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	F	215	215	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	S	225	225	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	S	140	140	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	A	222	222	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	W	325	325	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	V	349	349	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	S	229	229	putative ligand binding site
CKvs8jeInU	ce3225e8c0de78dc6ccf4e92a5e61625	395	CDD-3.21	cd15066	58	378	17	T	141	141	putative ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	L	138	138	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	D	142	142	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	F	431	431	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	Y	451	451	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	H	435	435	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	F	215	215	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	S	225	225	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	V	143	143	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	C	146	146	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	T	455	455	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	Y	459	459	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	V	221	221	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	S	224	224	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	CDD-3.21	cd15053	63	480	14	F	432	432	ligand binding site
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	PIRSR-2023_05	PIRSR603912-52	84	249	1	CDILLTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSRRRVAVMIAVVWFLSFAISCPLLFGLNNT--ANRDGTTC	135	213	DISULFID: 
0J490lXtEK	fe779c1dcdfb1f31e88f6940d998d16c	486	PIRSR-2023_05	PIRSR600732-5	406	486	1	C	486	486	LIPID: S-palmitoyl cysteine
Ogxj4OyvD7	3f531700c6439d68b5e6f4092d1e848f	514	PIRSR-2023_05	PIRSR600732-3	57	241	1	CDIWAAVDVLCCTASIMSLCAISIDRYIGVRYSLRYPSIVTEKKAVLVVVGVWVLSIVISIGPLLGWKQPAPPDE-RDC	127	204	DISULFID: 
Ogxj4OyvD7	3f531700c6439d68b5e6f4092d1e848f	514	PIRSR-2023_05	PIRSR600732-5	298	374	1	C	374	374	LIPID: S-palmitoyl cysteine
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	S	195	195	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	W	329	329	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	T	118	118	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	V	188	188	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	L	181	181	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	I	114	114	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	F	333	333	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	C	192	192	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	Y	361	361	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	C	117	117	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	F	353	353	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	Y	109	109	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	D	113	113	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	F	332	332	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	S	191	191	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	Y	336	336	putative ligand binding site
G9b28gN5VH	de09eca48921d819b81ef2a9d3e7501c	394	CDD-3.21	cd15324	34	382	17	F	357	357	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	H	324	324	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	V	102	102	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	S	183	183	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	F	321	321	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	Y	348	348	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	S	182	182	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	C	105	105	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	T	340	340	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	L	97	97	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	D	101	101	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	F	320	320	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	V	179	179	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	CDD-3.21	cd15308	36	369	13	T	344	344	putative ligand binding site
Yrr4ZSKKC9	6b677b76837143938e4a19625bbac9b6	380	PIRSR-2023_05	PIRSR600732-3	26	201	1	CDGLMTMDVMLCTASIFNLCAISIDRFIAVSIPLNYNRKHVDQRQIVLLSATWILALAVASPVMFGIN-NVPNRDHSEC	94	171	DISULFID: 
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	C	118	118	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	L	111	111	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	W	324	324	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	D	114	114	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	T	351	351	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	Y	355	355	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	W	110	110	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	F	328	328	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	P	344	344	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	F	327	327	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	D	348	348	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	A	201	201	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	M	334	334	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	I	115	115	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	T	119	119	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	S	197	197	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	F	347	347	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	CDD-3.21	cd15333	31	376	18	C	184	184	ligand binding site
dk0Aug7S4f	d0f39c402bf46f4ef102155156e9c68b	386	PIRSR-2023_05	PIRSR600732-3	48	221	1	CDIWLSSDITFCTASILHLCVIALDRYWAITDALEYSKRRTMRRAALMIVIVWVISVSISLPPLFWRQAKAHEEL-TEC	107	184	DISULFID: 
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	Y	431	431	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	V	129	129	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	I	205	205	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	S	215	215	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	T	133	133	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	Y	409	409	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	Y	124	124	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	S	219	219	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	F	406	406	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	F	423	423	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	C	132	132	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	V	212	212	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	W	402	402	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	F	405	405	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	D	128	128	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	F	427	427	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	CDD-3.21	cd15322	49	452	17	C	216	216	putative ligand binding site
ihdDnmX2iD	2fecc78ccdf9f41032ee1964bd5e772a	465	PIRSR-2023_05	PIRSR600732-5	375	460	1	C	457	457	LIPID: S-palmitoyl cysteine
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	S	195	195	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	Y	383	383	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	T	118	118	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	I	188	188	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	W	351	351	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	L	181	181	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	F	354	354	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	F	355	355	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	C	192	192	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	C	117	117	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	F	375	375	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	Y	109	109	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	D	113	113	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	S	191	191	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	V	114	114	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	Y	358	358	putative ligand binding site
5rjVc8vWLK	edd868fa75de00c245808389c4728270	415	CDD-3.21	cd15324	59	404	17	F	379	379	putative ligand binding site
XEbJPCtGac	7cefaf04e81c4d00f2900ee6dd354534	452	PIRSR-2023_05	PIRSR600732-5	371	452	1	C	452	452	LIPID: S-palmitoyl cysteine
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	PIRSR-2023_05	PIRSR600732-5	21	316	1	C	304	304	LIPID: S-palmitoyl cysteine
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	PIRSR-2023_05	PIRSR600732-5	21	316	1	C	305	305	LIPID: S-palmitoyl cysteine
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	PIRSR-2023_05	PIRSR600732-1	21	316	1	E	180	180	BINDING: Zn(2+)
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	C	102	102	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	F	254	254	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	Y	250	250	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	G	183	183	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	D	98	98	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	Y	94	94	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	V	176	176	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	G	187	187	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	L	274	274	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	T	190	190	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	E	270	270	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	W	247	247	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	D	186	186	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	T	103	103	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	F	251	251	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	Y	278	278	putative ligand binding site
ClUKTDfvJI	cf6e504adb21a3843f57466edbf6a9b4	422	CDD-3.21	cd15051	19	299	17	V	99	99	putative ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	PIRSR-2023_05	PIRSR603912-52	54	231	1	CKLWTSIDVLCVTASIETLCVIAMDRYFAITSPFKYQSHLTKNKARVIILLVWVISILTSFLPIQMDWDKADIPEAK--KC	112	190	DISULFID: 
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	K	146	146	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	K	274	274	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	P	144	144	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	T	278	278	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	I	141	141	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	V	231	231	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	Y	147	147	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	R	69	69	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	F	145	145	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	K	234	234	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	I	239	239	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	A	275	275	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	Q	235	235	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	L	279	279	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	T	142	142	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	A	232	232	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	V	228	228	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	R	137	137	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	Q	68	68	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	Q	148	148	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	K	238	238	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	A	140	140	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	S	149	149	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	24	L	236	236	G protein interaction site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	H	297	297	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	T	124	124	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	Y	312	312	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	D	119	119	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	S	210	210	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	W	115	115	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	V	123	123	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	D	198	198	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	F	294	294	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	F	199	199	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	S	209	209	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	Y	205	205	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	W	290	290	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	F	293	293	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	Y	320	320	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	S	213	213	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	V	120	120	ligand binding site
6YcyVMi9HU	2171136e77d8bace37f327abd3b9b8cb	412	CDD-3.21	cd15957	40	340	18	N	316	316	ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	F	329	329	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	A	203	203	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	S	206	206	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	T	129	129	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	F	333	333	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	W	120	120	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	S	210	210	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	C	128	128	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	L	313	313	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	F	310	310	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	D	124	124	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	V	196	196	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	W	306	306	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	S	207	207	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	F	309	309	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	V	125	125	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	CDD-3.21	cd15326	46	358	17	Y	337	337	putative ligand binding site
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	PIRSR-2023_05	PIRSR600732-3	53	232	1	CDIWAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGPLLGWKEPAPND-DKEC	117	194	DISULFID: 
mGoxLSwodS	170417c1dcb1c9b60027d8fbdabaf137	514	PIRSR-2023_05	PIRSR600732-5	288	364	1	C	364	364	LIPID: S-palmitoyl cysteine
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	T	331	331	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	Y	335	335	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	C	107	107	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	S	185	185	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	C	172	172	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	F	308	308	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	T	108	108	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	S	327	327	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	V	314	314	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	D	103	103	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	W	99	99	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	L	100	100	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	F	307	307	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	D	328	328	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	L	324	324	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	W	304	304	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	I	104	104	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	CDD-3.21	cd15334	24	357	18	A	189	189	putative ligand binding site
YwLM4N6m6Z	8aee9e1ed66cc3a3ea9b59045371d17c	366	PIRSR-2023_05	PIRSR600732-5	270	364	1	C	362	362	LIPID: S-palmitoyl cysteine
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	W	105	105	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	S	195	195	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	F	302	302	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	F	303	303	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	S	199	199	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	D	109	109	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	V	110	110	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	S	198	198	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	S	113	113	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	Y	306	306	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	F	327	327	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	F	188	188	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	S	202	202	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	Y	331	331	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	T	114	114	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	W	299	299	putative ligand binding site
uUYetHlvEd	a73a4eb2331e01adf5264f827f76f09b	385	CDD-3.21	cd15066	31	352	17	V	323	323	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	PIRSR-2023_05	PIRSR601681-50	37	214	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMIAIVWVLSFTISCPLLFGLNNT---DQNEC	107	182	DISULFID: 
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	C	118	118	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	F	110	110	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	H	394	394	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	D	114	114	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	S	194	194	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	Y	409	409	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	V	190	190	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	F	390	390	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	S	193	193	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	F	391	391	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	T	413	413	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	Y	417	417	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	CDD-3.21	cd15309	35	438	13	V	115	115	putative ligand binding site
9X41ZUX7sk	3998bab1559c96a7b123c75bd8a2aac2	444	PIRSR-2023_05	PIRSR600732-5	365	444	1	C	444	444	LIPID: S-palmitoyl cysteine
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	F	366	366	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	F	367	367	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	Y	394	394	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	V	188	188	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	A	273	273	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	S	276	276	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	S	280	280	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	T	192	192	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	D	187	187	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	F	390	390	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	W	183	183	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	Y	370	370	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	S	191	191	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	V	386	386	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	F	266	266	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	S	277	277	putative ligand binding site
rUy1106xNg	250f31210a9785195415b8d0b484192c	508	CDD-3.21	cd15066	109	415	17	W	363	363	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	PIRSR-2023_05	PIRSR600732-1	46	226	1	E	199	199	BINDING: Zn(2+)
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	PIRSR-2023_05	PIRSR600732-5	426	502	1	C	502	502	LIPID: S-palmitoyl cysteine
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	S	206	206	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	F	447	447	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	F	468	468	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	C	129	129	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	I	203	203	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	T	207	207	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	S	210	210	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	Y	451	451	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	L	196	196	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	Y	121	121	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	D	125	125	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	F	472	472	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	Y	476	476	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	V	126	126	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	W	444	444	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	T	130	130	putative ligand binding site
onW0cY5h5o	55c7b29c826df94ad00f39e96887b4ef	510	CDD-3.21	cd15321	40	497	17	F	448	448	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	D	158	158	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	G	241	241	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	R	331	331	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	F	308	308	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	I	155	155	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	E	330	330	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	L	334	334	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	F	307	307	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	R	314	314	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	T	163	163	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	L	327	327	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	Y	338	338	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	V	159	159	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	C	162	162	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	F	154	154	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	W	304	304	putative ligand binding site
0T1G2p4wdj	b123c1df68f04c04b2c3f11204c82228	393	CDD-3.21	cd15329	78	359	17	K	228	228	putative ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	W	116	116	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	W	276	276	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	C	124	124	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	T	305	305	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	Y	309	309	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	N	283	283	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	F	301	301	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	D	120	120	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	F	280	280	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	V	203	203	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	Y	279	279	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	V	121	121	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	A	206	206	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	S	207	207	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	T	125	125	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	CDD-3.21	cd14967	43	330	16	A	210	210	ligand binding site
bKXtRZnILM	ab1314d96c1c7be3f28f5ff6f71e69b8	367	PIRSR-2023_05	PIRSR600732-5	44	360	1	C	336	336	LIPID: S-palmitoyl cysteine
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	W	121	121	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	S	211	211	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	L	314	314	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	F	334	334	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	C	129	129	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	W	307	307	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	D	125	125	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	V	126	126	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	F	310	310	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	F	311	311	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	Y	338	338	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	I	197	197	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	S	207	207	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	F	330	330	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	T	130	130	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	A	204	204	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	CDD-3.21	cd15327	46	359	17	S	208	208	putative ligand binding site
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	PIRSR-2023_05	PIRSR600732-3	50	234	1	CNIWAAVDVLCCTASIMSLCIISIDRYIGVKYSLKYPTIMTERKAVIILIVVWLSSMVISIGPLLGWKEPPPENES-IC	118	195	DISULFID: 
ECanJJ4ncI	7bd082c3bf6b4d1c4b52778bdedc15e7	503	PIRSR-2023_05	PIRSR600732-5	289	365	1	C	365	365	LIPID: S-palmitoyl cysteine
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	PIRSR-2023_05	PIRSR600732-5	323	395	1	C	392	392	LIPID: S-palmitoyl cysteine
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	PIRSR-2023_05	PIRSR600732-5	323	395	1	C	393	393	LIPID: S-palmitoyl cysteine
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	A	251	251	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	Q	254	254	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	T	161	161	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	F	164	164	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	V	247	247	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	K	253	253	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	I	258	258	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	A	159	159	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	Q	167	167	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	I	160	160	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	E	250	250	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	T	325	325	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	S	168	168	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	R	165	165	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	K	257	257	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	K	321	321	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	R	88	88	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	P	163	163	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	V	255	255	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	R	156	156	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	L	326	326	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	Y	166	166	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	P	87	87	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	24	A	322	322	putative G protein interaction site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	Y	367	367	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	A	225	225	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	S	228	228	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	F	340	340	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	V	119	119	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	T	220	220	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	N	363	363	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	S	232	232	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	I	118	118	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	V	139	139	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	W	337	337	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	V	142	142	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	W	364	364	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	N	344	344	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	D	138	138	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	Y	224	224	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	F	341	341	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	F	218	218	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	S	229	229	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	V	360	360	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	CDD-3.21	cd15958	59	387	21	W	134	134	ligand binding site
lxlM6A3JbT	f3eb622a4f22fffce6a244b5f9fb9664	477	PIRSR-2023_05	PIRSR603912-52	64	254	1	CELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVCTVWAISALVSFLPILMHWWR--AESDEARRC	131	209	DISULFID: 
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	W	100	100	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	C	108	108	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	E	327	327	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	L	101	101	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	N	331	331	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	D	104	104	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	W	307	307	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	F	310	310	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	F	311	311	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	Y	338	338	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	A	190	190	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	A	334	334	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	S	186	186	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	S	330	330	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	V	317	317	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	I	105	105	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	T	109	109	putative ligand binding site
zJFuHTnbRq	ca2d8bd5c9415f169e3fb83ea43ef667	369	CDD-3.21	cd15334	25	360	18	C	173	173	putative ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	PIRSR-2023_05	PIRSR600732-5	325	410	1	C	410	410	LIPID: S-palmitoyl cysteine
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	T	379	379	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	S	206	206	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	Y	383	383	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	F	356	356	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	F	355	355	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	C	128	128	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	F	120	120	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	V	203	203	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	Y	375	375	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	D	124	124	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	H	359	359	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	S	207	207	ligand binding site
SFLXT9eJa9	883dc33401c42368307f7b17068bedcb	410	CDD-3.21	cd15310	44	404	13	V	125	125	ligand binding site
uEbFvw4aYe	2308282e418e55391a65c45c13b995ec	585	PIRSR-2023_05	PIRSR600732-5	481	568	1	C	568	568	LIPID: S-palmitoyl cysteine
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	S	201	201	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	V	108	108	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	T	300	300	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	W	296	296	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	G	197	197	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	T	112	112	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	D	107	107	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	S	198	198	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	F	278	278	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	T	281	281	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	H	103	103	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	W	274	274	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	S	111	111	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	F	277	277	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	Y	304	304	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	F	187	187	putative ligand binding site
cStClT5Dm0	19624d63f30ab4620cd5ac31493d8806	345	CDD-3.21	cd15055	32	325	17	A	194	194	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	F	308	308	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	D	114	114	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	Y	312	312	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	W	110	110	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	F	193	193	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	S	203	203	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	W	305	305	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	S	118	118	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	A	200	200	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	S	204	204	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	F	332	332	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	S	207	207	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	F	309	309	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	Y	336	336	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	T	119	119	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	V	328	328	putative ligand binding site
EG8X1IG6EU	9c2c49e8cd36f560a1912b9fbd45e861	403	CDD-3.21	cd15066	36	357	17	V	115	115	putative ligand binding site
4iunTgaR9K	d8aa910b2d8325edf5224a694ef976ea	457	PIRSR-2023_05	PIRSR600732-5	192	357	1	C	356	356	LIPID: S-palmitoyl cysteine
tWLDJkeSf6	c9d422e8959af3ca3c8eb437912e38f8	555	PIRSR-2023_05	PIRSR600732-5	347	423	1	C	423	423	LIPID: S-palmitoyl cysteine
tWLDJkeSf6	c9d422e8959af3ca3c8eb437912e38f8	555	PIRSR-2023_05	PIRSR600732-3	109	292	1	CDVWAAVDVLCCTASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWAVALVVSVGPLLGWKEPVPPDD-RFC	178	255	DISULFID: 
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	PIRSR-2023_05	PIRSR603912-52	26	215	1	CEFWTSIDVLCVTASIETLCVIAVDRYFAITAPFRYQSMLTKGKARVVILVVWVVSGLTSFLPIQMH--WYRASHKEALSC	94	172	DISULFID: 
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	S	131	131	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	L	218	218	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	R	128	128	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	F	127	127	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	K	216	216	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	I	221	221	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	A	257	257	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	Q	217	217	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	L	261	261	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	T	124	124	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	A	214	214	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	I	123	123	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	V	213	213	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	Q	50	50	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	Q	130	130	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	K	220	220	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	A	122	122	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	R	51	51	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	K	256	256	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	P	126	126	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	T	260	260	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	V	210	210	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	R	119	119	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	24	Y	129	129	G protein interaction site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	S	195	195	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	V	102	102	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	N	298	298	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	D	180	180	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	F	276	276	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	T	106	106	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	F	275	275	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	Y	302	302	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	W	97	97	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	V	105	105	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	F	181	181	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	S	191	191	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	Y	187	187	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	W	272	272	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	Y	294	294	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	D	101	101	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	S	192	192	ligand binding site
HMsATDtoEZ	ef52a0eeda795ca5c8c43bfc6d46ddf3	404	CDD-3.21	cd15957	22	322	18	N	279	279	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	T	363	363	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	Y	367	367	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	C	203	203	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	F	340	340	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	W	346	346	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	T	138	138	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	P	356	356	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	F	339	339	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	D	360	360	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	S	216	216	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	I	134	134	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	W	129	129	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	L	130	130	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	F	359	359	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	C	137	137	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	W	336	336	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	A	220	220	ligand binding site
bSuFG152uE	3a61f08e977bdd7f6cd0720bfca4b3ef	396	CDD-3.21	cd15333	50	388	18	D	133	133	ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	W	105	105	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	W	329	329	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	R	352	352	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	A	192	192	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	S	196	196	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	C	113	113	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	F	333	333	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	Y	360	360	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	V	106	106	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	H	349	349	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	D	109	109	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	L	356	356	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	R	339	339	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	S	353	353	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	C	180	180	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	F	332	332	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	T	114	114	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	CDD-3.21	cd15329	31	381	18	I	110	110	putative ligand binding site
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	PIRSR-2023_05	PIRSR600732-5	318	387	1	C	386	386	LIPID: S-palmitoyl cysteine
DK7w7bChZ3	613a63351827ab6ae8abf163a5ff9857	456	PIRSR-2023_05	PIRSR603912-52	32	223	1	CDMWVAFDITCCTASILNLCMISVDRYLAITKPLTYGVRRRSRRTYVSIGVTWVMSALVSVPPLLILGNEHGSESNP-TC	102	180	DISULFID: 
P9xGn7RVkv	445b29547d1599553410e830204d4ff1	404	PIRSR-2023_05	PIRSR600732-5	327	402	1	C	402	402	LIPID: S-palmitoyl cysteine
P9xGn7RVkv	445b29547d1599553410e830204d4ff1	404	PIRSR-2023_05	PIRSR603912-52	21	232	1	CDIFISLDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAVLISLTWLVGFLISIPPMLGWRTPE-DRANPNAC	103	181	DISULFID: 
YH2jvsJ8dY	cb63c1a138b70a8433d61e6df8cfe28d	366	PIRSR-2023_05	PIRSR600732-5	9	312	1	C	296	296	LIPID: S-palmitoyl cysteine
YH2jvsJ8dY	cb63c1a138b70a8433d61e6df8cfe28d	366	PIRSR-2023_05	PIRSR600732-5	9	312	1	C	295	295	LIPID: S-palmitoyl cysteine
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	S	323	323	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	T	107	107	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	F	308	308	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	A	326	326	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	C	106	106	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	V	314	314	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	L	99	99	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	D	327	327	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	T	330	330	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	F	307	307	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	Y	334	334	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	M	103	103	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	D	102	102	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	W	98	98	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	A	190	190	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	S	186	186	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	W	304	304	putative ligand binding site
0Q7LCHGK6O	d1df20c8da31240881c64f9cd3f1de1b	365	CDD-3.21	cd15335	23	355	18	C	173	173	putative ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	C	118	118	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	F	110	110	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	S	196	196	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	D	114	114	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	F	370	370	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	T	394	394	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	F	371	371	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	Y	398	398	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	I	193	193	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	S	197	197	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	H	374	374	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	Y	390	390	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	CDD-3.21	cd15310	34	419	13	V	115	115	ligand binding site
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	PIRSR-2023_05	PIRSR600732-5	339	425	1	C	424	424	LIPID: S-palmitoyl cysteine
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	PIRSR-2023_05	PIRSR600732-5	339	425	1	C	425	425	LIPID: S-palmitoyl cysteine
P21yIjBk1f	063a5a8770e99382c0bc9cf72dc58f9b	425	PIRSR-2023_05	PIRSR603912-52	43	222	1	CDVFVTMDVMMCTASILNLCAISIDRYTAVVKPVQYQYNTGQSSCRRVSLMIVVVWMLAFAVSCPLLFGFNTTGD----PSVC	107	185	DISULFID: 
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	C	123	123	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	P	336	336	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	S	201	201	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	D	340	340	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	C	188	188	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	T	124	124	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	V	327	327	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	W	317	317	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	D	119	119	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	W	115	115	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	L	116	116	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	F	339	339	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	F	321	321	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	T	343	343	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	Y	347	347	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	I	120	120	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	A	205	205	ligand binding site
6CTUEJKrXe	451b25a08e287f116c25f0b20f81d4ed	379	CDD-3.21	cd15333	36	368	18	F	320	320	ligand binding site
2VQ2kdTDs8	55a27c9e68921f6b5f822c02aab8d18c	427	PIRSR-2023_05	PIRSR600732-5	281	357	1	C	357	357	LIPID: S-palmitoyl cysteine
2VQ2kdTDs8	55a27c9e68921f6b5f822c02aab8d18c	427	PIRSR-2023_05	PIRSR603912-52	53	246	1	CEFWTSVDVLCVTASIETLCVIAIDRYIAITSPFRYQHLLTKTRARGIVCVVWAISALISFLPIMMHWW--RDENPDAIVC	125	203	DISULFID: 
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	C	118	118	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	F	110	110	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	H	394	394	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	D	114	114	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	S	194	194	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	Y	409	409	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	V	190	190	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	F	390	390	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	S	193	193	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	F	391	391	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	T	413	413	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	Y	417	417	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	CDD-3.21	cd15309	35	438	13	V	115	115	putative ligand binding site
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	PIRSR-2023_05	PIRSR601681-50	36	215	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMITVVWVLSFAISCPLLFGLNNT---DQNEC	107	182	DISULFID: 
FxfWh2TD0z	d831fa3e2bdaf9e2488ce75b746b0e30	444	PIRSR-2023_05	PIRSR600732-5	365	444	1	C	444	444	LIPID: S-palmitoyl cysteine
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	S	179	179	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	Y	351	351	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	I	172	172	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	T	97	97	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	L	165	165	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	F	372	372	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	Y	88	88	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	Y	376	376	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	W	344	344	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	C	96	96	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	D	92	92	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	F	348	348	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	S	175	175	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	V	93	93	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	F	347	347	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	S	176	176	putative ligand binding site
MYEUikYcJB	1bcad028cd41dfe7ed8b7115b5f54567	410	CDD-3.21	cd15321	7	397	17	F	368	368	putative ligand binding site
BHs3d472or	9f77f97f8982168ea8ce76b96e5c472b	309	PIRSR-2023_05	PIRSR600732-3	16	213	1	CNIWAAVDVLCCTASIMSLCIISIDRYIGVSYPLRYPSIVTEKRGLLALLCVWALSLVISIGPLFGWKEPAPEDET-IC	99	176	DISULFID: 
3CBG6hn40i	1478ef2889c1ea29bef07eff15ef47ed	369	PIRSR-2023_05	PIRSR600732-5	272	349	1	C	349	349	LIPID: S-palmitoyl cysteine
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	L	298	298	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	R	96	96	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	D	100	100	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	A	193	193	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	F	276	276	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	V	101	101	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	F	275	275	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	Y	302	302	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	A	200	200	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	T	105	105	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	C	196	196	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	F	186	186	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	W	272	272	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	S	197	197	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	W	294	294	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	T	104	104	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	CDD-3.21	cd15056	20	323	17	N	279	279	putative ligand binding site
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	328	328	LIPID: S-palmitoyl cysteine
LXRWfP7Vg6	64957fe8b53e3a23df7b94557cddb161	377	PIRSR-2023_05	PIRSR600732-5	22	332	1	C	329	329	LIPID: S-palmitoyl cysteine
6Uoim418Lz	4955ac6bcd7ff7a7347437fd33a0e0cc	346	PIRSR-2023_05	PIRSR600732-3	33	210	1	CYVWISFDVLCCTASIWNVTAIALDRYWSITRHLEYTLKTRKRISNVMIGLTWALSTIISLSPLFGWGEAYT-AAEESC	102	179	DISULFID: 
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	N	330	330	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	C	107	107	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	E	326	326	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	S	185	185	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	S	329	329	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	C	172	172	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	V	316	316	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	T	108	108	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	D	103	103	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	W	99	99	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	L	100	100	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	F	310	310	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	W	306	306	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	F	309	309	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	I	104	104	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	A	189	189	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	A	333	333	putative ligand binding site
S6lJgiQ41l	313f9dc78b0a50584e68ac68a2b1c55b	366	CDD-3.21	cd15334	24	359	18	Y	337	337	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	A	203	203	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	S	206	206	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	T	129	129	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	F	333	333	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	W	120	120	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	S	210	210	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	C	128	128	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	L	313	313	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	E	329	329	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	F	310	310	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	I	196	196	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	D	124	124	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	W	306	306	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	S	207	207	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	F	309	309	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	V	125	125	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	CDD-3.21	cd15326	45	358	17	Y	337	337	putative ligand binding site
lhDnsli570	46f402e3fcd38b397fb4d60ec41d0011	441	PIRSR-2023_05	PIRSR600732-5	288	364	1	C	364	364	LIPID: S-palmitoyl cysteine
PWjd4lRbiM	57cf90ce42182bc2ba1c248180730dab	459	PIRSR-2023_05	PIRSR600732-3	33	230	1	CDVWAAVDVLCCTASIMSLCVISIDRYIGVSYPLRHATIVTKRRAVITLVGLWALSLVISIGPLFGWKEPAPKDD-TIC	104	181	DISULFID: 
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	PIRSR-2023_05	PIRSR600732-5	31	354	1	C	348	348	LIPID: S-palmitoyl cysteine
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	C	118	118	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	D	114	114	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	W	280	280	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	S	205	205	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	W	110	110	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	N	287	287	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	A	201	201	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	S	204	204	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	F	284	284	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	W	322	322	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	M	318	318	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	I	115	115	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	T	119	119	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	F	314	314	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	F	283	283	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	S	208	208	putative ligand binding site
VovpXOpNy5	e5e9f0be95ebd60325e182a88421da2d	468	CDD-3.21	cd15057	48	342	17	A	194	194	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	D	131	131	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	W	127	127	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	V	218	218	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	L	211	211	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	S	221	221	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	Y	393	393	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	F	408	408	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	F	390	390	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	S	225	225	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	V	132	132	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	W	386	386	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	F	412	412	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	A	222	222	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	F	389	389	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	Y	416	416	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	C	135	135	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	CDD-3.21	cd15063	52	437	17	T	136	136	putative ligand binding site
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	PIRSR-2023_05	PIRSR600732-5	366	442	1	C	442	442	LIPID: S-palmitoyl cysteine
CTtVnK5pQa	3035273e7f5bb806093a4ffcb47ad54a	492	PIRSR-2023_05	PIRSR600732-1	366	442	1	Q	401	401	BINDING: Zn(2+)
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	V	321	321	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	T	108	108	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	S	199	199	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	W	285	285	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	F	317	317	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	D	103	103	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	W	99	99	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	N	292	292	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	S	107	107	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	F	289	289	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	A	195	195	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	S	198	198	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	S	188	188	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	W	325	325	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	S	202	202	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	I	104	104	putative ligand binding site
OFW3zRJQfE	82f02c316298ce9683745ea25651786f	452	CDD-3.21	cd15320	23	345	17	F	288	288	putative ligand binding site
ZTAWJjuGOA	0344783896d9fb2c725ad466047eb0c2	295	PIRSR-2023_05	PIRSR600732-3	28	231	1	CNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGVRALLCVWALSLVISIGPLFGWRQQAPEDET-IC	99	176	DISULFID: 
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	D	158	158	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	W	335	335	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	I	155	155	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	F	338	338	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	F	339	339	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	R	362	362	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	T	163	163	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	A	243	243	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	E	361	361	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	C	227	227	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	L	365	365	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	V	159	159	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	R	345	345	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	S	239	239	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	C	162	162	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	F	154	154	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	L	358	358	putative ligand binding site
mHWkgELohz	cb25b21e3e188ed7a82454e1d1eaadc1	424	CDD-3.21	cd15329	78	390	18	Y	369	369	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	T	139	139	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	A	219	219	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	S	222	222	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	Y	351	351	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	L	208	208	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	V	135	135	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	V	215	215	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	Y	376	376	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	C	138	138	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	W	344	344	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	V	368	368	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	D	134	134	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	W	130	130	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	F	348	348	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	T	372	372	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	S	218	218	putative ligand binding site
aPdY5V1uOS	887eb59e0afe96223c1bc29f8b3318bc	409	CDD-3.21	cd15060	55	397	17	F	347	347	putative ligand binding site
oQJAuoFYl6	b260c1bd627794dbbd98c116985b1c37	562	PIRSR-2023_05	PIRSR600732-3	94	277	1	CDVWAAVDVLCCTASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWAVALVVSVGPLLGWKEPVPPDER-FC	163	240	DISULFID: 
QQ58S3chME	eb715c6056ea1f0b4bf88de60520e2d6	356	PIRSR-2023_05	PIRSR603912-52	48	217	1	CYVWVSCDVLCCTASIWNVTAIALDRYWSISRHLQYTLKGRRRASTLMISTAWFLSAIISLSPLFGWGNDYYSP--ELLEC	104	182	DISULFID: 
QQ58S3chME	eb715c6056ea1f0b4bf88de60520e2d6	356	PIRSR-2023_05	PIRSR600732-5	257	353	1	C	353	353	LIPID: S-palmitoyl cysteine
HpehaSDGPK	7ca3be5c06ae9026e0dc583429857e1e	418	PIRSR-2023_05	PIRSR603912-52	68	231	1	CDIFISLDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAVLISLTWLVGFLVSIPPMLGWRTPQ-DRSDPDAC	103	181	DISULFID: 
6v71cA4wPA	9e9f33557e774d295a3ed16eb41d7314	432	PIRSR-2023_05	PIRSR603912-52	56	234	1	CDFLFSVDVLCVTASIDTLCVIALDRYLAIISPFRYQTLLTKTRARIGALVVWTVAVLISFLP--IHMQIYKANNNQSDAC	114	192	DISULFID: 
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	F	308	308	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	I	178	178	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	W	285	285	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	T	111	111	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	F	312	312	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	V	107	107	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	F	289	289	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	Y	316	316	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	C	110	110	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	V	185	185	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	S	188	188	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	D	106	106	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	M	292	292	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	A	189	189	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	W	102	102	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	S	192	192	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	CDD-3.21	cd15325	27	337	17	F	288	288	putative ligand binding site
1PKgVKI1on	2a783a6a1a7aa4b8a58eaf9ea74cab08	466	PIRSR-2023_05	PIRSR600732-3	28	231	1	CNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGVRALLCVWALSLVISIGPLFGWRQQAPEDET-IC	99	176	DISULFID: 
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	PIRSR-2023_05	PIRSR600732-5	324	400	1	C	400	400	LIPID: S-palmitoyl cysteine
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	PIRSR-2023_05	PIRSR603912-52	49	181	1	CDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTG----DPTVC	103	181	DISULFID: 
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	PIRSR-2023_05	PIRSR600732-1	324	400	1	Q	356	356	BINDING: Zn(2+)
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	D	110	110	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	F	345	345	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	T	369	369	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	Y	373	373	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	H	349	349	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	S	193	193	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	Y	365	365	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	V	111	111	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	C	114	114	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	F	106	106	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	F	346	346	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	V	189	189	ligand binding site
0Qx2mGPnBl	5632c0844a461dcc37f5a7c6e18d8467	400	CDD-3.21	cd15310	30	394	13	S	192	192	ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	D	115	115	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	W	111	111	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	S	196	196	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	F	290	290	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	I	112	112	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	W	286	286	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	F	289	289	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	Y	316	316	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	A	200	200	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	L	312	312	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	V	116	116	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	P	305	305	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	C	119	119	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	S	309	309	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	C	184	184	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	V	296	296	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	K	308	308	putative ligand binding site
sgfrUxg48l	7fbe0443d88bbe91a4fc3259b50baf1e	345	CDD-3.21	cd15328	35	337	18	T	120	120	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	F	409	409	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	V	134	134	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	S	233	233	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	I	226	226	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	F	413	413	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	I	219	219	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	T	138	138	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	Y	393	393	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	S	230	230	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	F	390	390	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	W	386	386	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	C	137	137	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	F	389	389	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	S	229	229	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	Y	129	129	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	D	133	133	putative ligand binding site
ZsVb4os2cb	838ee6cf5be2096ba2abf25a3f7c45fd	451	CDD-3.21	cd15322	54	438	17	Y	417	417	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	D	318	318	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	F	302	302	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	C	107	107	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	S	185	185	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	C	172	172	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	W	298	298	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	T	108	108	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	F	301	301	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	D	103	103	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	W	99	99	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	L	100	100	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	T	325	325	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	Y	329	329	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	N	322	322	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	S	321	321	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	V	308	308	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	I	104	104	putative ligand binding site
WZ0Hw4UsTM	0e310810d3fc9f473e13e1dc6fa9d565	360	CDD-3.21	cd15334	24	351	18	A	189	189	putative ligand binding site
7abZLMDRv5	c284b3834c49d9dc7f0fd3f700084a5b	417	PIRSR-2023_05	PIRSR601681-50	35	210	1	CGIYLSLDVLFCTSSIVHLCAISLDRYWSVTRAVQYNPKRTPKRIKQMIGIVWLISAVISLPPL--AAIDNNSSNTGC	105	180	DISULFID: 
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	D	110	110	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	W	106	106	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	I	107	107	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	F	290	290	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	A	196	196	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	W	286	286	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	F	289	289	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	Y	316	316	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	T	115	115	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	L	312	312	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	C	180	180	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	N	296	296	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	V	111	111	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	C	114	114	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	P	305	305	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	S	309	309	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	K	308	308	putative ligand binding site
Jgj82PVig0	6ec545819936e54bd6d28a433f8571b5	343	CDD-3.21	cd15328	30	337	18	S	192	192	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	S	99	99	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	A	171	171	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	W	260	260	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	S	185	185	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	N	267	267	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	V	295	295	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	I	96	96	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	F	291	291	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	F	264	264	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	S	182	182	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	F	263	263	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	T	100	100	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	D	95	95	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	W	91	91	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	S	181	181	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	W	299	299	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	CDD-3.21	cd15057	18	319	17	A	178	178	putative ligand binding site
5o4pPp22Vf	af0c4bebbb123a2519ab4ac369a33ba1	443	PIRSR-2023_05	PIRSR600732-5	8	341	1	C	325	325	LIPID: S-palmitoyl cysteine
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	T	139	139	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	F	431	431	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	V	135	135	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	C	138	138	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	L	211	211	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	Y	435	435	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	S	221	221	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	Y	409	409	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	D	134	134	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	C	222	222	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	F	406	406	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	Y	130	130	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	S	225	225	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	W	402	402	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	I	218	218	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	F	405	405	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	CDD-3.21	cd15321	49	456	17	F	427	427	putative ligand binding site
vpMwgz3vLP	ad3bfeb6e8136f1f8919ade7512200f4	468	PIRSR-2023_05	PIRSR600732-5	379	462	1	C	461	461	LIPID: S-palmitoyl cysteine
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	PIRSR-2023_05	PIRSR603912-52	44	227	1	CEFWTSIDVLCVTASIETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMH--WYRATHQEAINC	106	184	DISULFID: 
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	PIRSR-2023_05	PIRSR600732-1	268	327	1	Q	299	299	BINDING: Zn(2+)
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	Y	308	308	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	T	118	118	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	N	293	293	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	W	109	109	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	F	290	290	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	V	117	117	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	W	286	286	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	F	193	193	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	S	203	203	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	F	289	289	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	Y	316	316	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	Y	199	199	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	N	312	312	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	D	113	113	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	S	204	204	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	S	207	207	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	V	114	114	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	18	D	192	192	ligand binding site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	I	135	135	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	E	225	225	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	Q	142	142	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	K	232	232	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	A	134	134	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	R	228	228	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	A	271	271	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	L	275	275	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	R	63	63	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	K	140	140	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	P	138	138	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	V	222	222	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	E	62	62	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	R	131	131	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	Y	141	141	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	S	143	143	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	L	230	230	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	K	270	270	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	T	274	274	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	F	139	139	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	I	233	233	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	Q	229	229	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	T	136	136	G protein interaction site
RFGXqobs4X	3e9d25347d93e5c2b71f7d8151dd1e9c	413	CDD-3.21	cd15957	34	336	24	A	226	226	G protein interaction site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	PIRSR-2023_05	PIRSR600732-5	345	425	1	C	424	424	LIPID: S-palmitoyl cysteine
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	V	113	113	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	Y	373	373	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	S	199	199	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	F	370	370	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	Y	398	398	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	T	117	117	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	W	366	366	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	Y	108	108	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	S	203	203	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	F	369	369	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	F	390	390	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	I	196	196	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	C	116	116	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	L	189	189	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	F	394	394	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	D	112	112	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	CDD-3.21	cd15323	33	419	17	C	200	200	putative ligand binding site
mHAx5tEew1	60bed57a778fc37a5c6b4165c3adcf12	431	PIRSR-2023_05	PIRSR600732-1	345	425	1	Q	381	381	BINDING: Zn(2+)
HramW9On5L	783ae8c7495a64c291cb6700956cdbc3	454	PIRSR-2023_05	PIRSR600732-5	375	454	1	C	454	454	LIPID: S-palmitoyl cysteine
wNz6lpMPR5	517ab9aa772d43e5cf078d984817cafe	413	PIRSR-2023_05	PIRSR600732-5	331	408	1	C	408	408	LIPID: S-palmitoyl cysteine
wNz6lpMPR5	517ab9aa772d43e5cf078d984817cafe	413	PIRSR-2023_05	PIRSR603912-52	44	233	1	CDIFISLDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAVLISLTWLIGFLISIPPMLGWRTPE-DRSNPDAC	103	181	DISULFID: 
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	PIRSR-2023_05	PIRSR600732-5	377	463	1	C	462	462	LIPID: S-palmitoyl cysteine
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	D	110	110	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	Y	436	436	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	W	404	404	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	Y	106	106	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	S	194	194	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	F	408	408	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	T	115	115	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	I	191	191	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	S	198	198	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	C	195	195	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	L	184	184	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	F	407	407	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	F	428	428	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	V	111	111	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	C	114	114	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	Y	411	411	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	CDD-3.21	cd15321	25	457	17	F	432	432	putative ligand binding site
OPtLNHMxEK	61ff186a51df54477dbe2d122d0f0579	470	PIRSR-2023_05	PIRSR600732-1	30	219	1	E	187	187	BINDING: Zn(2+)
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	PIRSR-2023_05	PIRSR600732-5	256	336	1	C	332	332	LIPID: S-palmitoyl cysteine
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	F	169	169	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	V	92	92	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	S	180	180	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	D	297	297	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	C	95	95	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	W	275	275	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	V	176	176	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	T	96	96	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	Y	87	87	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	D	91	91	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	F	279	279	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	L	301	301	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	I	179	179	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	T	183	183	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	F	282	282	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	Y	278	278	putative ligand binding site
3kndjxAPF9	096471a2fa31cbae0addae54d961185c	340	CDD-3.21	cd15051	12	326	17	Y	305	305	putative ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	PIRSR-2023_05	PIRSR600732-3	36	242	1	CDFWLSSDITCCTASIMHLCVIALDRYWAITDAVEYSAKRTPKRAAIMIVLVWVFSISISLPPFF-WRQAKAEEEMLDC	118	195	DISULFID: 
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	W	121	121	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	L	122	122	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	M	333	333	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	M	344	344	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	C	129	129	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	Y	355	355	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	A	212	212	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	W	323	323	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	D	125	125	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	N	351	351	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	F	326	326	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	C	195	195	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	F	327	327	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	D	348	348	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	T	130	130	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	F	347	347	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	S	208	208	ligand binding site
cjvNWGmmTK	1913848bed4545b3fe23009337e2ad89	386	CDD-3.21	cd15333	42	376	18	I	126	126	ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	S	350	350	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	T	129	129	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	A	209	209	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	Y	357	357	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	F	349	349	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	W	120	120	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	M	337	337	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	C	128	128	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	T	213	213	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	C	197	197	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	D	124	124	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	W	327	327	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	T	121	121	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	F	330	330	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	V	125	125	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	F	331	331	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	L	353	353	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	CDD-3.21	cd15331	49	378	18	H	347	347	putative ligand binding site
hHDQviDuXc	14ea8f8983a784e3955180f8e86b2f79	392	PIRSR-2023_05	PIRSR600732-5	306	384	1	C	383	383	LIPID: S-palmitoyl cysteine
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	PIRSR-2023_05	PIRSR600732-5	356	450	1	C	450	450	LIPID: S-palmitoyl cysteine
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	V	134	134	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	F	206	206	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	Y	415	415	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	H	399	399	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	S	215	215	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	S	216	216	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	T	419	419	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	Y	423	423	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	V	212	212	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	F	396	396	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	C	137	137	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	F	395	395	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	L	129	129	ligand binding site
B8V1Vfsa8q	74dc36a70d5ad7f7d21c7fc6daf8dc51	450	CDD-3.21	cd15053	54	444	14	D	133	133	ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	PIRSR-2023_05	PIRSR600732-5	289	366	1	C	366	366	LIPID: S-palmitoyl cysteine
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	Y	340	340	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	T	107	107	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	N	314	314	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	S	190	190	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	V	103	103	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	W	307	307	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	T	336	336	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	D	102	102	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	S	187	187	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	Y	332	332	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	L	183	183	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	F	310	310	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	F	311	311	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	W	98	98	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	S	106	106	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	S	186	186	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	CDD-3.21	cd15067	23	361	17	F	176	176	putative ligand binding site
79Py93EM0n	a9cbfeef761895ad3d85f7b457e1e4a4	418	PIRSR-2023_05	PIRSR600732-1	289	366	1	Q	323	323	BINDING: Zn(2+)
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	T	107	107	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	Y	383	383	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	F	356	356	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	V	103	103	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	C	106	106	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	V	181	181	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	F	355	355	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	S	184	184	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	D	102	102	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	Y	359	359	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	Y	98	98	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	F	375	375	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	S	188	188	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	C	185	185	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	W	352	352	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	F	379	379	putative ligand binding site
UP6HfeKfau	8595c878940436c3ee28a2a2c8d8274d	417	CDD-3.21	cd15322	23	404	17	I	174	174	putative ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	C	123	123	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	P	336	336	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	S	201	201	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	D	340	340	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	C	188	188	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	T	124	124	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	V	327	327	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	W	317	317	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	D	119	119	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	W	115	115	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	L	116	116	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	F	339	339	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	F	321	321	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	T	343	343	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	Y	347	347	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	I	120	120	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	A	205	205	ligand binding site
kZxa6ms4fT	5f885e3f3ace69ec29ebc70ff401ec79	383	CDD-3.21	cd15333	36	368	18	F	320	320	ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	F	425	425	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	I	124	124	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	T	449	449	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	S	212	212	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	T	428	428	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	F	445	445	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	F	424	424	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	T	128	128	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	D	123	123	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	F	198	198	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	F	119	119	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	S	209	209	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	S	127	127	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	W	421	421	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	H	453	453	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	V	205	205	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	CDD-3.21	cd15067	44	474	17	S	208	208	putative ligand binding site
RRF2q6hVEw	7170c100795415dc401a5d2a05e0419d	517	PIRSR-2023_05	PIRSR600732-5	403	483	1	C	480	480	LIPID: S-palmitoyl cysteine
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	T	155	155	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	A	235	235	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	F	388	388	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	V	151	151	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	W	365	365	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	C	154	154	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	C	223	223	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	K	385	385	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	M	375	375	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	D	150	150	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	F	369	369	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	Y	396	396	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	T	147	147	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	W	146	146	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	L	392	392	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	S	239	239	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	S	389	389	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	CDD-3.21	cd15331	71	417	18	F	368	368	putative ligand binding site
JgIOJYAsJW	2931c27415a944635ba586a3fca6febc	429	PIRSR-2023_05	PIRSR600732-5	326	426	1	C	422	422	LIPID: S-palmitoyl cysteine
ipy3Nr1Y7C	964c0debb7a1a9ace1c69a33c17f08fb	454	PIRSR-2023_05	PIRSR600732-3	33	224	1	CSVWAALDVLCCTASILSLCVISIDRYLAVSYPLRYSAIATGRRGLAAVAALWGLSAAISVGPLFGWKEPDPEDESV-C	106	183	DISULFID: 
b9fIXPsHii	811e8c7f0c4f9119e4c39237ccc14f4d	458	PIRSR-2023_05	PIRSR603912-52	45	232	1	CDIFIALDVLCCTSSILHLCAIALDRYWAITNPIDYVNKRTPRRAVIMISLTWLVGFSISIPPMLGWRTPA-DRADPDAC	107	185	DISULFID: 
FNavqnaurn	a319b15c8d2d1e11a1ba4a40b23ee933	403	PIRSR-2023_05	PIRSR600732-5	323	398	1	C	398	398	LIPID: S-palmitoyl cysteine
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	W	409	409	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	S	419	419	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	D	163	163	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	W	159	159	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	F	413	413	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	Y	440	440	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	C	234	234	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	I	160	160	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	A	250	250	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	L	436	436	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	P	429	429	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	S	246	246	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	S	433	433	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	V	164	164	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	F	412	412	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	C	167	167	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	F	432	432	putative ligand binding site
NBGYzK3iVg	db436020e62ba2c8a341377c87b70d44	473	CDD-3.21	cd15331	84	461	18	T	168	168	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	W	105	105	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	S	195	195	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	F	302	302	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	F	303	303	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	S	199	199	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	D	109	109	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	V	110	110	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	S	198	198	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	S	113	113	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	Y	306	306	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	F	327	327	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	F	188	188	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	S	202	202	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	Y	331	331	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	T	114	114	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	W	299	299	putative ligand binding site
uatnMHEY3Q	e07d6a3b38a586c587f1cecc31adaa8c	370	CDD-3.21	cd15066	31	352	17	V	323	323	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	F	361	361	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	A	203	203	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	C	187	187	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	D	116	116	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	L	368	368	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	S	199	199	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	A	383	383	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	V	117	117	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	I	113	113	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	E	379	379	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	N	386	386	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	T	121	121	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	F	362	362	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	Y	390	390	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	C	120	120	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	G	382	382	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	F	112	112	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	CDD-3.21	cd15330	37	411	18	W	358	358	putative ligand binding site
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	PIRSR-2023_05	PIRSR603912-52	73	223	1	CDLFIALDVLCCTSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPE-DRSNPNEC	109	187	DISULFID: 
lFi8Xdf890	8b6d058c5383b19d219007e3ff876b31	421	PIRSR-2023_05	PIRSR600732-5	338	417	1	C	417	417	LIPID: S-palmitoyl cysteine
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	PIRSR-2023_05	PIRSR600732-3	48	242	1	CDMWLSSDITCCTASILHLCVIALDRYWAITDAVEYSKKRTPRRAAGMIGIVWIIAISISIPPLF-WRQAKAEGELTTC	118	195	DISULFID: 
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	W	121	121	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	L	122	122	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	C	129	129	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	A	212	212	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	D	125	125	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	F	326	326	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	D	347	347	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	C	195	195	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	T	350	350	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	Y	354	354	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	W	322	322	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	F	332	332	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	I	346	346	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	F	325	325	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	T	130	130	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	P	343	343	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	S	208	208	ligand binding site
SuTPtZY9fG	986ac1a5891ac8258045e184a483c764	386	CDD-3.21	cd15333	42	375	18	I	126	126	ligand binding site
hRN1Wy69Ah	68f6f12765efe89cd88281aff459ae47	390	PIRSR-2023_05	PIRSR600732-5	32	332	1	C	329	329	LIPID: S-palmitoyl cysteine
hRN1Wy69Ah	68f6f12765efe89cd88281aff459ae47	390	PIRSR-2023_05	PIRSR600732-5	32	332	1	C	330	330	LIPID: S-palmitoyl cysteine
hRN1Wy69Ah	68f6f12765efe89cd88281aff459ae47	390	PIRSR-2023_05	PIRSR600732-1	32	332	1	Q	289	289	BINDING: Zn(2+)
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	W	329	329	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	A	240	240	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	V	156	156	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	F	333	333	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	R	356	356	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	C	159	159	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	C	224	224	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	V	352	352	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	T	160	160	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	L	359	359	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	D	155	155	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	R	339	339	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	F	151	151	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	S	236	236	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	F	332	332	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	Y	363	363	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	I	152	152	putative ligand binding site
OyaeKE1frb	8a5ddb2a9f96a6398348d869249052c8	410	CDD-3.21	cd15329	75	384	18	E	355	355	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	F	350	350	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	F	351	351	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	Y	378	378	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	T	111	111	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	F	370	370	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	S	189	189	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	V	107	107	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	C	110	110	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	C	190	190	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	F	374	374	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	S	193	193	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	Y	354	354	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	I	186	186	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	D	106	106	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	I	179	179	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	H	102	102	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	CDD-3.21	cd15322	27	399	17	W	347	347	putative ligand binding site
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	PIRSR-2023_05	PIRSR600732-5	325	407	1	C	404	404	LIPID: S-palmitoyl cysteine
tFq6SZ4duR	91934952d2cf9db8a3d6d073e660d0e2	412	PIRSR-2023_05	PIRSR603912-52	21	226	1	CEIHLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKCIIFIVWVIAAVISFPPLIPMKKETG--KKDDPKC	99	177	DISULFID: 
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	PIRSR-2023_05	PIRSR600732-5	362	449	1	C	449	449	LIPID: S-palmitoyl cysteine
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	W	388	388	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	D	185	185	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	V	186	186	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	R	415	415	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	F	392	392	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	I	182	182	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	C	254	254	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	T	190	190	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	E	414	414	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	L	418	418	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	F	391	391	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	R	398	398	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	A	270	270	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	F	181	181	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	L	411	411	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	S	266	266	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	Y	422	422	putative ligand binding site
NYNy7HroOL	8d887482369ecee8c804698383be8b94	479	CDD-3.21	cd15329	105	443	18	C	189	189	putative ligand binding site
ot7OqrLzX5	0fbbd0052e4d8284db1834e3c8afa48b	363	PIRSR-2023_05	PIRSR600732-3	30	210	1	CEAWLSLDMTCCTCSILHLCVIALDRYWAITDAVEYARKRTARRACVMILSVWAISTLISMPPLF-WRRYDANSTSEKC	94	171	DISULFID: 
ot7OqrLzX5	0fbbd0052e4d8284db1834e3c8afa48b	363	PIRSR-2023_05	PIRSR600732-5	283	361	1	C	359	359	LIPID: S-palmitoyl cysteine
mat2rzz8WQ	e5e947b2254ea80cdbc9f1b96ed0b8a9	405	PIRSR-2023_05	PIRSR600732-3	30	217	1	CDALMTLDVMLCTASIYNLCAISLDRFIAVRAPLRYEHKRVNVRQAALIAATWFLSLALASPLALGA-NSNPERDPAVC	94	171	DISULFID: 
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	PIRSR-2023_05	PIRSR600732-5	308	410	1	C	405	405	LIPID: S-palmitoyl cysteine
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	S	227	227	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	F	351	351	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	S	372	372	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	M	358	358	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	T	143	143	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	A	223	223	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	F	371	371	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	V	139	139	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	C	142	142	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	L	375	375	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	W	348	348	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	C	211	211	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	K	368	368	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	D	138	138	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	T	135	135	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	Y	379	379	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	W	134	134	putative ligand binding site
pv1h7PjWkj	f2cf2b38894200d060da33ddffc7388e	412	CDD-3.21	cd15331	59	400	18	F	352	352	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	A	219	219	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	S	222	222	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	W	356	356	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	C	139	139	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	L	208	208	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	T	140	140	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	V	215	215	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	T	383	383	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	D	135	135	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	Y	387	387	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	F	131	131	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	E	379	379	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	F	360	360	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	F	359	359	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	S	218	218	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	Y	363	363	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	CDD-3.21	cd15060	55	408	17	I	136	136	putative ligand binding site
ROISpCVrjz	b699bc2f7d8d90c06892d600e739379d	429	PIRSR-2023_05	PIRSR600732-5	334	415	1	C	413	413	LIPID: S-palmitoyl cysteine
fSOOhYALAC	361fae64e1ee1f767be6281effd2fd83	428	PIRSR-2023_05	PIRSR600732-5	340	421	1	C	421	421	LIPID: S-palmitoyl cysteine
fSOOhYALAC	361fae64e1ee1f767be6281effd2fd83	428	PIRSR-2023_05	PIRSR600732-1	35	213	1	E	188	188	BINDING: Zn(2+)
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	I	103	103	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	T	107	107	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	W	324	324	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	S	201	201	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	F	287	287	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	V	320	320	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	D	102	102	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	S	187	187	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	S	198	198	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	W	284	284	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	W	98	98	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	F	316	316	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	N	291	291	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	S	106	106	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	S	197	197	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	F	288	288	putative ligand binding site
few0T6PIFn	529b7985d584c166b645ebe7d2f0848b	452	CDD-3.21	cd15320	22	344	17	A	194	194	putative ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	S	211	211	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	W	313	313	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	V	97	97	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	N	293	293	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	L	96	96	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	D	116	116	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	L	309	309	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	F	290	290	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	V	117	117	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	W	286	286	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	F	289	289	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	Y	316	316	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	N	312	312	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	F	197	197	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	S	207	207	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	T	199	199	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	W	112	112	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	Y	203	203	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	A	204	204	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	V	120	120	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	21	S	208	208	ligand binding site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	T	139	139	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	F	142	142	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	R	134	134	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	K	232	232	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	I	237	237	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	Q	233	233	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	A	230	230	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	E	229	229	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	A	271	271	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	S	146	146	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	L	275	275	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	R	143	143	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	K	236	236	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	P	141	141	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	M	234	234	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	A	137	137	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	Q	65	65	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	Q	145	145	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	I	138	138	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	Y	144	144	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	V	226	226	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	K	270	270	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	T	274	274	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	CDD-3.21	cd15958	38	336	24	R	66	66	putative G protein interaction site
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	PIRSR-2023_05	PIRSR600732-5	269	345	1	C	341	341	LIPID: S-palmitoyl cysteine
yWWKXX0tOb	3aef1687586730c6a22961dbd9c3eb60	389	PIRSR-2023_05	PIRSR600732-5	269	345	1	C	342	342	LIPID: S-palmitoyl cysteine
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	PIRSR-2023_05	PIRSR600732-5	402	478	1	C	478	478	LIPID: S-palmitoyl cysteine
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	D	142	142	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	T	447	447	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	Y	451	451	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	F	424	424	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	S	225	225	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	F	423	423	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	V	143	143	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	C	146	146	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	F	138	138	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	Y	443	443	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	V	221	221	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	S	224	224	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	CDD-3.21	cd15310	62	472	13	H	427	427	ligand binding site
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	PIRSR-2023_05	PIRSR600732-1	402	478	1	Q	434	434	BINDING: Zn(2+)
nWfn6CCof3	304cc00d793fd0760131779341c43651	478	PIRSR-2023_05	PIRSR603912-52	88	248	1	CDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDP----SIC	135	213	DISULFID: 
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	PIRSR-2023_05	PIRSR600732-3	67	247	1	CDFYIAVDVTCSTASIFNLVAISIDRYIAVTQPIKYSKHKNSTRVSLTIAIVWLVSAAIGSPIVLGLNT-SPERTPQLC	128	205	DISULFID: 
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	F	489	489	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	F	207	207	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	S	217	217	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	Y	131	131	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	D	135	135	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	N	468	468	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	S	216	216	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	S	139	139	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	F	465	465	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	I	213	213	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	V	136	136	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	T	493	493	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	F	464	464	ligand binding site
kS9rDJr2Qe	4dfe89ed8637453424761d796100dd7a	526	CDD-3.21	cd15053	72	518	14	Y	497	497	ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	D	137	137	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	V	138	138	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	V	218	218	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	L	211	211	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	S	221	221	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	Y	361	361	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	F	358	358	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	T	142	142	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	V	377	377	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	S	225	225	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	W	354	354	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	A	222	222	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	W	133	133	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	F	357	357	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	T	381	381	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	Y	385	385	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	CDD-3.21	cd15060	58	406	17	C	141	141	putative ligand binding site
a5QvoSesca	54ed33cb4b10d71f8d19e8a2f4d92780	419	PIRSR-2023_05	PIRSR600732-5	336	414	1	C	411	411	LIPID: S-palmitoyl cysteine
Z3FT53TCH4	138ca5965e2558775b2af96a0fd871bc	363	PIRSR-2023_05	PIRSR600732-5	282	359	1	C	359	359	LIPID: S-palmitoyl cysteine
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	Y	84	84	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	F	169	169	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	F	265	265	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	D	179	179	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	C	92	92	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	S	180	180	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	Y	293	293	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	Y	264	264	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	D	88	88	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	V	176	176	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	V	89	89	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	F	268	268	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	Y	285	285	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	W	261	261	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	T	183	183	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	T	93	93	putative ligand binding site
NZ3RVgxYOP	f13b23185a68d1023351ca5b2001ddab	351	CDD-3.21	cd15051	9	314	17	L	289	289	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	Y	356	356	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	T	145	145	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	A	225	225	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	C	209	209	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	E	348	348	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	L	352	352	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	S	221	221	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	C	144	144	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	F	136	136	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	F	326	326	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	D	140	140	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	W	322	322	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	F	325	325	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	R	332	332	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	V	141	141	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	I	137	137	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	I	345	345	putative ligand binding site
LbAfNvLG0L	d8c5a4b1676a3a57443787c4032f4ab6	403	CDD-3.21	cd15329	60	377	18	R	349	349	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	L	186	186	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	Y	276	276	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	A	299	299	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	Y	303	303	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	V	108	108	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	A	193	193	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	A	196	196	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	A	197	197	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	T	112	112	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	W	273	273	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	D	107	107	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	W	295	295	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	H	103	103	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	S	111	111	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	F	277	277	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	C	200	200	putative ligand binding site
RQEJxU8tdk	3d820480a9985cdf9d5ed8da4da67af2	343	CDD-3.21	cd15055	32	324	17	T	280	280	putative ligand binding site
KGjkcEE7cy	359fc950ad3bfedc3c0beb5ec43cf146	409	PIRSR-2023_05	PIRSR603912-52	37	232	1	CEFWTATDVLCVTASIETLCVIALDRYIAIMWPLRYQSMLTKRKACGMVIGVWAVAALISFLPIHMEWW--VSDEPEALSC	113	191	DISULFID: 
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	Y	437	437	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	V	135	135	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	S	215	215	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	C	138	138	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	F	130	130	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	F	418	418	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	D	134	134	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	F	417	417	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	S	214	214	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	T	441	441	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	Y	445	445	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	H	421	421	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	CDD-3.21	cd15310	54	466	13	V	211	211	ligand binding site
e1COKHaLv5	8ec9dd3de7fff5f531bdeea68e0c598f	472	PIRSR-2023_05	PIRSR600732-5	388	472	1	C	472	472	LIPID: S-palmitoyl cysteine
gMJfsA1GC0	5a1bfe1d8f966b2d18843a9519d70dfa	369	PIRSR-2023_05	PIRSR600732-5	21	313	1	C	313	313	LIPID: S-palmitoyl cysteine
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	I	103	103	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	T	107	107	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	W	324	324	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	S	201	201	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	F	287	287	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	V	320	320	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	D	102	102	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	S	187	187	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	S	198	198	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	W	284	284	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	W	98	98	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	F	316	316	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	N	291	291	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	S	106	106	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	S	197	197	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	F	288	288	putative ligand binding site
a22rRowKoj	0ecd34b4e8b1a3cc6e3356573aec3fd6	446	CDD-3.21	cd15320	22	344	17	A	194	194	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	C	123	123	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	M	120	120	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	T	124	124	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	D	119	119	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	L	366	366	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	W	115	115	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	R	362	362	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	A	202	202	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	S	363	363	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	C	190	190	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	F	342	342	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	I	116	116	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	Y	370	370	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	W	338	338	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	A	206	206	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	F	341	341	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	R	348	348	putative ligand binding site
Z3ooMzHzSd	69cddefba06174f43f6d6c8ef0e9d595	436	CDD-3.21	cd15329	40	391	18	R	359	359	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	PIRSR-2023_05	PIRSR600732-1	36	344	1	Q	301	301	BINDING: Zn(2+)
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	PIRSR-2023_05	PIRSR600732-5	36	344	1	C	342	342	LIPID: S-palmitoyl cysteine
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	S	211	211	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	W	287	287	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	F	308	308	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	D	114	114	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	F	290	290	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	F	291	291	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	A	197	197	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	W	110	110	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	S	118	118	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	W	316	316	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	S	207	207	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	I	115	115	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	T	119	119	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	N	294	294	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	A	204	204	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	V	312	312	putative ligand binding site
LchBVbvDS0	046fff05ac09748458472cc88e44008e	447	CDD-3.21	cd15057	35	336	17	S	208	208	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	F	286	286	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	V	97	97	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	S	185	185	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	S	100	100	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	L	174	174	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	W	264	264	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	T	101	101	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	A	181	181	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	S	184	184	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	N	271	271	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	W	92	92	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	S	188	188	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	F	268	268	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	T	290	290	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	D	96	96	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	F	267	267	putative ligand binding site
MQ9V4Zj61g	4c1fa38d26bd10665e387f5b893af59c	383	CDD-3.21	cd15065	18	315	17	Y	294	294	putative ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	S	195	195	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	V	113	113	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	T	417	417	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	Y	421	421	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	F	397	397	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	S	194	194	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	C	116	116	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	F	108	108	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	F	396	396	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	Y	413	413	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	V	191	191	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	H	400	400	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	D	112	112	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	CDD-3.21	cd15053	33	442	14	I	185	185	ligand binding site
7nQDPMneN2	9a614f4b005ebc666f226903eb3648fa	448	PIRSR-2023_05	PIRSR600732-5	370	448	1	C	448	448	LIPID: S-palmitoyl cysteine
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	PIRSR-2023_05	PIRSR600732-5	369	453	1	C	453	453	LIPID: S-palmitoyl cysteine
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	Y	404	404	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	D	99	99	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	W	95	95	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	S	215	215	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	W	397	397	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	F	419	419	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	S	219	219	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	F	401	401	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	A	216	216	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	F	423	423	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	V	100	100	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	V	212	212	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	L	205	205	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	Y	427	427	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	C	103	103	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	F	400	400	putative ligand binding site
gIsuMg05Mx	2e7c905491bb41d9c38bb5ccb00c1a84	486	CDD-3.21	cd15063	23	448	17	T	104	104	putative ligand binding site
Wm098GODX1	a896d7fe21bd41fbafac0edf2112bbe1	339	PIRSR-2023_05	PIRSR600732-5	250	324	1	C	323	323	LIPID: S-palmitoyl cysteine
Wm098GODX1	a896d7fe21bd41fbafac0edf2112bbe1	339	PIRSR-2023_05	PIRSR600732-5	250	324	1	C	322	322	LIPID: S-palmitoyl cysteine
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	PIRSR-2023_05	PIRSR600732-3	101	283	1	CDFYIAIDVTCSTASIFNLVAISIDRFIAVTQPIKYSKHKNSKRVALTIVFVWVVSAAIGSPIMLGLNT-SPERVPHLC	168	245	DISULFID: 
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	S	179	179	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	F	521	521	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	I	253	253	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	V	176	176	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	N	500	500	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	F	497	497	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	F	247	247	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	S	257	257	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	Y	171	171	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	D	175	175	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	T	525	525	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	S	256	256	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	F	496	496	ligand binding site
7jzVMWlr4y	753ff23e837af9434d1984cd296cf6e3	559	CDD-3.21	cd15053	96	550	14	Y	529	529	ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	A	331	331	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	Y	335	335	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	C	107	107	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	S	185	185	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	C	172	172	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	F	308	308	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	T	108	108	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	S	327	327	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	V	314	314	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	D	103	103	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	W	99	99	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	L	100	100	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	F	307	307	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	N	328	328	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	E	324	324	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	W	304	304	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	I	104	104	putative ligand binding site
tgIYdvGd8x	5afc6a885588ea2972090cdcbc5ba19a	366	CDD-3.21	cd15334	24	357	18	A	189	189	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	PIRSR-2023_05	PIRSR600732-5	288	369	1	C	369	369	LIPID: S-palmitoyl cysteine
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	W	105	105	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	L	106	106	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	S	334	334	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	V	321	321	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	C	113	113	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	E	331	331	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	D	109	109	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	N	335	335	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	A	195	195	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	W	311	311	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	S	191	191	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	C	178	178	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	F	314	314	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	M	110	110	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	T	114	114	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	T	338	338	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	F	315	315	putative ligand binding site
gYvledWOAb	9d594b6a0e05fd122bbb5e3ef14d2c44	373	CDD-3.21	cd15334	30	364	18	Y	342	342	putative ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	PIRSR-2023_05	PIRSR600732-1	59	257	1	E	226	226	BINDING: Zn(2+)
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	D	142	142	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	W	138	138	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	W	458	458	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	F	461	461	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	V	229	229	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	L	462	462	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	S	232	232	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	Y	489	489	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	T	147	147	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	A	233	233	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	I	485	485	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	S	236	236	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	Q	481	481	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	V	143	143	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	C	146	146	ligand binding site
49bi6K5NUV	165c86d612c890d9b744c3c46c401eba	526	CDD-3.21	cd14967	64	510	16	Y	465	465	ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	PIRSR-2023_05	PIRSR600732-3	28	231	1	CNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDET-IC	99	176	DISULFID: 
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	F	308	308	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	I	178	178	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	W	285	285	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	T	111	111	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	F	312	312	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	V	107	107	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	F	289	289	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	Y	316	316	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	C	110	110	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	V	185	185	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	S	188	188	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	D	106	106	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	M	292	292	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	A	189	189	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	W	102	102	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	S	192	192	putative ligand binding site
QbaNkPFcky	b64fd3f2fb58b52dbd938352f793e804	427	CDD-3.21	cd15325	27	337	17	F	288	288	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	S	206	206	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	T	113	113	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	A	209	209	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	W	280	280	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	F	195	195	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	D	109	109	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	W	302	302	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	A	202	202	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	N	287	287	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	L	306	306	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	V	110	110	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	F	284	284	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	R	105	105	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	T	114	114	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	F	283	283	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	Y	310	310	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	CDD-3.21	cd15056	29	331	17	C	205	205	putative ligand binding site
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	PIRSR-2023_05	PIRSR600732-5	30	340	1	C	336	336	LIPID: S-palmitoyl cysteine
sXb4pc8vkJ	eb8335188577192d127f260dc4e450aa	394	PIRSR-2023_05	PIRSR600732-5	30	340	1	C	337	337	LIPID: S-palmitoyl cysteine
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	PIRSR-2023_05	PIRSR600732-5	63	368	1	C	365	365	LIPID: S-palmitoyl cysteine
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	PIRSR-2023_05	PIRSR600732-5	63	368	1	C	364	364	LIPID: S-palmitoyl cysteine
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	W	308	308	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	T	145	145	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	W	330	330	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	N	315	315	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	C	234	234	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	L	334	334	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	F	312	312	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	T	144	144	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	S	235	235	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	R	136	136	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	D	140	140	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	F	311	311	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	Y	338	338	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	A	238	238	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	A	231	231	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	V	141	141	putative ligand binding site
fsCKb933p1	bd13c2793861382ca1f37872c0f25dac	423	CDD-3.21	cd15056	60	359	17	F	224	224	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	F	313	313	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	Y	340	340	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	C	134	134	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	A	209	209	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	S	212	212	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	D	130	130	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	M	316	316	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	A	213	213	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	W	126	126	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	S	216	216	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	F	312	312	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	F	332	332	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	I	202	202	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	W	309	309	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	T	135	135	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	F	336	336	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	CDD-3.21	cd15325	51	361	17	V	131	131	putative ligand binding site
4bfvNf8AFQ	1a7fff18af9e651fca63a96eed21a599	489	PIRSR-2023_05	PIRSR600732-3	53	234	1	CNIWAAVDVLCCTASIMSLCAISIDRYIGVSYPLRYPSIMTEKRGVLALLCIWVLSLVISIGPLFGWKQPAPEDDKI-C	123	200	DISULFID: 
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	PIRSR-2023_05	PIRSR600732-5	298	384	1	C	382	382	LIPID: S-palmitoyl cysteine
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	D	142	142	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	L	351	351	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	R	331	331	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	F	324	324	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	I	139	139	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	Y	355	355	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	E	347	347	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	W	321	321	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	T	147	147	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	A	227	227	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	C	211	211	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	V	143	143	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	L	344	344	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	S	223	223	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	F	325	325	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	C	146	146	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	R	348	348	putative ligand binding site
i0aI5XCRaQ	c3db80fbd0dbbce461913cc86760f43f	410	CDD-3.21	cd15329	62	376	18	F	138	138	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	W	196	196	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	F	447	447	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	C	204	204	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	M	467	467	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	Y	451	451	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	D	200	200	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	L	274	274	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	W	444	444	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	V	201	201	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	V	281	281	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	S	284	284	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	T	471	471	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	Y	475	475	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	T	205	205	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	A	285	285	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	S	288	288	putative ligand binding site
GLtb9yFptg	507c91cacf287fe4aae734ca40b6deea	506	CDD-3.21	cd15060	121	496	17	F	448	448	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	W	335	335	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	T	161	161	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	A	241	241	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	C	225	225	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	F	338	338	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	S	237	237	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	F	339	339	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	C	160	160	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	R	362	362	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	F	152	152	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	E	361	361	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	D	156	156	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	L	365	365	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	R	345	345	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	V	157	157	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	L	358	358	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	I	153	153	putative ligand binding site
HvO1fxK8st	79d61b86aed78d37e4e92473864bfab4	437	CDD-3.21	cd15329	76	390	18	Y	369	369	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	F	287	287	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	V	108	108	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	A	193	193	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	S	196	196	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	Y	291	291	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	C	111	111	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	S	200	200	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	F	312	312	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	T	112	112	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	Y	316	316	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	D	107	107	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	W	284	284	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	W	103	103	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	V	308	308	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	F	186	186	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	S	197	197	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	CDD-3.21	cd15066	29	337	17	F	288	288	putative ligand binding site
7BkXKS9SzI	56b3a387b94bffbe63abf32268890984	419	PIRSR-2023_05	PIRSR600732-5	255	344	1	C	343	343	LIPID: S-palmitoyl cysteine
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	F	425	425	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	Y	410	410	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	S	231	231	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	F	429	429	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	T	111	111	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	W	403	403	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	V	107	107	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	C	110	110	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	S	230	230	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	F	406	406	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	F	407	407	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	D	106	106	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	S	234	234	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	L	220	220	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	W	102	102	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	Y	433	433	putative ligand binding site
22Xr83NGlk	34d4a4fffbe4817ddc420ab46a1d7467	491	CDD-3.21	cd15063	27	454	17	V	227	227	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	PIRSR-2023_05	PIRSR600732-1	21	316	1	E	180	180	BINDING: Zn(2+)
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	PIRSR-2023_05	PIRSR600732-5	21	316	1	C	304	304	LIPID: S-palmitoyl cysteine
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	PIRSR-2023_05	PIRSR600732-5	21	316	1	C	305	305	LIPID: S-palmitoyl cysteine
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	C	102	102	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	F	254	254	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	Y	250	250	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	G	183	183	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	D	98	98	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	Y	94	94	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	V	176	176	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	G	187	187	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	L	274	274	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	T	190	190	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	E	270	270	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	W	247	247	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	D	186	186	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	T	103	103	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	F	251	251	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	Y	278	278	putative ligand binding site
ZsLtyGwWKV	ce7744e1595b98f3ec60ef90aaa2fe40	363	CDD-3.21	cd15051	19	299	17	V	99	99	putative ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	PIRSR-2023_05	PIRSR603912-52	66	254	1	CELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARALVCTVWAISALVSFLPILMHWWR--AESDEARRC	131	209	DISULFID: 
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	PIRSR-2023_05	PIRSR600732-5	313	384	1	C	381	381	LIPID: S-palmitoyl cysteine
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	PIRSR-2023_05	PIRSR600732-5	313	384	1	C	382	382	LIPID: S-palmitoyl cysteine
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	A	251	251	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	Q	254	254	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	T	161	161	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	F	164	164	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	V	247	247	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	K	253	253	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	I	258	258	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	A	159	159	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	K	310	310	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	Q	167	167	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	I	160	160	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	E	250	250	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	T	314	314	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	S	168	168	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	R	165	165	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	K	257	257	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	R	88	88	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	P	163	163	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	V	255	255	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	R	156	156	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	A	311	311	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	L	315	315	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	Y	166	166	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	24	P	87	87	putative G protein interaction site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	F	329	329	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	Y	356	356	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	A	225	225	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	N	352	352	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	S	228	228	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	V	119	119	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	T	220	220	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	S	232	232	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	I	118	118	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	V	139	139	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	W	353	353	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	V	142	142	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	N	333	333	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	D	138	138	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	Y	224	224	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	F	218	218	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	F	330	330	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	V	349	349	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	S	229	229	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	W	134	134	ligand binding site
3ZvFnprZFB	1b28bddc9e6a494e790e3f99d40fd02a	466	CDD-3.21	cd15958	59	376	21	W	326	326	ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	PIRSR-2023_05	PIRSR600732-3	32	213	1	CDALMTMDVMLCTASIFNLCAISVDRFIAVSIPLNYNRRQIDLRQTVLISTTWIFAFAVASPVIFGLNN-VPNRDPTLC	106	183	DISULFID: 
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	S	195	195	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	H	329	329	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	S	194	194	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	C	117	117	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	I	191	191	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	F	326	326	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	T	345	345	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	L	109	109	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	D	113	113	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	F	325	325	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	V	114	114	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	T	349	349	putative ligand binding site
Uj66wqobxX	1b5001cf58aea1bcfffd888c5c6435f2	382	CDD-3.21	cd15308	33	374	13	Y	353	353	putative ligand binding site
wHZy5Q8IJI	ecefeeec9e8a0e14b8ffdbb7b13afbeb	517	PIRSR-2023_05	PIRSR600732-5	432	510	1	C	509	509	LIPID: S-palmitoyl cysteine
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	Y	372	372	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	I	156	156	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	E	364	364	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	L	368	368	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	A	244	244	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	V	160	160	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	L	361	361	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	F	342	342	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	C	163	163	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	C	228	228	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	W	338	338	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	T	164	164	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	F	341	341	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	R	348	348	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	D	159	159	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	F	155	155	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	S	240	240	putative ligand binding site
BCm1ehxNP0	f7c45e2de663935ef5b0f80b6f22df39	427	CDD-3.21	cd15329	79	393	18	R	365	365	putative ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	PIRSR-2023_05	PIRSR600732-1	293	368	1	Q	327	327	BINDING: Zn(2+)
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	PIRSR-2023_05	PIRSR600732-3	42	224	1	CDIWLSSDITCCTASILHLCVIALDRYWAITDALEYSKRRTAGRAALMIAIVWVISICISMPPLF-WRQAKAHEILTDC	110	187	DISULFID: 
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	W	313	313	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	C	187	187	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	F	317	317	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	D	338	338	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	L	323	323	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	T	122	122	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	T	341	341	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	S	200	200	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	Y	345	345	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	I	118	118	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	W	113	113	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	L	114	114	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	F	337	337	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	F	316	316	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	C	121	121	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	P	334	334	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	A	204	204	ligand binding site
s8872GClnz	ea01b55c2c0574d862c440608f67b8b5	376	CDD-3.21	cd15333	34	366	18	D	117	117	ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	PIRSR-2023_05	PIRSR600732-5	359	438	1	C	438	438	LIPID: S-palmitoyl cysteine
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	H	388	388	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	Y	403	403	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	C	112	112	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	F	104	104	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	S	187	187	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	F	385	385	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	D	108	108	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	S	188	188	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	T	407	407	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	Y	411	411	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	V	109	109	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	V	184	184	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	CDD-3.21	cd15309	29	432	13	F	384	384	putative ligand binding site
NSAJ7DeBeo	cd454ab4ff02fc9199e78cb0e2461454	438	PIRSR-2023_05	PIRSR601681-50	30	209	1	CDIFVTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISVVWVLSFAISCPLLFGLNN---TASKVC	101	176	DISULFID: 
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	PIRSR-2023_05	PIRSR600732-5	293	367	1	C	365	365	LIPID: S-palmitoyl cysteine
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	PIRSR-2023_05	PIRSR600732-5	293	367	1	C	364	364	LIPID: S-palmitoyl cysteine
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	F	313	313	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	V	332	332	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	S	215	215	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	W	120	120	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	Y	339	339	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	V	128	128	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	F	312	312	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	N	335	335	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	A	211	211	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	S	214	214	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	V	105	105	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	T	206	206	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	L	104	104	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	D	124	124	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	Y	210	210	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	F	204	204	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	W	309	309	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	S	218	218	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	W	336	336	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	V	125	125	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	21	N	316	316	ligand binding site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	L	298	298	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	P	149	149	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	A	145	145	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	Q	73	73	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	Q	153	153	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	I	146	146	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	E	236	236	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	A	294	294	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	Y	152	152	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	M	241	241	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	R	74	74	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	Q	240	240	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	T	147	147	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	F	150	150	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	V	233	233	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	I	244	244	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	R	142	142	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	E	239	239	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	T	297	297	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	K	293	293	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	S	154	154	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	R	151	151	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	K	243	243	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	CDD-3.21	cd15958	46	359	24	A	237	237	putative G protein interaction site
E4wkUUcW9k	830583569af5d3a34c25b3d24628c94b	432	PIRSR-2023_05	PIRSR603912-52	60	243	1	CECWTSVDVLCVTASIETLCVIAIDRYLAITSPFRYQSLMTKKRAKIIVCVVWAISALVSFLPIM--MQWWRDDDPEALLC	117	195	DISULFID: 
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
jtXy4FxeIw	f23157ca5b211c808658c7acd16c099d	381	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	A	208	208	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	I	123	123	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	T	127	127	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	F	322	322	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	D	343	343	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	C	191	191	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	T	346	346	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	Y	350	350	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	W	318	318	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	F	321	321	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	C	126	126	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	L	119	119	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	F	342	342	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	P	339	339	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	S	204	204	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	D	122	122	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	V	328	328	ligand binding site
dScYTJASy3	09403fa24123a0079f4ccf2417b15017	382	CDD-3.21	cd15333	40	371	18	W	118	118	ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	S	323	323	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	T	107	107	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	F	308	308	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	A	326	326	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	C	106	106	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	V	314	314	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	L	99	99	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	D	327	327	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	T	330	330	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	F	307	307	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	Y	334	334	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	M	103	103	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	D	102	102	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	W	98	98	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	A	190	190	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	S	186	186	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	W	304	304	putative ligand binding site
TtPKEkbkkp	7a5eed0c6182ef98b79c1f59eeb61310	365	CDD-3.21	cd15335	23	355	18	C	173	173	putative ligand binding site
5fGW2js1Xm	1362394e54872adafb821d36eadf7692	438	PIRSR-2023_05	PIRSR600732-5	57	360	1	C	357	357	LIPID: S-palmitoyl cysteine
5fGW2js1Xm	1362394e54872adafb821d36eadf7692	438	PIRSR-2023_05	PIRSR600732-5	57	360	1	C	358	358	LIPID: S-palmitoyl cysteine
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	PIRSR-2023_05	PIRSR600732-3	54	238	1	CNIWAAVDVLCCSASIMSLCIISVDRYIGVKYSLKYPTIMTERKAGVILVVVWLSSMVISIGPLLGWKEPPPPD-ESIC	124	201	DISULFID: 
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	W	313	313	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	D	131	131	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	W	127	127	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	S	217	217	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	L	320	320	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	F	340	340	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	F	317	317	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	Y	344	344	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	I	203	203	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	S	136	136	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	S	214	214	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	V	132	132	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	F	316	316	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	C	135	135	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	S	213	213	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	F	336	336	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	CDD-3.21	cd15327	52	365	17	A	210	210	putative ligand binding site
0oe9qWxWgC	065d0f90b07bf838f700c3de47b64fc4	511	PIRSR-2023_05	PIRSR600732-5	295	371	1	C	371	371	LIPID: S-palmitoyl cysteine
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	L	111	111	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	D	115	115	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	V	193	193	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	S	196	196	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	H	366	366	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	V	382	382	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	V	116	116	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	F	362	362	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	C	119	119	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	T	386	386	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	S	197	197	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	F	363	363	putative ligand binding site
IZ5hNTt2vT	85e697c2569594e0d754eed2f059c765	419	CDD-3.21	cd15308	38	411	13	Y	390	390	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	328	328	LIPID: S-palmitoyl cysteine
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	PIRSR-2023_05	PIRSR600732-5	22	331	1	C	327	327	LIPID: S-palmitoyl cysteine
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	R	96	96	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	D	100	100	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	W	271	271	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	A	193	193	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	F	274	274	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	V	101	101	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	F	275	275	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	L	297	297	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	A	200	200	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	T	105	105	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	C	196	196	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	Y	301	301	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	W	293	293	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	N	278	278	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	F	186	186	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	S	197	197	putative ligand binding site
1rIDrP8iE4	aa70ff8ae54e885e04f0f440ab70989d	386	CDD-3.21	cd15056	20	322	17	T	104	104	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	H	361	361	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	I	221	221	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	V	144	144	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	F	358	358	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	C	147	147	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	S	225	225	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	F	357	357	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	L	139	139	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	D	143	143	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	I	377	377	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	T	381	381	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	S	224	224	putative ligand binding site
98pkxfYHE6	fd41293a424f690f697fd42588d7f1e7	414	CDD-3.21	cd15308	63	406	13	Y	385	385	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	F	495	495	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	S	516	516	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	M	502	502	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	T	175	175	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	V	171	171	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	T	512	512	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	C	174	174	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	A	515	515	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	L	519	519	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	W	492	492	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	A	254	254	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	D	170	170	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	T	167	167	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	C	242	242	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	Y	523	523	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	T	258	258	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	W	166	166	putative ligand binding site
Fo7mARSVcD	9273d1f821d0bed5a95e0e1673730b80	562	CDD-3.21	cd15331	91	544	18	F	496	496	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	W	105	105	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	C	113	113	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	F	290	290	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	D	109	109	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	W	286	286	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	F	289	289	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	Y	316	316	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	V	110	110	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	A	195	195	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	C	179	179	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	L	312	312	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	I	106	106	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	S	191	191	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	P	305	305	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	T	114	114	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	S	309	309	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	K	308	308	putative ligand binding site
M0MwiXXZRL	264a1d943eeb9bf10d77a85e8e4cc383	345	CDD-3.21	cd15328	29	337	18	T	296	296	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	C	155	155	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	R	363	363	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	C	220	220	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	F	340	340	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	T	156	156	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	D	151	151	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	E	362	362	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	L	366	366	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	F	147	147	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	F	339	339	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	R	346	346	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	S	232	232	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	L	359	359	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	I	148	148	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	Y	370	370	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	W	336	336	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	A	236	236	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	CDD-3.21	cd15329	71	391	18	V	152	152	putative ligand binding site
dDjkeKehtN	04764a898d6ddde92ce4920d143be137	425	PIRSR-2023_05	PIRSR600732-5	306	398	1	C	397	397	LIPID: S-palmitoyl cysteine
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	S	195	195	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	H	372	372	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	V	113	113	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	S	194	194	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	T	389	389	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	Y	393	393	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	F	369	369	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	C	116	116	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	F	108	108	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	V	191	191	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	D	112	112	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	I	185	185	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	F	368	368	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	CDD-3.21	cd15053	33	414	14	Y	385	385	ligand binding site
XEMbna5PTc	440b339ad8316d55593fff8b36bca73d	420	PIRSR-2023_05	PIRSR600732-5	342	420	1	C	420	420	LIPID: S-palmitoyl cysteine
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	PIRSR-2023_05	PIRSR600732-5	62	364	1	C	363	363	LIPID: S-palmitoyl cysteine
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	PIRSR-2023_05	PIRSR600732-5	62	364	1	C	364	364	LIPID: S-palmitoyl cysteine
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	W	308	308	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	V	145	145	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	N	315	315	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	N	334	334	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	F	312	312	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	F	225	225	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	S	235	235	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	T	227	227	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	W	140	140	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	Y	231	231	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	A	232	232	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	F	311	311	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	Y	338	338	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	V	148	148	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	S	236	236	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	S	239	239	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	F	330	330	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	D	144	144	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	D	224	224	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	20	T	141	141	putative ligand binding site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	L	170	170	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	V	257	257	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	P	169	169	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	R	260	260	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	A	165	165	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	A	293	293	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	L	297	297	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	I	166	166	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	Y	172	172	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	V	254	254	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	P	93	93	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	Q	171	171	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	L	264	264	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	R	94	94	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	L	262	262	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	T	167	167	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	E	173	173	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	M	174	174	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	R	162	162	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	I	265	265	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	K	292	292	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	Q	261	261	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	A	258	258	putative G protein interaction site
jAR04nMkoH	4e37ede87330a5604e4a65778ed6ef74	479	CDD-3.21	cd15959	65	358	24	T	296	296	putative G protein interaction site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	Y	84	84	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	F	169	169	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	F	265	265	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	D	179	179	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	C	92	92	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	S	180	180	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	Y	293	293	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	Y	264	264	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	D	88	88	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	V	176	176	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	V	89	89	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	F	268	268	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	Y	285	285	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	W	261	261	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	T	183	183	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	T	93	93	putative ligand binding site
OPaiUWVYAg	3632f1f210f4f0d628987eb2643dc887	382	CDD-3.21	cd15051	9	314	17	L	289	289	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	W	105	105	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	L	106	106	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	F	313	313	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	Y	340	340	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	C	113	113	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	P	329	329	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	A	196	196	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	V	320	320	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	D	109	109	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	D	333	333	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	T	336	336	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	C	179	179	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	F	314	314	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	M	110	110	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	T	114	114	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	A	332	332	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	S	192	192	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	CDD-3.21	cd15335	47	361	18	W	310	310	putative ligand binding site
R3rYagRgkA	0af6bed0db5315cdb9f4a726191272c9	388	PIRSR-2023_05	PIRSR600732-3	32	216	1	CEIWLSVDMTCCTCSILHLCVIALDRYWAITDAIEYARKRTAKRAGLMIVTVWTISIFISMPPLF-WRNHHSVSIPSEC	102	179	DISULFID: 
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	PIRSR-2023_05	PIRSR600732-5	279	357	1	C	357	357	LIPID: S-palmitoyl cysteine
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	PIRSR-2023_05	PIRSR600732-5	279	357	1	C	356	356	LIPID: S-palmitoyl cysteine
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	W	297	297	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	T	326	326	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	Y	330	330	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	T	81	81	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	N	304	304	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	S	164	164	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	F	301	301	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	W	72	72	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	F	150	150	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	L	322	322	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	D	76	76	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	S	161	161	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	L	157	157	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	F	300	300	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	V	77	77	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	S	80	80	putative ligand binding site
14Cv16S4pA	00a0f010b9e915ae7e048fad2aabda4d	366	CDD-3.21	cd15067	1	351	17	S	160	160	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	F	302	302	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	A	208	208	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	D	121	121	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	W	298	298	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	S	308	308	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	F	301	301	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	Y	328	328	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	V	122	122	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	C	192	192	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	I	118	118	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	L	324	324	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	T	126	126	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	S	321	321	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	K	320	320	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	S	204	204	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	W	117	117	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	A	317	317	putative ligand binding site
tebUrGcXXP	8266258a309cc28452980b258eb614f3	357	CDD-3.21	cd15328	41	349	18	C	125	125	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	S	195	195	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	W	292	292	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	N	277	277	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	T	113	113	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	A	198	198	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	H	104	104	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	A	191	191	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	F	274	274	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	C	112	112	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	F	184	184	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	W	270	270	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	F	273	273	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	Y	300	300	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	D	108	108	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	L	296	296	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	V	109	109	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	CDD-3.21	cd15055	29	321	17	A	194	194	putative ligand binding site
RX5cDS5ygC	31b7a86a36c4b7ee8d99e7901f4a0c1d	353	PIRSR-2023_05	PIRSR600732-5	29	328	1	C	327	327	LIPID: S-palmitoyl cysteine
